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Most human genes undergo alternative pre-mRNA splicing to produce multiple transcript 
isoforms which often code for functionally distinct and tissue-specific products. Splicing factors 
interact with pre-mRNA and the core splicing machinery to control alternative splicing and 
regulate the generation of tissue-specific transcriptomes. For example, alternative splicing 
contributes to the function and homeostasis of the adaptive immune system. CD4+ T cells are 
an integral component of the adaptive immune system and regulate effector functions of 
immune cells towards diverse pathogens. Several splicing factors that contribute to CD4+ T cell 
function have been identified. However, the full splicing regulatory programmes characterising 
these and other immune cell types remain to be elucidated. Further, CD4+ T cells are the 
primary host target cell of HIV-1 infection. The HIV-1 lifecycle is regulated in large part through 
the host gene expression pathway. For instance, the HIV-1 RNA undergoes extensive 
alternative splicing mediated via the host splicing machinery. The study of processes such as 
these would benefit from development of improved methods for the inference of alternative 
splicing networks.  
 
In this thesis, I have analysed RNA-seq datasets to understand how alternative splicing is 
regulated through the actions of RNA binding proteins and cis-acting RNA elements. Motif 
Activity Response Analysis (MARA) is an approach developed for the inference of tissue-
specific regulatory transcription factors. I propose that MARA may also be effectively 
employed for the inference of regulatory splicing factors. To this end, I applied MARA for the 
novel use case of analysing splicing factors. I compared this Splicing-MARA (S-MARA) to a 
commonly used motif enrichment approach for predicting which splicing factors regulate a 
given splicing programme. For this purpose, I used a large-scale splicing factor knockdown data 
resource produced through the ENCODE project, in addition to a published CD4+ T cell 
activation timecourse. Despite its previous use, splicing factor motif enrichment analysis has 
not undergone a formal assessment. We found that this method has utility in identifying 
regulatory splicing factors, providing proof-of-concept for the use of motif-based methods in 
prediction of regulatory splicing factors. Counter to expectations, S-MARA had poorer 
performance in identifying regulatory splicing factors as compared to the motif enrichment 





Further, the RNA binding protein Sam68 was investigated using a knockdown approach to infer 
its genome-wide splicing targets during the CD4+ T cell activation process. This revealed a 
widespread role for Sam68 in regulating mRNA abundance, whilst only a limited number of 
genes showed Sam68-dependent alternative splicing. Finally, the regulation of the HIV-1 
lifecycle by host RNA-binding proteins was investigated. We showed that suppression of CpG 
dinucleotides in the HIV-1 genome appears to maintain correct splicing of viral transcripts; 
whilst introduction of CpGs promotes use of a cryptic splice site which disrupts splicing, 
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Chapter 1. Introduction 
1.1 Splicing of pre-messenger RNA 
Pre-messenger RNA (pre-mRNA) splicing is the process of intron removal coupled with ligation 
of the remaining exons, an essential process in the formation of mature mRNA (Sharp, 1994). 
Within eukaryotes, splicing is an essential component of the gene expression pathway, whilst 
within archaea it is mostly confined to tRNAs (Tocchini-Valentini et al., 2011), and in 
prokaryotes is considered rare and restricted to non-coding RNAs (Reinhold-Hurek and Shub, 
1992).  
1.1.1 Alternative pre-mRNA splicing 
The use of alternative combinations of exons and splice sites from within a single gene 
contributes to the production of alternative mRNA and protein products (Sharp, 1994). 
Upward of 90% of human genes undergo alternative splicing (Pan et al., 2008; Wang et al., 
2008), with ten or more isoforms often being generated from a given expressed gene (Djebali 
et al., 2012). In some instances, alternative splicing can generate large numbers of mRNA 
products from a single gene, such as with the Drosophila Melanogaster gene Dscam, from 
which tens of thousands of isoforms are generated (Schmucker et al., 2000). Complexity and 
prevalence of alternative splicing varies across species and shows greater divergence than 
patterns of gene expression (Barbosa-Morais et al., 2012). The prevalence of alternative 
splicing appears to correlate with organismal complexity, with a higher proportion of genes 
being alternately spliced in primates compared with other vertebrates (Barbosa-Morais et al., 
2012), and in vertebrates relative to invertebrates (Kim et al., 2007). Alternative splicing is 
regulated in a highly tissue-dependent manner (Merkin et al., 2012) and contributes to the 
regulation of development and maturation processes (Kalsotra and Cooper, 2011). Mis-splicing 
of RNA is implicated in a variety of complex human disorders including cancer (David and 
Manley, 2010) and autism (Irimia et al., 2014); as well as single-gene disorders such as β+-
thalassaemia (Busslinger et al., 1981). Indeed, it has been postulated that disease associated 
mutations affecting splicing may be the most common form of hereditary mutation (López-
Bigas et al., 2005). 
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A variety of alternative splicing patterns are recognised, with classically defined splicing 
categories including exon skipping, mutually exclusive exon usage, alternative 5’ or 3’ splice 
site usage, intron retention, and usage of an alternate last exon (Figure 1-1A) (Park et al., 
2018). Usage of alternative first exons is an additional class of alternative splicing event (Figure 
1-1A), but is driven through alternative transcriptional start site usage, rather than directly 
though the splicing machinery. More complex patterns of splicing also exist, with some 
examples shown in Figure 1-1B. Recently, Vaquero-Garcia et al. developed a novel approach 
for quantifying usage of alternative splicing variants of arbitrary complexity (Vaquero-Garcia et 
al., 2016), and found that ~37% of analysed genome-wide human alternative splicing events 
involved complex patterns of splicing not described by the more classical definitions.   
 
 
Figure 1-1. Categories of alternative splicing events. Dark blue boxes are constitutive exons, 
and red, light-blue, and green boxes are alternatively spliced exons. Poly(A) depicts alternative 
polyadenylation sites. Bold arrows show alternative transcription start sites. As published in 
(Park et al., 2018). 
1.1.2 Alternative splicing in the generation of protein diversity 
Alternative mRNA isoforms can code for proteins of divergent function and structure (Nilsen 
and Graveley, 2010). The functional consequences of alternative protein isoforms are wide-
ranging, and include alterations to protein cellular localisation, ligand interactions, and 
enzymatic properties, amongst many others (Kelemen et al., 2013). However, the proportion 
of expressed alternative splicing events that are translated into distinct proteins genome-wide 
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is unclear. Several lines of evidence indicate a global correlation between alternative splicing 
and the generation of protein diversity. Weatheritt et al. employed ribosomal sequencing to 
study the ribosome-engaged fraction of the transcriptome (Weatheritt et al., 2016). With a 
focus on exon-skipping, this study identified a majority of mid-to-high abundance alternative 
splicing events as being detected via ribosomal sequencing, providing evidence that these 
splice variants may be translated. However, ribosomal occupancy does not guarantee a 
transcript will be translated, as the ribosome also functions in the quality control of mRNA 
(Inada, 2017). Liu et al. (Liu et al., 2017) utilised an alternative approach based upon 
correlating differential mRNA isoform abundance with differential protein abundance 
measured via a specialised mass spectrometry methodology (SWATH-MS), and found a high 
correlation between the two measures. To investigate potential effects of alternative splicing 
on protein-protein interactions, Yang et al. (Yang et al., 2016) used a yeast two-hybrid method 
to screen for protein interactions of alternative protein isoforms from several hundred human 
genes. This approach revealed that protein isoforms of a gene did not on average share more 
interaction partners than proteins produced from different genes, providing evidence that 
these alternative isoforms may contribute to diversity in the protein interactome. 
 
Conversely, the role of error and stochastic noise as a major driver of transcript isoform 
generation has also been promoted as a hypothesis. Melamud et al. proposed a model based 
upon simulation of isoform expression in which production of a majority of isoforms are a 
consequence of stochastic noise (Melamud and Moult, 2009). They observed that the number 
of expressed isoforms per gene was a function of the number of introns and the level of 
expression, suggesting that alternative splicing may be driven stochastically during the 
transcription process. Consistent with this model, integration of multiple proteomic analyses 
indicates that for most highly expressed protein-coding genes, a single isoform is dominant 
across diverse tissues (Ezkurdia et al., 2015). Additionally, alternative exons show weaker 
evidence of selective pressure as compared to constitutive exons that form part of dominant 
isoforms (Liu and Lin, 2015; Tress et al., 2017a). Thus, whilst specific cases of alternative 
splicing leading to the generation of functionally distinct isoforms are well documented (Nilsen 
and Graveley, 2010), the proportion of alternative splicing events that contribute to the 
generation of proteomic diversity as a whole remains a contested topic (Blencowe, 2017; Tress 
et al., 2017b). 
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1.1.3 Alternative splicing in the control of gene expression 
In addition to the generation of protein isoforms, alternative splicing contributes to the 
stability, transport, and translation of RNA molecules (Braunschweig et al., 2013). For instance, 
splicing is tightly linked with nonsense-mediated decay (NMD), a conserved quality control 
process that prevents aberrant expression of mutant or incompletely processed transcripts 
containing premature termination codons (PTC) (Hwang and Kim, 2013). NMD is enhanced by 
deposition of the exon junction complex (EJC), a large protein complex deposited 20-24nt 
upstream of exon-exon junctions during splicing (Hwang and Kim, 2013), and later removed by 
the ribosome during translation (Gehring et al., 2009). However, in cases of a PTC, frequently 
when present 50-55nt upstream of the terminal exon-exon junction (Nagy and Maquat, 1998), 
the EJC associates with upstream frameshift proteins to trigger termination of translation and 
release from the ribosome (Isken et al., 2008), with these transcripts subsequently being 
degraded through mechanisms involving exonucloeolytic or endonucleolytic cleavage 
(Schoenberg and Maquat, 2012). Alternative splicing is a source of PTC generation, and it has 
been estimated that 10-20% of such PTC-events represent cases of the directed control of 
steady-state transcript abundance initiated at the level of splicing (Pan et al., 2006). 
Interestingly, many of these splicing-NMD coupled events target RNA-binding proteins (RBPs) 
with splicing function, thus providing a regulatory feedback loop mechanism (Lareau et al., 
2007; Plocik and Guthrie, 2012; Saltzman et al., 2008). 
 
An additional layer of RNA quality control involves the retention of potentially aberrant 
transcripts within the nucleus. Export of mRNA from the nucleus is closely coupled with 
splicing, whereby recruitment of the transcription/export (TREX) complex occurs co-
transcriptionally in a manner dependent on the splicing machinery (Masuda et al., 2005). The 
TREX complex facilitates transport of spliced RNAs through the nuclear pore via interactions 
with the NXF1 nuclear export receptor (Stutz et al., 2000). The presence of retained introns in 
incompletely spliced transcripts is known to prevent nuclear export, with such transcripts 
being retained in the nucleus where they are subsequently targeted for degradation in a 
mechanism that has not been fully elucidated (Yap and Makeyev, 2013). As with NMD, in some 
cases, such coupling of intron retention with RNA degradation is thought to provide a directed 
mechanism for controlling levels of gene expression. Yap et al. identified intron retention 
coupled to control of steady-state mRNA levels for a number of neuronal development related 
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genes, with this process facilitating the cell-type specific transcript expression (Yap et al., 
2012).  
1.1.4 Assembly and action of the spliceosome 
Several broad mechanisms of splicing exist, including tRNA splicing (Randau and Söll, 2008), 
self-splicing (Pyle, 2016), and spliceosomal mediated splicing (Irimia and Roy, 2014), with the 
latter being the predominant mechanism by which most pre-mRNAs are spliced. The 
spliceosome is a large, nucelar, ribonucleoprotein complex (Will and Lührmann, 2011). Two 
spliceosomes of different composition exist, the U2-dependent spliceosome (or major 
spliceosome), and the U12-dependent spliceosome (or minor spliceosome) which is 
responsible for splicing of the rare U12 intron class (Patel and Steitz, 2003). The major 
spliceosome is composed of five small nuclear RNAs (snRNAs - U1, U2, U4, U5, and U6) bound 
to seven proteins to form a complex of small nuclear ribonucleoproteins (snRNPs) (Shi, 2017). 
Interaction between pre-mRNA and the spliceosome is mediated through binding of these 
snRNA and protein components with several core splicing sequence elements situated in the 
pre-mRNA (Figure 1-2). The 5’ and 3’ splice sites mark the donor and acceptor sites at which 
intronic sequences are cleaved and exonic sequences subsequently joined. The canonical 
splice site sequence is AG-GU, with the AG being prior to the cut site at the 3’ intronic end, and 
GU subsequent to the cut site at the 5’ intronic end (Figure 1-2) (Mount, 1982). Non-canonical 
splice site sequences are also used, although with relatively low frequency (Burset et al., 
2000). The other constitutive splicing sequences are the branch point sequence (BPS), which is 
located upstream of the 3’ intron end and is less strongly conserved than the splice sites 
(Plaschka et al., 2019), and the polypyrimidine tract (PYT), which spans approximately 2-24nt 
downstream of the BPS, and is composed of pyrimidines with a bias towards uridine (Gao et 
al., 2008) (Figure 1-2).  
 
Formation of the spliceosome into a conformation with catalytic activity is a dynamic stepwise 
process. The initial step is mediated via base-pairing of the U1 snRNP to the 5’ splice site, and 
of the 3’ splice site and PYT by the U2AF35 and U2AF65 components of the U2 auxiliary factor 
(U2AF) heterodimer, respectively (Figure 1-2) (Shi, 2017). Subsequently, the U2 snRNP base-
pairs with the BPS in an ATP-dependent manner that is facilitated by U2AF at the 3’ splice site. 
This is followed by recruitment of the remaining subunits in the form of the U4/U6.U5 tri-
snRNP. After further remodelling, involving removal of the U1 and U4 snRNPs, a final structure 
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with a catalytic active site is produced (Shi, 2017). This final spliceosome structure facilitates 
interaction between respective components situated at either end of the intron, and is thus 
said to be centred round the intron in a process of “intron-definition”. However, in metazoans, 
the spliceosome initially forms around the exon through a process of “exon-definition”, 
whereby binding of the U1 snRNP at a 5’ splice site and U2 snRNP near to an upstream 3’ splice 
site enhance one another in a cross-exon manner (Hertel, 2008). Introns are often many times 
longer than exons (Sakharkar et al., 2004), and initial assembly in an exon-definition manner 
over a relatively shorter distance is thus thought to facilitate the subsequent intron-focused 
spliceosome structure that must span a greater length of RNA (Moldón and Query, 2010). 
 
Figure 1-2. Selected components of the splicing reaction. 
Larger boxes depict exons flanking an internal intron. Spliceosome components and core 
splicing factors are shown in green, auxiliary factors which contribute to alternative splicing 
are shown in blue. Consensus splicing elements are depicted: BPS = branch point sequence, 
PYT = polypyrimidine tract, Y = pYrimidine (C/U), R = puRine (A/G), N = aNy nucleotide. SR = 
Serine and arginine-rich protein, hnRNP = heterogeneous nuclear ribonucleoprotein. 
U2AF35/65 = components of the U2 auxiliary factor (U2AF) heterodimer. 
 
After complete assembly, the multi-stage splicing reaction can be orchestrated by the 
spliceosome. The splicing reaction is centred round two phosphodiester transesterifications. 
The pre-mRNA is initially cleaved at the 5’ splice site via transesterification of the BPS 
adenosine with the exonic splice site guanosine. This results in base pairing of these 
nucleotides and formation of a looped structure known as the intron lariat (Shi, 2017). The U2 
and U4/U6 snRNPs are then involved in repositioning of the 5’ site and BPS sequences (Shi, 
2017). A subsequent transesterification reaction cleaves the intron at the 3’ splice site, 
allowing covalent bonding between the 3’ and 5’ splice sites and resulting in joining of the 
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donor and acceptor exons. At this point, the intron lariat and associated snRNPs are released 
to complete the splicing reaction (Shi, 2017). 
1.1.5 Auxiliary splicing factors and alternative splicing 
The core splicing sequence elements show high levels of degeneracy in higher eukaryotes, and 
simulation studies suggest that they typically encode only half of the information required for 
accurate definition of exon/intron boundaries (Lim and Burge, 2001). Further, large introns 
often contain pairs of so-called ‘decoy’ splice sites, sequences with high similarity to the 
consensus splice sequences and which form the presence of pseudoexons (Krawczak et al., 
1992). However, these sites are rarely spliced, highlighting the capacity for the splicing 
machinery to differentiate such false sites (Sun and Chasin, 2000). This capacity is thought to 
derive in part from additional sequence information present in the form of variable cis-
regulatory motifs. These sequence motifs are present in both exons and introns and can 
function to either enhance or repress spliceosome assembly and splicing of a given exon 
(Figure 1-2). These features are referred to collectively as splicing regulatory elements (SREs), 
and can be sub-categorised as exonic splicing enhancers (ESE), exonic splicing silencers (ESS), 
intronic splicing enhancers (ISE), or intronic splicing silencers (ISS), depending upon their 
location and impact on splicing (Wang and Burge, 2008). Compared with the constitutive 
splicing elements, SREs have diverse sequence composition and higher levels of degeneracy 
(Wang and Burge, 2008). 
 
SREs contribute to the regulation of splicing via facilitating the binding of trans-acting splicing 
factors through interactions with RNA binding domains (Dvinge, 2018). In turn, splicing factors 
modulate elements of splceosomal activity such as splice site recognition or assembly. In 
addition to constitutive splicing, trans-acting splicing factors also regulate alternative splicing, 
whereby the activity of a splicing factor may promote use of a given splice site pair at the 
expense of a neighbouring site. As such, splicing factors are a class of proteins which receive 
much attention in the study of alternative splicing mechanism. Two major classes of splicing 
factor are the serine and arginine-rich (SR) protein and heterogeneous nuclear 
ribonucleoprotein (hnRNP) families. The SR proteins are characterised by an arginine and 
serine rich C-terminal domain (RS domain), and an N-terminal RNA recognition motif (RRM) 
domain (Jeong, 2017). SR proteins show a preference for binding exonic purine-rich sequences 
(Änkö et al., 2012; Pandit et al., 2013; Sanford et al., 2004), and are generally considered to be 
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splicing enhancers which act through binding to ESEs (Jeong, 2017). hnRNP proteins are 
members of several different gene families but commonly contain variable combinations of 
four specific RNA-binding domains: the RRM, the quasi-RRM, a hnRNP K-homology (KH) 
domain, and an arginine/glycine rich (RGG) domain (Geuens et al., 2016). Members of the 
hnRNP family are classically recognised as splicing repressors which bind ESSs of diverse 
sequence composition (Wang and Burge, 2008). Whilst the classical roles of hnRNPs as splicing 
repressors and SR proteins as splicing enhancers holds true in many cases, knockdown studies 
have revealed large-scale induction of both exon skipping and inclusion directly mediated by 
SR proteins and hnRNPs (Fu and Ares, 2014; Llorian et al., 2010; Pandit et al., 2013). Trans-
acting splicing factors can exert effects at numerous stages in the splicing reaction. SR proteins 
are known to interact with the U1 snRNP and U2AF to facilitate spliceosomal assembly (Black, 
2003), and additionally may act to stabilize base-pairing of the BPS with the U2 snRNP (Shen 
and Green, 2006). Downstream steps of the splicing reaction are also subject to such 
regulation. For instance, hnRNP L has been shown to inhibit incorporation of the U4/U6.U5 tri-
snRNP via binding to an ESS, thus acting to regulate spliceosome assembly rather than initial 
splice site recognition (House and Lynch, 2006). 
 
The precise regulation of spliceosome activity is additionally controlled through the specific 
sequence context of SREs and the combinatorial actions of opposing or enhancing splicing 
factors. The actions of many splicing factors are dependent on their location of binding. For 
instance, hnRNP L has opposing enhancing or repressing activity when binding its CA-rich motif 
in exonic (Rothrock et al., 2005) or intronic (Hui et al., 2005) contexts respectively, a pattern 
that is also observed with other hnRNPs (Chen et al., 1999; Chou et al., 1999; Mauger et al., 
2008). Similarly, SR proteins are known to have inhibitory effects when bound to upstream 
intronic regions through interfering with the downstream exon definition process (Erkelenz et 
al., 2013; Havlioglu et al., 2007). 
 
Additionally, SREs exhibit combinatorial effects on splicing regulation. For instance, 
combinations of motifs are known to exhibit cooperative effects in promoting exon skipping 
(Han et al., 2005), and pairs of motifs are often found flanking exons in a fashion that 
synergistically promotes exon-definition (Ke and Chasin, 2010). Such combinatorial and 
context dependent effects of SREs have been found to follow common patterns and rules, 
leading to the concept of a “splicing code” through which alternative splicing may be predicted 
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as a function of cis acting motifs and the actions of trans-acting factors (Wang and Burge, 
2008). However, whilst progress has been made towards modelling the splicing regulatory 
code via deep learning, this remains a challenging and open area of research (Barash and 
Vaquero-Garcia, 2014; Jha et al., 2017). Indeed, analysis of exonic sequences has led to the 
estimation that upwards of 1000 hexamers may have splicing regulatory function (Stadler et 
al., 2006). Thus, a given transcript will often contain many potential regulatory elements of 
which only a subset is utilised in vivo. An additional layer of information which may facilitate 
this precise utilisation and function of SREs is that of pre-mRNA secondary structures. Recent 
high-throughput in vitro analyses have identified many RBPs with strong preferences to 
specific RNA structural features (Burge et al., 2018). Further, a majority of transcripts are 
spliced co-transcriptionally (Brugiolo et al., 2013), providing opportunities for cross-regulation 
between the splicing and transcriptional machinery. Alternative splicing and transcription are 
kinetically coupled, whereby faster rates of transcription reduce the time for interaction 
between splicing factors and SREs, and therefore promote exon skipping, particularly at exons 
with weaker splicing signals (Kornblihtt et al., 2013). In turn, epigenetic factors such as exonic 
methylation levels can mediate the rate of transcriptional elongation via RNA polymerase II, 
and thus regulate levels of exon inclusion. Such an effect has been demonstrated with the 
transcription factor CCCTC binding factor (CTCF) (Shukla et al., 2011). Epigenetic modifications 
can also influence alternative splicing via the direct recruitment of splicing factors, as in the 
role of H3K46me3 in enhancing SRSF1 recruitment via the Psip1/Ledgf adapter protein 
(Pradeepa et al., 2012). 
1.1.6 Control of splicing networks 
The regulation of alternative splicing and its contribution to tissue specific transcriptomes is 
thought to be controlled in large part by the actions of key splicing factors (Jangi and Sharp, 
2014). The concerted action of splicing factors is achieved through numerous mechanisms 
which give rise to a stable gene expression system whilst maintaining responsiveness to 
changing external stimuli (Jangi and Sharp, 2014). Negative autoregulation is a common 
feature of splicing networks, often mediated via coupling of splicing with NMD (Lareau et al., 
2007; Ni et al., 2007; Saltzman et al., 2008). It can function to maintain steady sate expression 
levels by buffering against changes in transcription or protein stability (Nevozhay et al., 2009). 
Conversely, positive feedback commonly features in splicing networks and is associated with 
signal amplification and promotion of binary states such as cellular differentiation (Becskei et 
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al., 2001). For example, during neurogenesis, the transcriptional repressor REST is alternatively 
spliced by the splicing factor nSR100 to produce an isoform with reduced activity (Raj et al., 
2011). This in turn increases nSR100 expression in acting as a positive reinforcement 
mechanism (Raj et al., 2011). Cross-regulation also appears to be a common motif in splicing 
regulatory networks (Fu and Ares, 2014). For instance, cross-regulation between several 
members of the hnRNP family is known to occur, and numerous hnRNP genes contain 
regulatory binding sites for other hnRNP proteins (Huelga et al., 2012).  
 
Alternative splicing plays a key role in a number of signal transduction pathways (Fu and Ares, 
2014). In particular, the activity of many SR proteins is dependent upon their phosphorylation 
status, which in turn can be regulated by extracellular cues such as growth factor signalling 
(Zhou et al., 2012) or stimulation of the T cell receptor (TCR) upon antigen presentation (Topp 
et al., 2008). Activation of splicing factors can result in signal amplification (Jangi and Sharp, 
2014), whereby the downstream targets of splicing factor activation consist of both initial 
primary targets, in addition to secondary targets resulting from the altered splicing of those 
primary targets (Huelga et al., 2012; Jangi et al., 2014). 
 
Further, alternative splicing frequently regulates the inclusion of disordered protein domains. 
Such disordered domains in turn modify the post-translational modification or protein-protein 
interactions of these alternatively spliced proteins (Buljan et al., 2013). As such, the regulation 
of disordered domains provides a mechanism through which alternative splicing can modulate 
protein-protein interaction networks. Indeed, disordered domains play a role in the phase 
separation of splicing factors in the formation of nuclear/splicing speckles (Itakura et al., 2018). 
Nuclear speckles are nuclear domains enriched in splicing factors and other RBPs and are 
located within interchromatin regions (Galganski et al., 2017). These speckles are dynamic 
structures, with exchange of components between speckles and the nucleoplasm or sites of 
active transcription. As such, nuclear speckles function in the assembly, modification, and 
temporary storage of pools of splicing factors, to facilitate dynamic splicing regulation. 
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1.2 Alternative splicing in CD4+ T cells 
1.2.1 Role of CD4+ T cells in the adaptive immune system 
The vertebrate immune system is composed of two complementary arms - the innate system 
and the adaptive system. The innate immune system comprises of physical defence barriers 
such as the skin, in addition to immune cells such as granulocytes (basophils, neutrophils, and 
mast cells), dendritic cells, and macrophages (Turvey and Broide, 2010). Innate immunity is 
mediated via recognition of conserved molecular patterns that identify potential pathogens 
and in turn activate defensive responses such as phagocytosis or activation of adaptive 
immune responses (Akira et al., 2006). Conversely, the adaptive immune system produces 
highly specific responses towards pathogens, and provides longer-lasting protection via the 
process of immune memory (Bonilla and Oettgen, 2010). The adaptive immune system is 
composed of B and T lymphocytes. B cell development takes place within the bone marrow, 
and mature B cells are responsible for mediating the antibody response via an antigen-specific 
immunoglobulin molecule - the B cell receptor (BCR) (LeBien and Tedder, 2008). T cell 
maturation occurs within the thymus, whereby thymocytes that originated from the bone 
marrow as haematopoietic precursors develop into two distinct lineages expressing a clonally 
restricted TCR – the TCRαβ+ and TCRγδ+ lineages (Schwarz and Bhandoola, 2006). The TCRαβ+ 
cells are the major lineage and are comprised of CD4+ T helper (Th) cells and CD8+ cytotoxic T 
lymphocytes (CTLs) (Kreslavsky et al., 2010). CD4+ T cells are primarily associated with 
regulating the actions of other immune cells, including B cells and CD8+ T cells, whilst CD8+ T 
cells function to destroy virus-infected cells and tumour cells (Bonilla and Oettgen, 2010). T cell 
maturation is a complex multi-stage process which includes TCR gene rearrangement, 
selection via interaction with antigen-presenting cells (APC), and expression of lineage 
specifying surface molecules (e.g. CD4 or CD8) (Takahama, 2006). The specificity of the 
adaptive immune response is mediated by the extensive repertoire of expressed TCR and BCR 
variants, which is in turn generated through extensive somatic gene recombination (Roth, 
2014). CD4+ T cells are implicated in various allergic and autoimmune conditions, and 
modulation of CD4+ T cells is therefore of therapeutic interest. For instance, dendritic cells can 
induce hyporesponsiveness towards specific antigen in CD4+ cells, which raises the potential 
for manipulation of hyporesponsiveness as a potential autoimmune therapeutic strategy 
(Maggi et al., 2015).  
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Some CD4+ T cells, such as regulatory T (Treg) cells, are considered to be fully polarised effector 
Th cells upon release from the thymus (Hsieh et al., 2012). A majority however, remain in a 
naïve state, and are capable of further polarisation into functionally distinct Th subsets 
(Luckheeram et al., 2012).The process of a naïve CD4+ T cell polarising to a functional effector 
is driven by interaction of the TCR with its cognate antigen, which leads to so-called cellular 
“activation” and subsequent proliferation (Luckheeram et al., 2012). Antigen presentation to 
CD4+ cells is mediated by professional APCs, such as B cells, macrophages, or dendritic cells, 
which express a major histocompatibility complex (MHC) class II cell surface protein (Rock et 
al., 2016). The TCR engages with the antigen presented on the MHCII molecule, with CD4 
acting as a co-receptor. For cellular activation to proceed, a co-stimulatory interaction 
between CD28 on the CD4+ T cell and a B7 protein on the APC is also necessary, as absence of 
co-stimulation leads to anergy and apoptosis as part of a mechanism to prevent inappropriate 
immune responses (Kalekar et al., 2016). TCR engagement causes phosphorylation of CD3, an 
intracellular component of the TCR, and of CD4, which initiates the Th cell activation pathways 
through activation of Src family kinases by the intracellular component of the phosphatase 
CD45 (Courtney et al., 2018). This activation signal stimulates release of interleukin 2 (IL-2), a T 
cell growth factor, and upregulation of a subunit of the IL-2 receptor (CD25), promoting 
proliferation in both an autocrine and paracrine manner (Malek and Castro, 2010). After 
activation and the initiation of proliferation, CD4+ cells produce IL-4 and IFN-γ, in addition to 
IL-2, and are said to be in a Th0 cell state (Kim et al., 2001). An additional subset of activated 
CD4+ T cells that express neither IL-4 or IFN-γ, referred to as non-polarised activated T cells, 
are also recognised (Kim et al., 2001). 
 
Helper T cells exhibit wide-ranging effects through the interaction with different immune cell 
types, and the specific function of a given Th cell is determined through polarisation of Th0 cells 
towards distinct effector subsets. There are an increasing number of recognised Th subsets, 
defined by their expression of key cytokines, chemokines, and associated receptor molecules, 
which in turn confer phenotypic effector functions (Saravia et al., 2019). Determination of Th 
subtypes is determined through the combinatorial effects of manifold factors surrounding the 
T cell activation process including APC type, presence of specific costimulatory molecules, and 
composition of the local cytokine milieu (Saravia et al., 2019). In response to these stimuli, 
specification to each subset is then driven by the activations of master transcription factors 
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which orchestrate activation of subset-defining effector regulatory programmes (Tao et al., 
1997).  
 
The classically defined Th subsets are Th1 and Th2 cells. Polarisation towards the Th1 class is 
driven through the combined actions of IFN-γ and IL-12 (Trinchieri et al., 2003). IL-12 is 
secreted by APCs in response to activation of pattern recognition receptors (Trinchieri and 
Sher, 2007). In addition to directly driving Th1 polarisation, IL-12 stimulates IFN-γ production by 
T cells and natural killer cells (NK) (Luckheeram et al., 2012), further driving Th1 polarisation. 
The Th1 master transcription factor T-bet is activated via STAT1 which in turn is activated by 
IFN-γ (Afkarian et al., 2002). T-bet both drives expression of Th1 promoting genes such as IL1-2 
receptor β2 (IL2Rβ2), in addition to repressing the expression of genes involved in polarisation 
to other lineages, such as the Th2 promoting IL-4 (Djuretic et al., 2007). Th1 cells are associated 
with defence against intracellular pathogens through the pleiotropic actions of their major 
cytokines, IFN-γ, IL-12, and TNF-β, towards a variety of immune cells. For instance, IFN-γ 
stimulates macrophages to phagocytose intracellular pathogens, and IL-2 promotes the 
effector functions of CD8+ cells (Kim et al., 2006). Polarisation to the Th2 subset is controlled by 
IL-2 and IL-4, with these cytokines being secreted by Th2 cells in an autocrine positive feedback 
mechanism. The master transcription factor of Th2 cells is GATA3, which is upregulated upon 
the IL-4-dependent activation of STAT6 (Zhu et al., 2001). GATA3 acts to promote Th2 
polarisation through various mechanisms including downregulating STAT4 to suppress Th 1 
differentiation (Usui et al., 2003), and upregulating the pro-Th2 transcriptional repressor Gfi-1 
(Zhu et al., 2006). Th2 cells regulate the response to extracellular parasites and produce a 
variety of effector cytokines including IL-4, IL-5, IL-9, IL-10, IL-13, and IL-25, which collectively 
regulate the effector functions of numerous cell types such as basophils, eosinophils, mast 
cells, and B cells (Luckheeram et al., 2012). For instance, IL-4 stimulates the production of 
immunoglobulin E (IgE) by B cells, whilst IL-5 is involved in eosinophil activation, such as in the 
defence against helminths (Luckheeram et al., 2012). In addition to Th1 and Th2 cells, a number 
of other regulatory subsets exist. An increasing body of evidence indicates that Th subsets 
exhibit a degree of plasticity, with intermediary phenotypes and reprogramming between 
different subsets, as opposed to the presence of terminally differentiated lineages (O’Shea and 
Paul, 2010; Zhou et al., 2009). This plasticity may allow flexibility in the immune response to 
different pathogens (Becattini et al., 2015), but inappropriate plasticity is associated with 
autoimmunity (DuPage and Bluestone, 2016).  
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1.2.2 Alternative splicing in CD4+ T cells 
In addition to the actions of key transcription factors and transcriptional regulatory 
programmes, alternative splicing also plays a role in CD4+ T cell activation, polarisation, and 
homeostasis. From a genome-wide perspective, widespread alternative splicing has been 
documented in studies of activation using T cell lines (Ip et al., 2007; Martinez et al., 2012). 
Butte et al. demonstrated that stimulation of the TCR and CD28 in primary CD4+ T cells had 
synergistic effects on driving a programme of alternative splicing in several thousand genes, 
which was at least partially regulated via the upregulation of the splicing factor hnRNP LL 
(Butte et al., 2012). Ni et al. identified the widespread down-regulation of intron retention 
coupled with increased gene expression upon CD4+ T cell activation, particularly in genes in 
the proteasome pathway which is necessary for T cell proliferation and the release of 
cytokines (Ni et al., 2016). 
 
One of the best studied examples of alternative splicing in CD4+ T cells is the transmembrane 
tyrosine phosphatase CD45 - encoded by the PTPRC gene. CD45 is expressed on the surface of 
all nucleated hematopoietic cells and has roles in proximal antigen recognition and cytokine-
mediated signalling (Alexander, 2000). CD45 couples initial TCR engagement with downstream 
signalling by dephosphorylating tyrosine residues of the Src kinase Lck (Sieh et al., 1993). Exons 
4, 5, and 6 of PTPRC are variable cassette exons encoding extracellular domains which undergo 
post-translational glycosylation (Alexander, 2000). Upon T cell activation, these cassette exons 
are preferentially skipped. This leads to a protein lacking the glycosylated domains, which in 
turn leads to CD45 homodimerization and reduced phosphatase activity, thereby decreasing 
TCR signalling in a negative feedback mechanism (Xu and Weiss, 2002). Expression of CD45 
isoforms distinguishes different lymphocyte subsets, with naïve T cells expressing CD45 
isoforms containing combinations of the three cassette exons, and activated cells expressing 
an isoform with all three exons spliced out (CD45RO) (McNeill et al., 2004). Differential 
expression of CD45RA (the isoform containing exon 4) and CD45RO is commonly used to 
differentiate between naïve and memory cells respectively, whilst expression of CD45RBC 
(which contains exons 4 and 6) is also seen in naïve cells (McNeill et al., 2004).  
 
Control of CD45 alternative splicing is regulated by the combinatorial actions of a number of 
splicing factors (Figure 1-3) (Yabas et al., 2015). One of the first regulators of CD45 splicing 
identified was hnRNP L which binds to the activation response sequence (ARS), a motif present 
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in exons 4, 5, and 6, to repress splicing (Rothrock et al., 2005; Tong et al., 2005). Genome-wide 
analysis in a model T-cell-line has identified diverse targets under splicing control of hnRNP L 
(Cole et al., 2015). These effects were mediated by direct pre-mRNA binding of hnRNP L, in 
addition to indirect mechanisms involving epigenetic regulation (Cole et al., 2015). The hnRNP 
L paralogue, hnRNP LL, acts together with hnRNP L to repress splicing of CD45 exons 4 and 6 
when its expression is upregulated upon T cell activation (Figure 1-3) (Oberdoerffer et al., 
2008; Topp et al., 2008; Wu et al., 2008). Although hnRNP LL shows affinity towards the ARS, it 
neither binds to nor regulates splicing of exon 5 (Motta-Mena et al., 2010). Another splicing 
factor that contributes to skipping of CD45 alternative exons is PTB-associated splicing factor 
(PSF, gene name = SFPQ). PSF was first identified as a splicing factor through a screen of 
proteins which bind to the variable exons of CD45 (Melton et al., 2007; Topp et al., 2008). PSF 
binding is independent of hnRNP L and hnRNP LL and involves sequences outside of the ARS. 
The activity of PSF is regulated through phosphorylation by glycogen synthase kinase 3 in a 
manner sensitive to TCR signalling (Heyd and Lynch, 2010). 
 
 
Figure 1-3. Control of alternative splicing at the CD45 locus. Transcription via Pol II at the 
CD45 locus is shown, with the speed of elongation being regulated via CTCF binding to exon 5. 
Co-transcriptional splicing of CD45 alternative exons is shown. The repressive action of hnRNP 
L (L), hnRNP LL (LL), and PSF, and enhancing action of SRSF1 and CTCF is depicted. The 
activation response sequence (ARS) is depicted in red and the ESE in green. As published in 
(Martinez and Lynch, 2013). 




Several mechanisms of CD45 splicing enhancer activity have also been elucidated. The SR 
protein SRSF1 was identified as factor that promotes inclusion of exon 5 in resting naïve cells 
through binding to an ESE (Motta-Mena et al., 2010; Tong et al., 2005). SRSF1 and hnRNP L 
directly compete for binding to CD45 exon 5 to regulate mRNA inclusion levels. SRSF1 also 
regulates the alternative splicing of the CD3ζ chain of the TCR upon T cell activation, in a 
manner that enhances mRNA stability and translation through the regulated inclusion of a 3’ 
terminal intron (Moulton and Tsokos, 2010). Inclusion of CD45 exon 5 is also regulated by the 
transcription factor CTCF. CTCF is recognised for its insulator activity (Singh et al., 2012), and 
also acts to decrease the rate of RNA polymerase II elongation by binding to exonic sequences, 
which in turn favours exon inclusion (Shukla et al., 2011). CTCF binding to CD45 exon 5 is 
regulated via its methylation status, with memory cells showing increased methylation at this 
locus which prevents CTCF binding and therefore enhances exon skipping (Shukla et al., 2011).  
 
In addition to roles in mediating activity of proximal signalling components, alternative splicing 
contributes to a number of other processes in CD4+ T cell biology. For instance, TCR signalling 
strength was shown to modulate hnRNP A1 and hnRNP L splicing activity in a manner that 
regulated the ratios of polarisation towards Treg or other Th subtypes (Hawse et al., 2017). The 
T-cell-restricted intracellular antigen 1 (TIA1) is a regulator of FAS exon 6 skipping, and upon T-
cell activation, it’s activity is reduced in order to promote expression of an anti-apoptotic 
isoform (Izquierdo and Valcárcel, 2007; Liu et al., 1995). The regulation of apoptosis is critical 
for T cell homeostasis and development, such as in the control of central tolerance and the 
removal of autoreactive lymphocytes (Rathmell and Thompson, 2002). Alternative splicing is 
also important to the generation of functional cytokine receptors. For instance, IL-7Rα  is 
alternatively spliced to produce a soluble and secreted form (Goodwin et al., 1990) necessary 
for survival of peripheral CD4+ T cells (Kondrack et al., 2003). 
 
The precise function and regulatory mechanisms underlying the majority of alternative splicing 
events identified in CD4+ T cells have not been determined. A major goal in the study of 
immune function is to fully model and predict the splicing networks characterising processes 
such as T cell activation or polarisation (Martinez and Lynch, 2013). Understanding the details 
of splicing regulation in the immune system may have clinical implications. For instance, 
elucidating the mechanisms of immune disorders linked to mis-splicing, or predicting the 
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effects of polymorphisms on the splicing machinery (Cooper et al., 2009; Martinez and Lynch, 
2013).  
1.3 The HIV-1 lifecycle and its regulation by host RNA-binding 
proteins  
1.3.1 HIV-1 is the etiological agent of the AIDS pandemic  
Acquired immune deficiency syndrome (AIDS) is the clinical manifestation of late-stage human 
immunodeficiency virus (HIV) infection. The characteristics of AIDS, including increased 
susceptibility to common and opportunistic infection, are a result of a depletion of the CD4+ T 
cell population - the primary host target of HIV replication (Okoye and Picker, 2013). There are 
two main types of HIV - type 1 and 2, which originate from different cross-primate zoonotic 
events, with HIV type 1 (HIV-1) being the pandemic form (Sharp and Hahn, 2011). 
Antiretroviral therapy, where effectively distributed, has proven highly successful in reducing 
the number of deaths due to AIDS (World Health Organization; UNAIDS; UNICEF., 2011). 
Substantial challenges remain however, such as the large proportion of people predicted as 
being unaware of their HIV positive status (UNAIDS, 2014), and the continuing documentation 
of novel drug resistance mutations (Wensing et al., 2014). As such, HIV infection remains a 
major global health issue. 
1.3.2 The HIV-1 lifecycle 
The HIV-1 lifecycle is a complex multistage process (Figure 1-4). Entry to the host cell involves 
the fusion of the viral and cellular membrane via interactions between the HIV-1 envelope 
(Env) glycoproteins with host receptors CD4 (Klatzmann et al., 1984) and co-receptors CCR5 
(Alkhatib et al., 1996) or CXCR4 (Feng et al., 1996). After entry into the cell, the HIV-1 RNA 
genome is reverse transcribed to cDNA by the viral reverse transcriptase (Hu and Hughes, 
2012). After reverse transcription, the cDNA is incorporated into a nucleoprotein complex 
containing both host and viral proteins termed the preintegration complex (PIC) (Craigie and 
Bushman, 2012). The PIC is imported through the nuclear pore and the HIV-1 cDNA is 
integrated into the host DNA in a process catalysed by the viral integrase (Craigie and 
Bushman, 2012), with the host LEDGF/p75 protein acting as a cofactor (Ciuffi et al., 2005). The 
resulting integrated HIV-1 cDNA, referred to as the provirus, then utilises the host gene 
expression machinery to facilitate RNA transcription, 5’ capping, splicing, polyadenylation, 
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nuclear export, and translation (Karn and Stoltzfus, 2012). The viral Tat transactivator protein 
is required for efficient transcriptional elongation (Rice, 2017). Nuclear export of the 
incompletely spliced transcripts requires interaction between Rev, the Rev-response element 
(RRE) in the viral RNA, and host nuclear export factor CRM1 (Yi et al., 2002). The Gag 
polyprotein, which encodes the HIV-1 structural proteins capsid, matrix, and nucleocapsid, 
orchestrates the assembly of new virus-like particles at the plasma membrane (Bell and Lever, 
2013). Budding of viral particles is mediated by the host ESCRT pathway (Usami et al., 2009), 
and is the process by which the viral lipid envelope is acquired. After budding, the final 
maturation process occurs which involves proteolysis of Gag and Gag-Pol polypeptides to yield 




Figure 1-4. Stages of the HIV-1 lifecycle. 1) Glycoproteins present on the viral envelope bind 
with cell surface receptors. 2) The HIV-1 and host cell membranes fuse, allowing entry of the 
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viral core to the cytoplasm. 3) The viral capsid uncoats and the HIV-1 genome is reverse 
transcribed into cDNA. 4) The preintegration complex enters the nucleus via nuclear pore 
complexes. 5) The viral cDNA is integrated with the host genome forming a provirus. 6-9) The 
provirus utilises the host gene expression pathway for: 6) transcription, 7) RNA processing 
such as splicing, 5’ capping, and polyadenylation, 8) nuclear export facilitated by the HIV-1 Rev 
protein, and 9) translation. 10) New virus-like particles are assembled, before 11) budding 
from the cell and 12) maturation. Schematic provided by Michael Malim.     
 
1.3.3 HIV-1 depends upon the host splicing machinery  
HIV-1 possesses a ~9kb genome containing nine open reading frames (ORFs) capable of 
producing 15 distinct proteins (Watts et al., 2009) (Figure 1-5). The integrated provirus is 
transcribed as a full-length pre-mRNA, under control of the HIV-1 promoter which resides 
within the 5’ long terminal repeat (Karn and Stoltzfus, 2012). In addition to being the source of 
genomic RNA utilized for packaging into new viral particles, the full-length unspliced transcript 
acts as the pre-mRNA for subsequent splicing or is translated to produce the Gag and Gag-pol 
polypeptides after nuclear export (LeBlanc et al., 2013). Two classes of spliced transcripts are 
produced, the singly spliced, intron-containing transcripts, which are ~4kb in length and 
encode the viral envelope protein Env and auxiliary proteins Vif, Vpu, and Vpr, and the 
completely spliced transcripts encoding Tat, Rev, and Nef (Sertznig et al., 2018).  




Figure 1-5. The HIV-1 genome, splice sites, and classes of viral transcripts. Top: The 9 HIV-1 
ORFs frames are depicted, flanked by the 5’ and 3’ long terminal repeats (LTR) (black boxes). 
Initiation of transcription from the 5’ LTR promoter is depicted. The canonical 5’ and 3’ splice 
sites (SS), in addition to the Rev-response element (RRE) are shown below. Bottom: The major 
HIV-1 transcript isoforms are depicted, grouped according to their degree of splicing. Figure 
from (Mahiet and Swanson, 2016). 
 
To facilitate this extensive splicing, HIV-1 exploits the host splicing machinery, and indeed, 
screens for human HIV-1 dependency factors have identified numerous splicing factors as 
essential to viral replication (Sertznig et al., 2018). The HIV-1 genome contains numerous 
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canonical splice donor and acceptor sites, the coordinated use of which gives rise to the set of 
alternatively spliced viral transcripts (Figure 1-5). As with alternative splicing of host 
transcripts, cis-acting splicing regulatory elements play an important role in regulating the 
relative usage of donor and acceptor pairs through the actions of regulatory splicing factors.  
 
Experimental approaches focused on introducing mutations to the HIV-1 genomic RNA have 
facilitated identification of splicing enhancer and suppressor elements for the majority of the 
canonical HIV-1 splice sites (Sertznig et al., 2018). For instance, when the A7 3’ splice site is 
paired with D4, this results in removal of an intron which allows the formation of tat, rev, and 
nef mRNAs (Figure 1-5). The appropriate usage of A7 is predominantly controlled through two 
regulatory elements: exonic splicing enhancer three (ESE3) and exonic splicing suppressor 
three (ESS3) (Sertznig et al., 2018). ESE3 promotes binding of SRSF1 which stabilizes 
association of the U2AF65 subunit with A7 (Staffa and Cochrane, 1995). The ESS3 is a bipartite 
element comprised of two neighboring motifs (AGAUC and UUAG) and acts to repress A7 (Si et 
al., 1998). Suppressive activity is mediated through cooperative binding of hnRNP A/B proteins 
to the ESS3, which act to unwind local RNA secondary structures causing displacement of 
SRSF1 bound to ESE3 (Damgaard et al., 2002; Okunola and Krainer, 2009). Structural analysis of 
ESS3 has identified the presence of a stem loop structure which is critical for binding by hnRNP 
A1 (Rollins et al., 2014).  
 
1.3.4 Human anti-HIV factors 
Each step in the HIV-1 lifecycle relies upon numerous dependency factors, the result of viral 
adaptation in co-opting the host cellular environment. In addition, the host-pathogen 
coevolution process has resulted in numerous antiviral factors and reciprocal HIV-1 evasion 
mechanisms (Doyle et al., 2015). One class of human anti-HIV-1 proteins, termed restriction 
factors, have the potential to fully or partially restrict viral replication, but have mechanisms of 
evasion by wild-type HIV-1. HIV-1 restriction factors include TRIM5α, BST-2/Tetherin, members 
of the APOBEC3 protein family (APOBEC3G, APOBEC3F, APOBEC3D and some APOBEC3H 
variants) (Doyle et al., 2015), and the recently identified SERINC3 and SERINC5 (Rosa et al., 
2015; Usami et al., 2015). These restriction factors, many of which are RBPs which directly bind 
to viral RNA, target different stages of the HIV-1 replication cycle, and all have known viral 
evasion mechanisms (Doyle et al., 2015). For example, BST-2, which encodes the Tetherin 
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protein, inhibits the cellular release of viral particles from Vpu-deficient HIV-1 by forming 
protein bridges between the viral and cellular membranes (Neil et al., 2008; Van Damme et al., 
2008). In wild-type HIV-1 however, Vpu prevents trafficking of tetherin to the cell membrane 
and induces its ubiquitin-mediated degradation (Neil, 2013). In addition to these restriction 
factors, a further class of anti-HIV-1 proteins are those which reduce viral replication efficiency 
but do not appear to have direct viral evasion mechanisms. These proteins, referred to as HIV-
1 resistance factors, are presumed to lack HIV-1 evasion mechanisms due to exerting a 
reduced selective pressure relative to the restriction factors (Doyle et al., 2015). The HIV-1 
host resistance factors include MX2, IFITM1, IFITM2, and IFITM3, with SAMHD1 being a less 
clear case – having a demonstrated viral evasion mechanism in HIV-2 (Vpx) but being of 
unclear biological importance in HIV-1 infection (Doyle et al., 2015). As with the HIV-1 
restriction factors, these resistance factors operate at different stages of the viral replication 
cycle. The IFITMs, for instance, interfere with membrane fusion to prevent viral cell entry 
(Compton et al., 2014; Lu et al., 2011; Tartour et al., 2014), whilst MX2 reduces nuclear entry 
and integration of viral cDNAs (Goujon et al., 2013). 
 
1.3.5 Therapeutic targeting of host protein-HIV-1 interactions 
As an essential component of the HIV-1 replication cycle, alternative splicing has been 
considered as a potential antiviral therapeutic target. Targeting of host dependency factors is 
appealing since this can increase the genetic barrier to viral drug resistance relative to the use 
of viral targets (Tang and Shafer, 2012). As an illustrative example, IDC16 was identified as a 
compound that interferes with SRSF1 activity, and was shown to reduce HIV-1 replication in 
vitro via disrupting viral splicing (Bakkour et al., 2007). Importantly, treatment with IDC16 did 
not affect the splicing of a panel of selected host genes.  
 
In addition to targeting HIV-1 dependency factors such as the splicing machinery, directly 
facilitating the host innate immune response to the virus represents a further therapeutic 
strategy. The possibility of inhibiting the HIV-1 auxiliary proteins necessary for evasion of host 
restriction factors is an area of active research. For instance, small molecule inhibitor screens 
have been employed to successfully identify compounds which protect APOBEC3G from Vif-
mediated degradation (Cen et al., 2010) such as through disrupting the formation of Vif-
ubiquitin ligase complexes (Miyakawa et al., 2015). Similarly, a small molecule that enhances 
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Tetherin mediated restriction by inhibiting Vpu-Tetherin association and subsequent 
degradation has been described (Mi et al., 2015). Further elucidating the intricacies of host 
protein-HIV-1 interactions throughout the viral lifecycle is thus of interest in identifying new 
therapeutic avenues.  
1.4 Profiling splicing networks and inference of regulatory 
splicing factors 
1.4.1 Approaches to studying alternative splicing 
Alternative splicing has been conventionally studied through reverse transcription polymerase 
chain reaction (RT-PCR) (Harvey and Cheng, 2016). The development of expressed sequence 
tag (ESTs) technology, a method for sequencing fragments of mRNA, allowed the identification 
of widespread alternative splicing across the genome (Modrek and Lee, 2002). In the mid-
2000s, the development of splicing microarrays provided a further advancement and 
facilitated a high-throughput approach to the study of alternative splicing (Lee and Roy, 2004). 
However, microarray analysis is limited to the investigation of pre-defined splicing events. In 
2008, several landmark studies employed short-read RNA sequencing (RNA-seq) to profile 
alternative splicing of both known and novel splicing events across the genome (Mortazavi et 
al., 2008; Pan et al., 2008; Wang et al., 2008). The high-throughput nature of RNA-seq and the 
ability to discover novel isoforms have led to it arguably becoming the gold standard for 
analysis of alternative splicing (Park et al., 2018). So-called “third generation” technologies, 
such as PacBio isoform sequencing, have allowed the sequencing of full length mRNA isoforms 
(Au et al., 2013; Sharon et al., 2013), however the lower-throughput nature of these 
techniques presents a challenge for quantification of relative isoform or splice event usage (Au 
et al., 2013). 
 
Whilst RNA-seq is currently the gold-standard for profiling the contributions of alternative 
splicing in regulating the transcriptome, it does have limitations. For instance, RNA-seq 
captures steady-state transcript levels which are a function of both synthesis and degradation 
processes. As such, transiently expressed transcripts may be challenging to capture. Since 
splicing-NMD targets transcripts for degradation, the upregulation of such transcripts through 
alternative splicing can paradoxically decrease the total number of such transcripts through 
subsequent degradation. Sequencing of the nuclear RNA fractions provides a strategy through 
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which to more directly capture splicing processes such as intron retention and splicing-NMD 
(Zeng and Hamada, 2020). Further, native elongating transcript sequencing (NET-seq) 
facilitates sequencing of actively transcribed RNA, and thus allows direct investigation of co-
transcriptional splicing (Nojima et al., 2015). 
  
The popularity of short read RNA-seq has led to a multitude of algorithms for its use in the 
analysis of alternative splicing (Harvey and Cheng, 2016; Hooper, 2014). These approaches fall 
into several broad strategies, with one distinction being whether quantification is performed 
on the full transcript isoform or individual splicing event level. Quantification of full-length 
transcripts is challenging with short read technology, and sensitive to the use of reference 
transcriptome (Conesa et al., 2016), whilst the de novo reconstruction of isoforms is associated 
with challenges to both sensitivity and accuracy (Steijger et al., 2013). However, recent 
alignment-free quantifications allow rapid quantification of isoform abundances in addition to 
estimation of the associated uncertainty in assigning short reads to individual isoforms (Bray et 
al., 2016; Patro et al., 2017). Hybrid approaches that utilise initial isoform abundance 
estimations to infer relative usage of alternative splice events also exist, including the recently 
developed SUPPA2 (Trincado et al., 2018). Methods that aim to quantify individual splicing 
events, rather than full isoforms, may be further divided into those that focus upon the 
quantification of exons [e.g. DEXseq (Anders et al., 2012) or DDGseq (Wang et al., 2013)], 
splice junctions [e.g. MAJIQ (Vaquero-Garcia et al., 2016) or Leafcutter (Li et al., 2018)], or a 
combination of the two [e.g. SplAdder (Kahles et al., 2016), VAST-TOOLS (Tapial et al., 2017), 
or rMATS (Shen et al., 2014)]. Usage of junction-spanning reads is valuable in that such reads 
provide direct evidence for the usage of a particular splicing event. However, these reads 
represent only a reduced fraction of a total read library.  
 
Commonly used metrics for quantification of alternative splicing are percent spliced in (PSI or 
Y), which quantifies the relative inclusion of a given exon or splicing event, and the selection 
or splicing index, which is a measure of the relative usage of a junction or exon when 
compared to the whole gene (Carazo et al., 2018). MAJIQ employs a percent selected index 
(also PSI) which captures the relative usage of each splice junction with all of its potential 
partner acceptor/donor junctions (Vaquero-Garcia et al., 2016). Many of these more recent 
methodologies demonstrate performance improvements over their predecessors [e.g. (Kahles 
et al., 2016; Shen et al., 2014)]. However, new approaches continue to be developed, and a 
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true gold standard approach cannot necessarily said to have been established (Carazo et al., 
2018). 
1.4.2 Profiling RNA-protein interactions 
To understand the regulation of alternative splicing, the pre-mRNA targets of regulatory 
splicing factors must be determined. Methods for probing RNA-protein interaction may be 
RNA or protein-centric. A long-standing methodology is the gel electrophoresis mobility shift 
assay (EMSA), which involves combining mixtures of protein and nucleic acid (Ryder et al., 
2008). Electrophoresis is used to separate these mixtures through a gel, whereby protein-RNA 
complexes will travel a different distance than un-complexed proteins or RNA, due to shifts in 
size, charge, and shape. Other methods involve use of UV cross-linking followed by protein 
immunoprecipitation, broadly termed cross-linking immunoprecipitation (CLIP). These 
methods facilitate a high-throughput a approach when combined with RNA-seq, such as RNA 
immunoprecipitation sequencing (RIP-seq) (Keene et al., 2006), and more recently, high-
throughput cross-linking and immunoprecipitation sequencing (CLIP-seq) based methodologies 
(Hafner et al., 2010; Huppertz et al., 2014; Licatalosi et al., 2008; Van Nostrand et al., 2016). 
These approaches allow identification of in vivo protein-bound transcripts, of which a subset 
will represent functional interactions in the regulation of splicing or other RNA processing 
events. The identified RNA sequences are generally much longer than the RBP-bound region, 
which may only be several nucleotides (Carazo et al., 2018). However, bioinformatic (Zhang 
and Darnell, 2011) or methodological (Huppertz et al., 2014) adaptations to CLIP-seq allow 
individual nucleotide resolution of bound sites to be achieved. The resultant sets of protein-
bound sequences can be used for determining RBP binding models, which in turn facilitate 
prediction of RBP binding potential in a given biological system without the use of further 
experimental work (Marchese et al., 2016). Alternatively, in vitro approaches based upon 
determining protein-RNA hybridisation efficiencies against pools of oligonucleotides can be 
used as input for the inference of such RBP binding models. These techniques include 
RNAcompete (Orenstein et al., 2016; Ray et al., 2013), RNA Bind-n-Seq (RBNS) (Burge et al., 
2018), and RNA-SELEX (Jolma et al., 2010), which have all been used for high-throughput 
determination of both primary and secondary RNA structural preferences. 
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1.4.3 Motif models for RNA-binding proteins 
RBPs show diverse RNA binding preferences, with multiple layers of sequence information 
determining affinity towards a given sequence. Reflecting this complexity, a wide range of 
approaches for the modelling of RBP binding preferences have been developed (Sasse et al., 
2018). Classical methods for describing sequence motifs include the consensus sequence and 
the position specific scoring matrix (PSSM) (Stormo, 2000). PSSMs represent the relative 
frequencies of consecutive nucleotides in a linear sequence, with each position in the motif 
considered independently. The use of PSSMs can be extended to capture position 
interdependencies in the form of dinucleotides (diPSSM) (Riley et al., 2015), with more 
complex models capturing tri-nucleotide dependencies and higher-order interactions (Siebert 
and Söding, 2016). A number of implicit models based upon machine learning approaches have 
recently been developed which show high performance and are able to capture various higher-
order complexities (Alipanahi et al., 2015; Budach and Marsico, 2018; Ghandi et al., 2014). 
Similarly, preferences towards binding RNA secondary structures are represented using 
models of varying complexity, from site-specific structural models describing a single structure 
per binding site, to models capturing higher-order position-specific structural preferences 
(Sasse et al., 2018). 
1.4.4 Inference of regulatory splicing factors  
1.4.4.1 Motif enrichment analysis 
In order to fully understand the splicing network underlying a biological system, the key 
regulatory splicing factors must be determined. A common goal in the study of alternative 
splicing is therefore the prediction of which splicing factors and associated binding elements 
regulate alternative splicing in a given system. Various strategies that incorporate high-
throughput splicing measurements with splicing factor binding data have been employed to 
this end (Carazo et al., 2018). A common strategy involves scanning RNA sequences 
surrounding alternatively spliced regions for the presence of potential regulatory elements, 
often through the use of PSSMs describing known splicing factor binding preferences. These 
binding predictions are then combined with an analysis of differential splicing of these regions 
under biological conditions of interest (Figure 1-6). Potential regulatory splicing factors can 
then be identified through analysis of over-representation or enrichment. Assessing for motif 
enrichment commonly involves comparing the distribution of predicted splicing factor binding 
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sites in differentially spliced regions relative to background genomic regions. Over-
representation of motifs for a given splicing factor then provides evidence of a putative 
regulatory relationship (Figure 1-6).  
 
Figure 1-6. Schematic of a typical motif enrichment analysis workflow. (A) Alternative splicing 
events are defined genome-wide. (B) Regions surrounding alternative splice junctions are 
scanned for the presence of known or de novo identified motifs. (C) Usage of alternative 
splicing events is quantified per sample. (D) Differentially spliced events between biological 
conditions of interest are identified. (E) Enrichment for motifs within differentially spliced 
events is tested for using one of a variety of statistical approaches.  
 
Such a motif enrichment workflow has been employed to study alternative splicing in diverse 
systems. Chen et al. studied alternative splicing during differential lineage commitment of 
hematopoietic stem cells (Chen et al., 2014). They employed a custom approach to identify 
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differentially spliced events, and scanned the corresponding exons and upstream and 
downstream introns separately for the presence of motifs representing binding preferences 
for 85 RBPs identified through a 2013 RNAcompete study conducted by Ray et al. (Ray et al., 
2013). Enrichment for motifs in sequences flanking differentially spliced events was assessed 
via hypergeometric testing, and allowed identification of putative regulators of splicing during 
hematopoietic stem cell differentiation. Danan-Gotthold et al. identified a group of 
differentially spliced exons that were conserved across multiple human cancers and which 
were enriched for motifs of several splicing factors (Danan-Gotthold et al., 2015). Differentially 
spliced cassette exons were used for a de novo motif identification analysis before mapping 
the identified motifs to known splicing factor motifs and assessment for enrichment via 
hypergeometric testing. Validating this approach, knockdown of the identified splicing factors 
was found to result in a similar set of differentially regulated exons to those characterising the 
profiled cancers. Similarly, Sebestyén et al. found repeated enrichment for several splicing 
factor motifs amongst differentially regulated cassette exon regions in 11 human tumour types 
(Sebestyén et al., 2016). One of the identified splicing factors, MBNL1, was validated for a role 
in contributing to the cancer-related splicing landscape via extensive experimental follow-up. 
Sebestyén et al. used the motif scanning tool FIMO (Bailey and Elkan, 1994) – originally 
developed for analysis of DNA motifs, with the Ray et al. RNAcompete PSSM data (Ray et al., 
2013) for motif identification, before motif enrichment testing was performed with a custom 
approach. Finally, Zhang et al. used RSAT (Nguyen et al., 2018) to perform both motif 
identification and enrichment analysis for the identification of regulatory splicing factors in 
MYCN driven neuroblastoma (Zhang et al., 2016). RSAT calculates expected motif occurrences 
using a background model which are then compared to the observed frequencies in sequences 
of interest to allow P-value estimation for motif over-representation (van Helden et al., 1998).  
 
An alternative approach named CoSpliceNet was developed by Aghamirzaie et al. (Aghamirzaie 
et al., 2016). Their approach centred round identifying modules of co-expressed transcript 
isoforms and potential driver splicing factors, rather than directly measuring differential 
splicing. The MEME suite (Bailey et al., 2009) was then used for identification of de novo motifs 
separately in flanking upstream and downstream exonic and intronic regions of transcripts 
from each of the defined modules. The identified motifs were associated with splicing factors 
in a post-hoc fashion, which facilitated the identification of both known and candidate novel 
regulators of Arabidopsis thaliana embryonic development.  




Other methods for the identification of splicing regulatory features have incorporated a 
comparative genomics approach (Sugnet et al., 2006; Voelker and Berglund, 2007; Yeo et al., 
2007). Voelker and Berglund employed a comparison between seven eutherian mammals to 
identify conserved k-mers flanking splice junctions, a subset of which were found to be 
enriched in alternatively spliced regions (Voelker and Berglund, 2007). Again, a number of 
these conserved and putative splicing regulatory k-mers could then be mapped to known RBP 
motifs in a post-hoc manner.  
 
1.4.4.2 Regression-based approaches 
A further class of methods is focused on regression modelling of isoform or splicing 
quantifications as a function of sequence features (Das et al., 2007; Wen et al., 2013; Xin Wang 
et al., 2008; Zhang et al., 2012). These approaches tend to employ a de novo motif 
identification process in which a large sequence space is initially considered before potential 
functional sequences are defined which can then be mapped to experimentally defined motifs 
where possible. Xin Wang et al. used splicing microarrays to identify a set of differentially 
spliced cassette exons between human liver and heart as the basis for their approach (Xin 
Wang et al., 2008). Upstream and downstream exonic and intronic regions flanking each splice 
junction were considered as separate regulatory regions which were scanned for their 
frequency of all possible hexamers. Exon inclusion levels were then modelled as a linear 
function of the frequencies of each hexamer, with the functional effects of hexamers 
estimated as coefficients in the model. This model was run in an iterative process with a 
random selection of hexamers included each time, and performance of the model assessed via 
a least squares approach, minimising the difference between observed and predicted exon 
inclusion levels, and providing a method for hexamer scoring. The top 15 hexamers were 
considered as potential tissue-specific regulatory motifs, and these included known binding 
motifs for several splicing factors with previously identified roles in regulating alternative 
splicing in cardiomyocytes. Wen et al. implemented a similar regression-based approach, again 
focused on hexamers in putative regulatory regions flanking splice junctions of alternatively 
spliced exons across human tissues, but additionally considered potential combinatorial effects 
between pairs of splicing regulatory elements (SREs) (Wen et al., 2013). Due to the vast 
number of potential pairwise combinations of hexamers, a multi-stage model was used. 
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Initially, filtering of hexamers with low correlations to exon inclusion rates was performed, 
followed by further selection of potential SREs and SRE-pairs with an adaptive lasso regression 
approach. Significance of each SRE/SRE pair was then assessed using the ordinary least squares 
method. Using this workflow, the authors were able to predict sets of SREs and SRE-pairs that 
potentially contributed to tissue-specific alternative splicing. Again, the predicted SREs 
contained cases of known splicing factor motifs with previously recognised roles in regulating 
tissue-specific splicing, in addition to examples of predicted SRE pairs that have been 
previously demonstrated to exhibit combinatorial co-operative effects in regulating exon 
inclusion. 
 
These regression-based methods have several potential strengths over motif enrichment-
based procedures. Firstly, effects of different motifs are estimated as coefficients in a single 
model, and combinatorial effects may be explicitly modelled, rather than considering each 
motif in isolation as with an enrichment procedure. Further, since motif enrichment 
approaches rely solely on sequence data and require selection of a background sequence set 
for comparison, the results are sensitive to the choice of this background (Wen et al., 2013). 
Indeed, commonly applied corrections for underlying sequence composition such as GC 
content may introduce bias to the analysis by excluding AU or GC rich regulatory sequences 
(Wen et al., 2013). Further, since regression-based approaches directly incorporate 
quantitative data on splicing into the model, they are able to identify sequences which have a 
direct correlation with alternative splicing, and as such have been argued to be less sensitive to 
biases introduced by underlying sequence composition (Wen et al., 2013). 
1.4.5 Developing methods for the inference of regulatory splicing factors 
1.4.5.1  Motif Activity Response Analysis (MARA) 
In 2009, the FANTOM Consortium published an approach for the integrative modelling of 
motifs termed Motif Activity Response Analysis (MARA) (The FANTOM Consortium et al., 
2009). MARA is an approach for the inference of regulatory transcription factors using 
genome-wide gene expression quantifications and motif-based predictions of transcription 
factor binding sites in gene promoters. Since its original publication, MARA has been further 
developed and released as a web-based automated analysis tool (Balwierz et al., 2014). The 
MARA approach uses as input a matrix describing genome-wide counts of potential 
transcription factor binding sites within gene promoter regions. Promoter regions were 
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defined using information on transcription start sites acquired through deepCAGE sequencing 
data (Balwierz et al., 2009). Kilobase regions surrounding these transcription start sites are 
analysed for the presence and frequency of transcription factor binding sites using the MotEvo 
algorithm (Arnold et al., 2012) with 190 PSSMs that represent ~350 transcription factors. 
MotEvo considers sequence conservation levels across seven mammals combined with a 
model of constraints surrounding transcription factor binding site evolution. The result is a 
matrix with a score per promoter-motif pair which describes the sum of probabilities for all 
identified transcription factor binding sites within each promoter. This matrix is used as input 
for the MARA algorithm along with a corresponding matrix of promoter-matched gene 
expression quantifications. MARA employs a linear regression approach whereby the 
expression at each promoter is assumed to be a linear function of the binding site frequencies 
for all measured motifs/transcription factors. As with linear modelling approaches applied to 
splicing variation, the parameters that are estimated are coefficients that describe the activity 
of each motif in contributing to variation in the outcome variable. In this case, such “motif 
activities” describe the relationship between motif frequency at promoters and the average 
effect on gene expression across the genome, with the effects of different motifs being 
additive. Formalised, the equation that is solved is: 
 
Equation 1. The MARA model. 




where Ep,s is the sample and promoter specific expression, As,m is the sample and motif specific 
activity that is estimated, and Np,m is the number of motif counts per-motif at each promoter. 
This model is solved using singular value decomposition and an 80/20 cross-validation approach, 
whereby 80% of promoters are used as a training set and predictive performance on the 
remaining 20% is optimised whilst a Bayesian prior distribution is used to avoid overfitting. Ridge 
regression has also been used to solve this equation (Madsen et al., 2018). Both of these 
approaches are suited for the handling of sparse or collinear input data (Mandel, 1982; Zou and 
Hastie, 2005) - common features of motif count matrices owing to both the frequency of zero 
counts for transcription factor binding sites in some promoters, and the high correlations of 
count distributions for pairs of similar motifs. The fitted model typically explains a small but 
significant percentage of the variance in gene expression (Balwierz et al., 2014). However, the 
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true aim of MARA is in the estimation of motif activities, which represent the relative 
contribution of the motif-associated transcription factors to gene expression in a given biological 
sample. Changes in motif activity across samples from different biological conditions, such as 
from a time series experiment, provide evidence of potential regulatory roles in the control of 
















MARA has been applied to a wide-range of biological systems and has consistently been shown 
to recover known key regulators, in addition to predicting novel regulators (Balwierz et al., 
2014). In its seminal application (The FANTOM Consortium et al., 2009), MARA was used to 
infer the identity, time-dependent activity profiles, and target genes for candidate 
transcription factor regulators of differentiation in the THP-1 cell line. A panel of 28 top 
Figure 1-7. Example of MARA as applied to a time series of endothelial cell inflammatory 
response induced by tumour necrosis factor. Sequence logos depicting PSSMs for the 
three most significant motifs identified are shown. Two of the motifs are associated with 
binding of several potential transcription factors, as depicted. Error bars show standard 
deviations of inferred activities. The temporal profile of these motifs is suggestive of an 
active role of the associated transcription factors in driving TNF-induced gene expression 
changes. IRF1 and NF-κ 
B are known regulators of the endothelial inflammatory response, validating the predicted 
activities 215. As published in 209. 
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candidates were selected for experimental follow-up via small interfering RNA (siRNA) 
knockdown. A majority of the knockdown-induced modulations to gene expression were in 
line with the actions of these transcription factors as predicted by MARA, illustrating the value 
in the MARA approach. MARA has several strengths as a regression-based motif analysis 
strategy. Firstly, in estimating motif activity, MARA leverages the full, genome-wide data 
captured through an RNA-seq or microarray experiment, and does not require definition of a 
subset of differentially regulated events through thresholding of P-values. Additionally, MARA 
is centred on the estimation of motif activities per sample, facilitating the inference of relative 
activities of regulatory factors across biological conditions. The majority of regression-based 
methods applied for inference of regulatory SREs employ a de novo sequence analysis method. 
MARA, with a focus on the use of experimentally defined PSSMs associated with regulatory 
factors ab initio, identifies motifs of interest that are more directly interpretable. In contrast, 
de novo SRE/motif approaches lead to the generation of large numbers of candidate motifs of 
unknown function, some of which may influence splicing through indirect mechanisms such as 
through modulating the local sequence context surrounding splicing factor binding sites or by 
influencing RNA secondary structures. Finally, MARA is flexible with regards to the length of 
input motif, and does not require selection of a k-mer length in order to narrow the number of 
searched sequences to a tractable space. 
1.4.5.2 Proposing a novel analysis approach – Splicing Motif Activity Response 
Analysis 
To date, MARA has been applied to model the regulation of gene expression by transcription 
factors and microRNAs, in addition to the regulatory roles of transcription factors in 
influencing chromatin state (Balwierz et al., 2014) or enhancer occupancy (Madsen et al., 
2018). However, MARA has not been leveraged for the study of splicing thus far. Whilst various 
mechanistic differences exist between the control of alternative splicing and of transcription, 
there is a commonality between the processes that should render splicing amenable to 
investigation with MARA. As variation in gene expression is in part driven by the presence of 
transcription factor binding sites within gene promoters, variation in splicing is in part driven 
by the occurrence of splicing factor binding sites flanking alternative splice junctions, and by 
the concerted tissue or condition specific actions of these splicing factors.  
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1.5 Thesis aims 
Alternative splicing is both widespread throughout the genome and highly regulated across 
tissue-types and within biological processes from development to disease. For instance, the 
splicing of several loci critical to proper development and function of CD4+ T cells, which are 
key regulators of the cellular adaptive immune response, is well described (Yabas et al., 2015). 
Genome-wide patterns of differential splicing in CD4+ T cells, such as upon stimulation of the 
TCR, are consistently observed in in vitro studies (Ip et al., 2007; Martinez et al., 2012). The 
elucidation of how these networks of gene splicing are controlled through the actions of 
splicing factors remains an important goal, and will ultimately improve understanding of how T 
helper cells act to influence the adaptive immune response. CD4+ T cells are also the primary 
host cell of the HIV-1 retrovirus. The lifecycle of HIV-1 is dependent upon the interactions 
between viral components with numerous host proteins. Generation of new viral particles 
relies upon the host gene expression pathway, and thus involves the actions of RBPs in 
regulating processes such as the splicing, nuclear export, and translation of HIV-1 transcripts 
(Karn and Stoltzfus, 2012). Therefore, splicing factors and other RBPs are common HIV-1 
dependency factors. The study of such HIV-1 dependency factors, in addition to host 
restriction factors with HIV-1 repressive properties, represents a potential avenue for 
development of new therapeutic strategies.  
 
RNA-seq has become one of the most powerful approaches to studying alternative and 
differential splicing due to its transcriptome-wide and high-throughput properties, and the 
capacity to uncover novel splicing variants. In order to fully characterise the programmes of 
differential splicing identified through RNA-seq studies, knowledge of the mechanisms of 
spliceosomal control are needed. To this end, a common analysis strategy is the integration of 
RNA-seq-derived differential splicing profiles with models of RBP binding preferences, 
commonly in the form of PSSMs (Carazo et al., 2018). This strategy allows inference of putative 
regulatory splicing factors in a given biological system. In the analogous field of transcription 
factor biology, such strategies are arguably more sophisticated, whereby quantitative models 
of transcriptional activity and transcription factor binding site predictions are commonly 
applied to infer key regulatory interactions (Balwierz et al., 2014; The FANTOM Consortium et 
al., 2009). Improved methods for the inference of regulatory splicing factors could be applied 
to any field of biology in which the mechanisms of differential splicing are of interest.  
Chapter 1 Introduction 
49 
 
Here, I propose to implement a workflow for the application of MARA to model splicing factor 
motif activity (S-MARA) and to assess the viability of this approach for the inference of 
regulatory splicing factors within a given biological system. The power of MARA in predicting 
regulatory transcription factors has led to its widespread use, and the strengths of the 
approach warrant an investigation into its application to the study of splicing. The 
performance of S-MARA will be assessed using a large-scale knockdown project resource 
generated through the ENCODE project (Burge et al., 2018; Davis et al., 2018; Nostrand et al., 
2018). S-MARA will be compared to a motif enrichment analysis approach - which has been a 
frequently employed method in recent years for inference of alternative splicing regulators in 
a given biological system (Carazo et al., 2018). Additionally, to investigate the value of S-MARA 
in uncovering both known and promising novel candidate regulatory splicing factors, I will 
apply the approach to a timecourse of CD4+ T cell activation and polarisation. As discussed, 
the CD4+ T cell activation process is characterised by widespread regulation of alternative 
splicing. However, the function and regulatory factors controlling this programme of 
alternative splicing are only partially understood, and the further elucidation of this splicing 
network is an ongoing research aim. 
 
In this thesis, I aim to analyse RNA-seq datasets to understand how alternative splicing is 
regulated through the actions of RNA binding proteins and cis-acting RNA elements. I propose 
that Motif Activity Response Analysis may be effectively applied for the inference of regulatory 
splicing factors. I therefore aim to apply this, as well as additional methodologies, to study the 
actions of RNA-binding proteins in the context of CD4+ T cell activation and the HIV-1 lifecycle.  
 
The specific aims of this thesis are: 
 
1. Implement an analysis workflow to perform Splicing Motif Activity Response Analysis (S-
MARA).  
2. Benchmark the performance of S-MARA in inferring regulatory splicing factors using 
splicing factor knockdown-RNA-seq data.  
3. Further understanding of the roles of key splicing factors in regulating alternative splicing 
in CD4+ T cells: 
3.1. Apply S-MARA to predict known and novel candidate regulators of splicing during the 
CD4+ T cell activation process.  
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3.2. Profile the role of the RNA-binding protein Sam68 in regulating alternative splicing in 
CD4+ T cell activation.  








Chapter 2. Materials & Methods 
2.1 RNA-seq pre-processing  
Initial quality control of RNA-seq FASTQ files was performed using FastQC v0.11.5 (Simon, 
2010), followed by compilation of individual quality reports with MultiQC v1.4 (Ewels et al., 
2016). The Trim Galore! wrapper to Cutadapt v0.4.2 (Martin, 2011) was used for removal of 
adapter sequences and low quality (phred score < 20) read ends, with resulting reads less than 
20nt in length discarded. Read alignments were performed with HISAT2 (Kim et al., 2019) using 
the HISAT hg38 index - an expansion of the hg38 reference genome to include information on 
Refseq transcripts and common SNPs. Alignment-free quantifications were performed for the 
Sam68 knockdown RNA-seq data, using Kallisto v0.42.4 (Bray et al., 2016) against GENCODE 
version 27 basic annotation transcripts. Kallisto sequence bias correction was turned on, and 
the default value of 100 bootstraps was used for estimates of quantification variance.  
2.2 Statistical analysis and data visualisation 
Unless otherwise stated, statistical analyses were performed using R v3.6.1 (R Core Team, 
2019). Principal component analysis (PCA) was employed via the “prcomp” base R function, 
and linear modelling for PCA regression was performed with the “lm” base R function. Analysis 
and visualisation of intersections between gene or junction sets resulting from differential 
analyses was performed using the SuperExactTest R package (Wang et al., 2019). Heatmaps 
were created using the pheatmap R package v1.0.12 (Kolde, 2019). Visualisation of local 
splicing variations (LSVs) and junction PSIs was performed with the MAJIQ “voila” module 
(Vaquero-Garcia et al., 2016). The motifStack R package (Ou et al., 2018) was utilised for 
visualisations of PSSMs as sequence logos. Finally, analysis of receiver operating characteristic 
(ROC) area under the curve (AUC) was performed using the pROC R package (Robin et al., 
2011). 95% confidence intervals of the AUC were calculated using a stratified bootstrapping 
approach according to default parameters of the pROC package ‘roc’ function. All other plots 
were generated using the ggplot2 R package (Wickham, 2012). 




2.3 Differential splicing analysis 
An initial comparison of several splicing analysis tools was performed: SplAdder (Kahles et al., 
2016), SUPPA (Alamancos et al., 2015), VAST-TOOLS v1.1.0 (Tapial et al., 2017), and MAJIQ 
v1.1.7a (Vaquero-Garcia et al., 2016). SplAdder was run using the GENCODE v25 
comprehensive reference annotation, with the highest confidence level of 3 used for splice 
event detection. SUPPA was used to define alternative splice events (specifically exon skipping, 
alternative 3’/5’ splice site usage, mutually exclusive exon usage, or intron retention) from 
Kallisto derived transcript quantifications, prior to differential splicing analysis. For analysis 
with VAST-TOOLS, read data were aligned using the VAST-TOOLS aligner against the custom 
VAST database of human splicing variants; before quantification and differential splicing 
analysis was performed with VAST-TOOLS “count events” and “diff” functions. MAJIQ was 
selected for further use after initial comparisons with other splicing tools. The recommended 
reference genome - GRCh38.p8, was used in combination with RNA-seq sample data to define 
LSVs with the MAJIQ “build” module. MAJIQ differential splicing analysis was performed with 
the “dpsi” and “dvoila” modules using default parameters, such as for minimum numbers of 
quantifiable reads per sample for inclusion of each LSV. 
2.4 Differential gene expression analysis 
The Kallisto-Sleuth pipeline (Pimentel et al., 2017) was used for differential gene expression 
analysis, with the exception of the ENCODE data (see below). Kallisto (Bray et al., 2016) uses a 
pseudo-alignment approach allowing quantification directly from FASTQ files. Further, the 
speed of pseudo-alignment allows a bootstrapping procedure which facilitates estimation of 
quantification uncertainties. These estimates of uncertainty are incorporated as additional 
variance parameters in downstream differential gene expression analysis by the accompanying 
analysis tool Sleuth. The Kallisto-Sleuth approach was used for analysis of the Sam68 data 
(Chapter 5) and CpG HIV-1 data (Chapter 6), and no analysis of gene expression was performed 
in Chapter 4, where the focus was exclusively on splicing. For the analysis of ENCODE project 
knockdown RNA-seq (Chapter 3), pre-computed gene expression counts were obtained via the 
ENCODE portal (Davis et al., 2018) (ENCODE accessions in Appendix 8.1). The ENCODE analysis 
pipeline utilizes RSEM (Li and Dewey, 2011) for expression quantification, using STAR-aligned 
(Dobin et al., 2013) BAM files as input. For convenience, these pre-computed gene expression 
quantifications were used, rather than additionally running Kallisto on these ENCODE data. 




Since Sleuth is designed for use with Kallisto-derived gene quantifications, and requires 
estimates of the uncertainty of quantification, an alternative differential gene expression 
analysis approach was employed for these data. To this end, limma (Ritchie et al., 2015) was 
applied for analysis of differential gene expression with these ENCODE samples, directly using 
the gene-level counts downloaded from the ENCODE portal. Benjamini-Hochberg correction 
was applied for calculation of all false discovery rates (FDR). 
2.5 Gene ontology enrichment analysis 
Gene Ontology (GO) enrichment analysis was performed against the “Biological Process” 
ontology (2019) with the gProfileR R package v0.7 (Reimand et al., 2018). Analysis was restricted 
to ontology categories with fewer than 100 gene members. The gene set counts and sizes (g:SCS) 
(Reimand et al., 2007) framework for multiple testing correction was used, and resulting 
significant terms were hierarchically filtered with the “moderate” stringency setting. 
Background gene sets were defined as genes expressed above a minimum threshold: for analysis 
of Sam68 knockdown data, a threshold of one transcripts per million (TPM) in at least one 
sample was used, for analysis of CD4+ T cell timecourse data, an alternative filtering strategy 
based upon quantifiable LSVs was used – see “Analysis of CD4+ T cell Activation and Polarisation 
Timecourse Data” section. To define related groups of enriched GO terms as depicted in the GO 
enrichment results figure (Figure 4-3), pairwise semantic similarity between significant terms 
was obtained via the GOSemSim R package v3.10 (Yu et al., 2010) using the “Wang” metric 
(Wang et al., 2007) based upon analysis of the GO graph structure. Hierarchical clustering was 
performed using these similarity scores, and terms were grouped with a tree cutting algorithm 
(Langfelder et al., 2008). 
2.6 Splicing Motif Activity Response Analysis (S-MARA) workflow 
2.6.1 Compilation of splicing factor motifs 
In order to utilise a motif-based approach to study splicing, various splicing factor motifs in the 
form of PSSMs were compiled. RBPmap (Paz et al., 2014) is an RNA motif mapping tool which 
utilises a motif database consisting of 92 human motifs defined by Ray et al. through use of 
RNAcompete - a high-throughput in vitro assay (Ray et al., 2013), in addition to 26 motifs from 
other heterogeneous experimental sources. These PSSMs were obtained as part of the 
RBPmap v1.1 package (obtained from http://rbpmap.technion.ac.il/). These data were 




combined with 131 motifs derived through a 2018 RNA-Bind-n-Seq (RBNS) study (Burge et al., 
2018) (obtained through communication with author – Daniel Dominguez). 
 
RBP motifs were filtered against a custom-defined list of 122 splicing factors. A 2014 census 
(Gerstberger et al., 2014) defined 1542 human RBPs, of which 692 were defined as primarily 
binding to mRNA targets. Of these, 247 genes were annotated with at least one of a number of 
defined GO “Biological Process” terms relating to roles in alternative splicing, as investigated 
through the biomaRt R package (Durinck et al., 2009). The selected splicing terms of interest 
were: "RNA splicing", "mRNA splicing, via spliceosome", "regulation of alternative mRNA 
splicing, via spliceosome", "regulation of RNA splicing", "mRNA splice site selection", "positive 
regulation of mRNA splicing, via spliceosome", "alternative mRNA splicing, via spliceosome", 
"regulation of mRNA splicing, via spliceosome", "positive regulation of RNA splicing", "mRNA 
5'-splice site recognition", "mRNA 3'-splice site recognition", "pre-mRNA 3'-splice site binding", 
"negative regulation of RNA splicing", "pre-mRNA 5'-splice site binding", and "mRNA cis 
splicing". At this stage, 135 RBPs for which the major function is in regulating mRNA translation 
(i.e. translation initiation factors or poly(A) binding proteins) or cytoplasmic RNA stability were 
removed from the splicing factor list. Several additional splicing factors were then manually 
added to this list (ELAVL3, ELAVL4, HNRNPAB, HNRNPCL1, HNRNPDL, HNRNPUL2, MATR3, 
TIAL1, SRRM3, and EWSR1). The resulting set of 122 splicing factors is in Appendix 8.3. 
 
Intersecting this splicing factor list with the set of RBP motif data resulted in 148 motifs 
representing binding preferences for 74 splicing factors (Appendix 8.3). This splicing factor-
motif set contained a number of redundant motifs, including cases in which different 
experimental approaches produced highly similar but non-identical PSSMs for a given splicing 
factor. To address this redundancy, splicing factor-motifs were further processed with the 
MotIV v1.39.0 R package (Mercier and Gottardo, 2018). Initially, motif PSSM information 
content was calculated and trailing edges with < 0.3 bits of information were trimmed. Motifs 
were compared in a pairwise manner using the MotIV “motifDistances” function. In brief, 
PSSMs were aligned via the Smith-Waterman local alignment algorithm. Per nucleotide 
Pearson correlation coefficients were then computed from the aligned PSSMs, before taking 
the average correlation across the PSSM as a similarity measure for each pair of motifs. The 
resulting correlation coefficients were then used for hierarchical clustering with the “average” 
agglomeration method. Finally, the resulting distance tree was used to define clusters of 




motifs as those with in-group distances (1 – average Pearson correlation coefficient) < 0.001. 
Motifs within each group were aligned and averaged per nucleotide position to generate 
consensus motifs via the MotifStack R package (Ou et al., 2018). This process resulted in a final 
set of 103 splicing factor motifs (see Results Figure 3-2). 
2.6.2 Generation of motif count matrices 
For the prediction of potential splicing factor binding sites, genomic regions of interest flanking 
splice junctions were first defined. MAJIQ quantifies relative splice junction usage as a percent 
selection index (PSI), which describes the relative usage of a single splice donor or acceptor 
with each of the possible pairing splice acceptor/donors in an LSV (Figure 2-1). Each PSI value 
therefore describes the usage of a fixed junction with one of several variable junctions (Figure 
2-1). The RNA sequences flanking each variable junction potentially contain motifs that 
promote the binding of splicing factors and influence the relative usage of this splice junction, 
and thus its PSI. For each variable junction, these “regulatory regions” were defined as the 
area spanning 300 nt upstream-and-300 nt downstream of the junction (600 nt in total). This 
range corresponds with the region thought to contain the majority of SREs based upon 
previous investigations (Barash et al., 2010; Zhang et al., 2005). If a neighbouring exon 
boundary was less than 300 nt from a given variable junction, then it was used as the start/end 
point of that regulatory region instead (illustrated by the green splice junction in Figure 2-1). 
These regulatory regions were used to create FASTA sequence files of the corresponding hg38 
genomic sequence via the “getfasta” function of BEDTools v2.25.0 (Quinlan, 2014). Finally, 
these FASTA files were scanned for the presence of potential splicing factor binding sites using 
the command line implementation of RBPmap v1.1.0 with our custom-defined set of 103 
compiled splicing factor PSSMs. For each sequence, the cumulative number of motif matches 
with a probability < 0.001 relative to the default background model was calculated per motif 
using a sliding window approach. The resulting splice junction motif count matrix, in addition 
to the splice junction usage (PSI) matrix, was then provided as input to MARA. 





Figure 2-1. Schematic of an example local splicing variation and corresponding RNA regions 
scanned for the presence of splicing factor motifs. F = Fixed splice junction. V = variable splice 
junctions. Coloured motif search areas match the corresponding variable splice junctions. Red 
and blue variable junctions represent alternative 3’ splice sites. Red, blue, and purple junction 
search areas are 600 nt long. The green junction has a smaller motif search area (regulatory 
region), representing a case where flanking exon boundaries are closer than 300 nt from the 
variable junction. 
2.6.3 Motif Activity Response Analysis (MARA) 
The Integrated Analysis of Motif Activity and Gene Expression Changes of Transcription Factors 
(IMAGE) (Madsen et al., 2018) implementation of MARA was employed (version 1.1 as obtained 
from https://github.com/JesperGrud/IMAGE). Specifically, R code for the calculation of motif 
activity and target prediction was extracted from the “Regression.R” script. The estimation of 
motif activity was performed as detailed by the IMAGE authors (Madsen et al., 2018). In brief, 
the motif matrix is first centred so that the mean count for each motif is zero. The PSI matrix is 
logit transformed (with the “logit” base R function) to create unbounded values from the set of 
0-1 bounded PSI values, before per-sample centering and scaling is performed. Motif activities 
are calculated using ridge regression via the glmnet R package (Zou and Hastie, 2005). The use 
of motif count frequencies as predictors presents a problem of multi-collinearity, whereby 
similar motifs have similar count distributions. This in turn can present a problem of over-fitting 
when estimating motif activities. This problem motivates the use of ridge regression, in which 
an optimised regularization parameter (l), favours smaller β coefficients and reduces variance 
in a variance-bias tradeoff. Optimal l was determined through 10-fold cross-validation, whereby 
a 90%/10% split of junction data is iteratively used as a training/test set respectively. 
 




The original MARA model centres on gene expression values. A representation of the model that 
is solved for PSI values is as follows:  
 
Equation 2. Modelling splicing as a function of motif activities. 
𝑃𝑆𝐼𝑗 = 	&𝐴!,# ∙ 𝑁%,#
#
 
PSIj is the PSI at a specified junction, As,m is the per-sample per-motif activity that is estimated 
via ridge regression, and Nj,m is the number of motif counts per-motif per-junction. Resulting 
motif activity values were zero-centred prior to downstream analysis. 
 
IMAGE implements a “leave-one-out” analysis for inference of regulatory relationships between 
transcription factor-motifs and target genes. In this procedure, the above model is run in a 
reduced form in which the counts for the motif whose targets are to be identified are set to 
zero. Expressed as applied to splice junction data as herein, the difference in estimated PSIj 
accuracy (observed PSIj – estimated PSIj) between the full and reduced model is then calculated. 
Targets for each motif are then defined as those in which PSIj estimation accuracy is decreased 
in the full model, and for which motif counts are non-zero, with the decrease in estimation 
accuracy relative to the full model used as a score to represent the strength of association 
between each junction and motif. This procedure was applied for the prediction of splicing 
factor target splice junctions using the ENCODE knockdown data. Target splice junctions were 
predicted for each splicing factor motif using the above model applied to knockdown samples 
of the associated splicing factor along with all control samples, in a per-knockdown manner. This 
approached mirrored the analysis of splicing factor knockdown-induced differential splicing.  
2.7 Motif enrichment analysis 
Motif count enrichment analysis was performed against splice junction sets of interest defined 
through differential splicing analysis performed using MAJIQ. For each motif, count 
distributions were compared between junctions of interest and “background junction sets”, 
which consisted of all other splice junctions with evidence for use in the RNA-seq data, but 
which were not in the “group of interest”. One tailed Wilcoxon rank sum tests were used to 
test the probability of the null hypothesis that motif counts were not greater in the junction 
set of interest relative to background splice junctions. FDR correction was performed, and an 
FDR < 0.05 was taken as evidence that a given motif was over-represented (“enriched”) 




amongst splice junctions of interest, thus providing evidence of a potential regulatory role for 
the given splicing factor motif in the regulation of alternative splicing amongst those splice 
junctions. 
2.8 Analysis of ENCODE project RNA-binding protein knockdown data 
Table 2-1. ENCODE project shRNA-treated samples. 





K562 219 48 7 
HepG2 225 50 7 
 
Data describing shRNA knockdowns of 241 RBPs across two cell lines (HepG2 and K562) were 
obtained from the ENCODE data portal (Table 2-1). MAJIQ was applied to quantify per-sample 
LSVs genome-wide using pre-aligned BAM files (as available through the ENCODE portal), with 
default MAJIQ filters applied such as a minimum of three reads per-LSV per-sample. Additional 
filtering of LSVs was then performed, whereby only LSVs with sufficient read coverage to be 
quantifiable in at least 80% of samples per-cell-line were considered for downstream analysis 
with MARA. These ENCODE data were generated in 49 batches, and batch correction of PSI 
values was therefore performed via the “ComBat” function of the sva R package v3.32.1 (Leek 
et al., 2012). Analysis of significant changes in motif activity induced by RBP knockdowns was 
performed via Student’s t-test followed by FDR estimation. Linear modelling for predictors of 
significant knockdown-induced changes in motif activity was performed using the base R “lm” 
function. Further, a metric for quantifying the knockdown-induced change in motif activity 
across all 103 splicing factor-motifs (global change in motif activity) was defined. To this end, 
the Euclidean distance between vectors of motif activity between all pairwise combinations of 
control samples with knockdown samples was calculated. The average of these distances was 
then used to represent the global change in splicing factor motif activities. 
 




2.9 Analysis of CD4+ T cell activation and polarisation timecourse data 
Table 2-2. CD4+ T cell timecourse samples 
Condition Biological 
donors 
Time points (hrs) 
None/naive 3 0 
CD3 & CD28 stimulation plus Il-2 treatment 
(Th0) 
3 0.5, 1, 2, 4, 6, 12, 24, 48, 
72 
CD3 & CD28 stimulation plus IL-2 & IL-4 
treatment (Th2) 
3 0.5, 1, 2, 4, 6, 12, 24, 48, 
72 
 
FASTQ files were obtained from the Sequence Read Archive (Table 2-1). After alignments, BAM 
files from technical replicates were merged with the Picard-tools v1.113 “MergeSamFiles” 
function (obtained from http://broadinstitute.github.io/picard/). For the per-sample application 
of MARA, the full set of quantifiable LSVs and corresponding splice junctions for each sample 
were used as input (i.e. numbers of input LSVs/junctions varied somewhat per sample). For 
other analyses which make simultaneous use of data from multiple samples, a consensus set of 
LSVs was defined as those with non-zero variance in PSI, and with sufficient read data to be 
quantifiable in at least 50% of samples using MAJIQ default parameters.  
2.9.1 Definition of correlation modules from motif activities and junction PSIs 
In order to identify distinct profiles of temporal regulation across the timecourse of CD4+ T cell 
activation, a module analysis in the form of Weighted Gene Co-expression Analysis (WGCNA) 
(Langfelder and Horvath, 2008) was applied. WGCNA uses a correlation-based approach, and 
takes as input a correlation matrix which describes, for instance, the correlations of gene 
activities across a timecourse. These correlations are scaled by an optimized parameter in order 
to transform the topology of the resulting network to be ‘scale-free’, an observable property of 
many biological networks (Zhang and Horvath, 2005). Subsequently, modules of highly 
correlated genes can be identified through a hierarchical clustering-based approach, with the 
resolution of these modules adjustable according to several user-determined parameters. 
WGCNA is generally applied to gene expression estimates, but can equally be applied to other 
measures of gene activity such as splicing (Iancu et al., 2015). 
 




Motif activity was calculated through MARA as described. Motif activity values were then 
hierarchically clustered via average linkage of Euclidean distances, and the resulting distance 
tree was used to define modules with the “cutreeDynamic” algorithm (Langfelder et al., 2008) 
of the WGCNA R package. Minimum module size was set to three motifs, and the “deepSplit” 
parameter which determined sensitivity to cluster splitting, was also set to three. As the 
dimensionality of the splice junction PSI data was much greater, the full WGCNA workflow was 
employed via the “blockWiseModules” function to define co-splicing modules of splice 
junctions. The “signed hybrid” network type was used so that negatively and positively 
correlated junctions were grouped into separate modules. Initial module definition was 
performed with the “deepSplit” parameter set to 3, and a minimum module size of 30 junctions. 
Modules were summarised using the first principal component and, in keeping with WGCNA 
nomenclature, these values are referred to as eigenJunctions or eigenMotifs, for modules of 
junctions or motifs respectively. Pairs of modules with an eigenvalue Pearson correlation of >= 
0.75 were merged prior to further analysis.  
2.9.2 Statistical analysis of motif activity and junction PSI 
To model relationships between time after activation in CD4+ T cells and variables of interest 
(junction PSI, motif activity, eigenJunctions, and eigenMotifs), linear mixed effect spline 
modelling was performed via the lmms R package v1.3.3 (Straube et al., 2015). Null intercept-
only models were contrasted with full models in which coefficients for time-after-activation and 
cell type (Th0/Th2), or cell type-time interactions terms were fitted, allowing the significance of 
these experimental parameters in explaining the variables of interest to be assessed. Naïve CD4+ 
T cells were excluded from these statistical analyses since only a single replicate per donor (time 
point zero) was available for this condition. 
2.10 Sam68 knockdown experimental procedures 
Table 2-3. Samples used in Sam68 knockdown experiment. 
shRNA target Activation status Biological donors 
Sam68 (shRNA 1) Both resting & activated 3 
Sam68 (shRNA 2) Both resting & activated 3 
Both resting & activated Both resting & activated 3 
None/untransduced Both resting & activated 3 
 
N.B. Experimental work detailed below was performed by Laura Hidalgo. 





CD4+ T cells were isolated from peripheral blood mononuclear cells from three donors before 
in vitro culture and activation via CD3/CD28 stimulation to facilitate subsequent transductions 
(day 0). At day 1, cells were either 1) left untransduced as a control, 2) transduced with a 
control scrambled shRNA, or 3) transduced with one of two shRNAs targeted to the Sam68 
mRNA. The ΔLNGFR transduction tag system (Lauer et al., 2000) was used, which facilitated 
isolation of successfully transduced cells at day 5. After a further three days (at day 8), RNA 
was extracted from cells from each of the three conditions, which are now in a resting state 
having not been exposed to the activation stimulus for a number of days. On the same day, 
cells were re-activated via further CD3/CD28 stimulation, before final isolation of RNA from 
these re-activated cells a day later (day 9). RNA samples were then used for poly(A) selected 
RNA-seq using an Illumina TruSeq stranded mRNA library preparation kit following the 
manufacturer’s protocol. This resulted in a total of 24 RNA-seq libraries – 4 treatment 
conditions (untransduced, control shRNA, Sam68 shRNA 1, Sam68 shRNA 2), 2 activation states 
(resting, re-activated), and 3 donors (biological replicates). 
 
Analysis of resulting RNA-seq libraries was performed as described in specific Methods 
subsections – “RNA-seq pre-processing”, “Statistical analysis and data visualization”, 
“Differential splicing analysis”, “Differential gene expression analysis”, “Gene ontology 
enrichment analysis”, and “Motif enrichment analysis”. 
2.11 Analysis of the effects of introducing CpG dinucleotides to 
the HIV-1 genome 
Table 2-4. Samples used for analysis of HIV-1 CpG content. 










2.11.1 Introduction of CpG dinucleotides to the HIV-1 genome – experimental 
procedures 
N.B experimental work detailed below was performed by Irati Antzin-Andeutza and Mattia 
Ficarelli. Detailed further in (Ficarelli et al., 2020). 
 
The pHIV-1NL4-3 plasmid, which contains the HIV-1 proviral sequence from the pHIV-1NL4-
3 isolate (Adachi et al., 1986) was used for production of infectious HIV-1. Modified viral 
constructs HIV-1gag22-165CM, HIV-1gag22-261CM and HIV-1gag22-378CM were used, which have the 
designated sequences from the patented pHDMHgpm2 vector (Gray et al., 2005). These 
constructs contain modifications to the gag region which have increased the number of CpG 
dinucleotides whilst preserving coding sequence (codon modification). Additionally, a 
construct with CpGs introduced into env was used, HIV-1env88-561CM, which was produced as 
detailed in (Ficarelli et al., 2019). These viral constructs were used to transfect HeLa cells in 
order to generate infectious viral particles. 
 
For the production of ZAP knockout cell lines by CRISPR-Cas9, ZAP-targeting guide sequences 
were inserted into a lentivirus-based CRISPR plasmid. These plasmids were used to transfect 
HEK293T cells, and virus-containing supernatant was then harvested 48 h after transfection, 
and used to transduce HeLa cells in order to deplete ZAP. 
 
For analysis of the relative production of viral proteins and RNA, HeLa cells were transfected 
with either wild-type or CpG codon modified plasmids. The cells were lysed 48 h post-
transfection, and the medium was recovered for analysis of either proteins or RNA. To analyse 
HIV-1 protein abundance, virions were pelleted via centrifugation. The resulting pellets were 
then used as substrate for immunoblotting against HIV-1 p24Gag, gp160/120, or Hsp90 as a 
control. To analyse RNA abundance, RNA was extracted from media after cell lysis. 
Quantitative PCRs (qPCRs) were performed in triplicate. Genomic RNA was quantified using 
primers which specifically amplify the full-length unspliced RNA, whilst total RNA was 
quantified using primers which amplify all HIV-1 transcripts whether spliced or unspliced. To 
generate RNA-seq libraries, the Illumina TruSeq stranded mRNA library preparation kit was 
used, before sequencing was performed with the Illumina HiSeq instrument. 
 




The TZM-bl cell infectivity assay (Sarzotti-Kelsoe et al., 2014) was used to measure relative 
infectious viral particle production. To this end, supernatant was recovered from HeLa cells 48 
h post-transfection and used to infect TZM-bl cells overnight. Forty-eight hours post-infection, 
the cells were lysed, and the amount of infectious-virus production was measured as relative 
light units per second after induction of β-galactosidase using the Galacto-Star system.  
2.11.2 Analysis of RNA-seq libraries from HeLa cells transfected with CpG 
modified HIV-1 viruses 
RNA-seq reads were aligned to the human genome (hg38) and HIV-1 NL4-3 genomic RNA 
simultaneously using Hisat2. HIV-mapping junction spanning reads were isolated using 
regtools (Feng et al., 2018) to allow per-junction read counting. To visualise read data spanning 
specific splice junctions of interest, data from replicates were first merged using the Picard 
(http://broadinstitute.github.io/picard) “MergeSamFiles” function, before sashimi plots were 
generated using the Gviz R package (Hahne and Ivanek, 2016). Other aspects of the analysis 
were performed as described in specific Methods subsections: “Statistical analysis and data 
visualization”, and “Differential gene expression analysis”. 
 
Table 2-5. Data sources in this study. 
Description Associated 
paper/s 
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Chapter 3. Assessing the Performance of Motif Activity 
Response Analysis (MARA) Applied to Splicing Factor Biology 
3.1 Introduction 
MARA is a promising approach for inferring drivers of pre-mRNA splicing regulation within a 
given biological system. In order to apply MARA to the inference of splicing factor behaviour 
(S-MARA), a workflow must be implemented to generate the appropriate splicing-based input. 
When MARA is utilised to identify putative regulatory transcription factors, two sources of 
data are used: 1) genome-wide quantitative measurements (e.g. of gene expression), and 2) a 
matrix of matched motif counts representing potential regulatory factor binding sites (i.e. 
counts of transcription factor motif occurrences). Thus, to adapt MARA for analysis of 
alternative splicing, we have implemented a workflow to quantify genome-wide splicing 
variation from RNA-seq data, and to quantify splicing factor motif occurrences in RNA 
sequences flanking splice junctions. 
 
Additionally, MARA has been optimised and validated for the purposes of inferring 
transcription factor motif activity (Balwierz et al., 2014; Madsen et al., 2018; The FANTOM 
Consortium et al., 2009), but not splicing factor motif activity. Whilst there is an analogy in 
how both splicing and gene expression are regulated through the actions of proteins towards 
in cis motifs, there are also several differences between these processes which may be 
relevant to MARA. A pertinent example is that splicing factor motifs are often shorter; with 
lower information content than transcription factor motifs (Burge et al., 2018; Madsen et al., 
2018). In light of this, we assessed the ability of MARA to infer changes in splicing factor motif 
activities which reflect differential splicing across biological conditions. 
 
Recent work conducted through the ENCODE project has generated several hundred RBP-
knockdowns across HepG2 and K562 cell lines (Burge et al., 2018; Nostrand et al., 2018). This 
work provides an excellent resource for investigating the functional contribution of RBPs to 
gene expression and RNA regulation, and a number of the shRNA-induced knockdown targets 
were splicing factors. As such, these data present an opportunity to apply MARA to samples in 
which splicing factor activity has been experimentally altered through a reduction in gene 
expression. Further, these data represent splicing factors with a range of RNA binding 




preferences and motifs. The ability of S-MARA to link differential splicing with specific pre-
defined regulatory motifs was assessed. S-MARA was compared to a motif enrichment analysis 
approach, which is a commonly applied method for inference of regulatory splicing factors 
(Carazo et al., 2018; Chen et al., 2014; Sebestyén et al., 2016). 
 
The motif enrichment strategy is primarily chosen here to provide a baseline comparison for S-
MARA. However, assessing motif enrichment as a procedure for inference of regulatory 
splicing factors is also of interest in itself. To our knowledge, this is the first formal assessment 
of the performance of a splicing-based motif enrichment analysis in identifying regulatory 
splicing factors. 
3.2 Aims 
To understand the full gene expression programme underlying a given biological process 
requires knowledge of context-specific regulatory splicing factors. I propose that application of 
MARA to the analysis of RNA-seq data will allow inference of such regulatory splicing factors. 
Splicing MARA could be applied to any biological system in which alternative splicing is of 
interest. I therefore aim to: 
1. Implement a data processing workflow to generate splicing-based input matrices for 
MARA. 
2. Assess the ability of MARA to infer changes in splicing factor motif activity induced 
through knockdown of splicing factors. 
3. Contrast results from S-MARA with a motif enrichment approach based on differential 
splicing analysis followed by motif enrichment testing. 
3.3 Results 
3.3.1 Preliminary investigation of splicing analysis tools and compilation of splicing 
factor motifs 
3.3.1.1 Comparison of RNA-seq differential splicing analysis tools 
An ever-increasing number of approaches for RNA-seq based differential splicing analysis exist. 
Since there is not an established gold standard per se (Carazo et al., 2018; Ding et al., 2017; 
Hooper, 2014), several tools which employ different methodologies were selected for 




comparison in a pilot study (Table 3-1). Several published RNA-seq data sets from studies of 
primary CD4+ T cell activation were utilised for this purpose. Ni et al. stimulated human CD4+ 
T cells via CD3/CD28 and isolated RNA for sequencing both prior to activation and at 18 hours 
post-activation (Ni et al., 2016). LaMere et al. isolated naïve and memory CD4+ T cells from 
PBMCs and activated them via CD3/CD28 stimulation in combination with IL-2, before 
performing  RNA-seq prior and at 1, 5, and 14 days post-activation (LaMere et al., 2017). 
Differential splicing of CD45 upon CD4+ T cell activation, or in memory relative to naïve cells, 
was utilised as a positive control splicing event. Specifically, the ability of the selected analysis 
tools to detect exclusion of exon 4 in the activated/memory state was assessed. Expression of 
the isoform containing exon 4 (CD45RA), is used as a marker of the naïve state, such as by 
LaMere et al. in their study (LaMere et al., 2017). 
 
Table 3-1. Features of differential splicing analysis tools selected for comparison. 
Tool Approach to defining splicing events Splicing Model 
MAJIQ (Vaquero-
Garcia et al., 2016) 
Reference genome plus RNA-seq evidence Local splicing variants 
(LSVs) of arbitrary 
complexity 
SplAdder (Kahles 
et al., 2016) 
Splicing graph constructed using reference 
genome and augmented with RNA-seq data 
Exon-based 
SUPPA (Alamancos 
et al., 2015) 
Splicing events defined via comparison of 
reference transcriptome isoforms 
Isoform/Exon-based 
VAST-TOOLS 
(Tapial et al., 2017) 
Uses custom splice junction database 
derived through integrating reference 
genome with diverse expression data 
Exon-based 
 
CD45 splicing events were not reported by SplAdder or SUPPA. The version of SplAdder at the 
time of analysis (version 1) pre-processes a reference transcriptome and removes any genes 
which partially share genomic co-ordinates (e.g. overlapping sense-anti-sense transcripts) to 
prevent issues associated with assigning aligned RNA-seq reads to specific splice junctions in 
such instances. This approach is undesirable as it seems to be overly conservative, excluding 
many genes of interest. SUPPA defines exon skipping events as cases in which a single cassette 




exon differentiates transcript isoforms. Splicing at the CD45 locus exceeds the simplicity of this 
model and is thus not reported by SUPPA. Note that newer versions of both SplAdder and 
SUPPA have been released since this analysis was performed. MAJIQ and VAST-TOOLS 
successfully detected preferential exclusion of CD45 exon 4 in memory CD4+ T cells relative to 
naïve cells in the LaMere et al. dataset (Figure 3-1). However, neither tool reported a change 
to exon 4 splicing at 18h post-activation in the Ni et al. dataset (Figure 3-1), which may be due 
to the splicing kinetics of this event. Both VAST-TOOLS and MAJIQ coincidentally identified 
1998 genes as differentially spliced at 18 hrs post-activation of CD4+ T cells, with 634 of these 
genes being identified by both tools. This is a significant overlap (p = < 0.001) as assessed via 
hypergeometric test using a background of all genes having sufficient read coverage to be 
analysed by either tool [9076]). Therefore, both VAST-TOOLS and MAJIQ were deemed 
appropriate analysis tools producing partially overlapping results. MAJIQ defines and 
quantifies splicing events of arbitrary complexity, whereas VAST-TOOLS focuses on analysis of 
classically defined splicing events and could thus be considered more limited in this capacity. 
On this basis, MAJIQ was selected for all further analyses. 
 
 
Figure 3-1. Splicing of CD45 exon 4 in different CD4+ T cell states. (A) Results reported by 
VAST-TOOLS. (B) Results reported by MAJIQ. Exon 4 was represented by MAJIQ as two LSVs. 
Violin plots show the distribution of the estimated PSI for the colour-matching junction in each 




LSV schematic. Data comparing resting with activated CD4 T cells from (Ni et al., 2016). Data 
comparing naïve with memory CD4+ T cells from (LaMere et al., 2016). 
3.3.1.2 Splicing factor motifs 
A set of 103 splicing factor-motifs, which collectively capture the binding preferences of 74 
splicing factors, was compiled for downstream application of MARA (Figure 3-2; see Chapter 2 
for details of motif sources). Many splicing factors were represented by multiple motifs, and 
the median number of motifs for a given splicing factor was two. In cases where several motifs 
from different splicing factors were highly similar, these motifs were represented by a single 
consensus position specific scoring matrix (PSSM) (see Chapter 2 for details on consensus 
motif generation). 
 




Figure 3-2. Splicing factor motifs utilised for S-MARA. Motifs are clustered according to 
Pearson correlation of the PSSMs after Smith-Waterman local alignments, and similar motifs 
have been merged to generate a consensus.  
 
These motifs ranged in length from 4 to 9 nt (median = 5 nt), with an information content 
ranging from 3.77 to 18 bits (median = 7.52 bits). To allow comparison with the characteristics 
of transcription factor DNA motifs, the database of the IMAGE motif activity analysis tool 
(Madsen et al., 2018) was used, which contains a total of 1579 transcription factor motifs. The 
median transcription factor motif length was 12 nt, and the median information content was 
12.104 bits, significantly greater than for the splicing factor motifs (p < 2.2 x 10-16 Wilcoxon 
rank sum test) (Figure 3-3). This highlights an important difference between DNA and RNA 
binding motifs which could potentially influence the application of MARA to splicing factor 
biology. 
 
Figure 3-3. Information content of motifs associated with splicing factors or transcription 
factors. SF = splicing factor, TF = transcription factor. Data for 1579 TF motifs from the IMAGE 
database (Madsen et al., 2018) and the 103 SF motifs compiled for this study.  
3.3.2 Pre-processing and quality control of ENCODE RNA-seq data 
3.3.2.1 Effects of RBP knockdown on splicing in HepG2 and K562 cell lines 
The ENCODE project shRNA knockdowns were conducted across 49 batches, with each batch 
containing two non-specific shRNA treated controls and a variable number of duplicate 




knockdown samples in which different RBPs were targeted. A total of 48 control and 438 
knockdown samples in K562 cells, and 50 control and 450 knockdown samples in HepG2 cells 
were used, totalling knockdowns for 241 RBPs. To determine the magnitude of depletion in 
each experiment, differential gene expression analysis was used to compare knockdown and 
control samples. This revealed that the RNA abundance of the RBP of interest was significantly 
reduced (FDR < 0.05) in 210/219 knockdowns in K562 cells, and 222/225 in HepG2, with a 
mean reduction in expression of 47% (Figure 3-4). Of the 241 RBPs analysed in the ENCODE 
dataset, 38 of these were present in our compiled splicing factor motif set (Figure 3-2), 
represented by a total of 67 different motifs. The majority of these splicing factors had a 
significant reduction in gene expression, with the exception of TRA2A in K562 cells and SRSF3 
in HepG2 cells. The mean reduction in gene expression of splicing factors specifically was 
45.6%. The knockdown data for these 38 RBPs (33 depleted in both cell lines, five in just one 
cell line) were selected for motif activity analysis.  
 
Figure 3-4. Volcano plot of RNA binding protein knockdowns in HepG2 and K562 cells. 
Horizontal and vertical lines mark FDR of 0.05 and the mean log2 fold change respectively. 
RNA-binding proteins annotated as splicing factors and having associated motif data are 
indicated as those being used for the MARA-based analysis. FDR is plotted on a -log10 scale. 
 
The pool of splice junctions considered for analysis was defined as those with sufficient read 
coverage (see Chapter 2) in at least 80% of samples for each cell line independently, resulting 




in ~116,000 junctions in HepG2 cells and ~113,000 junctions in K562 cells. The number of 
splice junctions with a significantly altered PSI after RBP-knockdown varied widely, with 
splicing factors affecting more junctions on average than non-splicing factor RBPs, as expected 
(p = 1.6 x 10-13 - Wilcoxon rank sum test) (Figure 3-5). Knockdown of HNRNPC in HepG2 cells 
had the largest effect on splicing, whilst AARS knockdown in K562 cells had the smallest overall 
effect (Figure 3-6). The magnitude of the knockdown-induced splicing effect was overall similar 
between HepG2 and K562 cells, with a Pearson correlation of 0.61 between numbers of 
differentially spliced junctions per knockdown. However, several cell-type specific effects were 
present. For instance, focusing specifically on splicing factors (Figure 3-7), HNRNPC and 
HNRNPA2B1 knockdown had more pronounced effects in K562 cells, whilst U2AF2 and 
HNRNPK knockdown had larger effects in HepG2 cells.  
 
Figure 3-5. Effects of RNA-binding protein knockdowns on splicing in HepG2 and K562 cells. 
Knockdowns producing altered splicing of more than 300 splice junctions are labelled with the 
target RNA-binding protein.  





Figure 3-6. Volcano plots of RNA-binding protein knockdowns. (A) HNRNPC knockdown in 
HepG2 cells. (B) AARS knockdown in K562 cells. The horizontal lines mark 95% probability of a 
change in PSI >= 20%. Vertical lines mark -20%, and 20% change in PSI.  
 
 
Figure 3-7. Effect of splicing factor knockdown in HepG2 or K562 cells.  
The numbers of differentially spliced junctions upon knockdown of splicing factors are shown. 
Data relating to select splicing factors are labelled. 




3.3.2.2 ENCODE data batch adjustment 
Since ENCODE RBP-knockdown samples were processed in batches, potential batch effects 
were investigated. PCA analysis of genome-wide splice junction PSI values separated samples 
by batch along the first two PCs (Figure 3-8A). Batch effect adjustment of the PSI matrix via 
ComBat (Leek et al., 2012) removed the batch effect visually as assessed via PCA (Figure 3-8B). 
Comparing samples across batches is desirable since this allows greater numbers of control 
samples to be included in analysis of each knockdown, increasing statistical power. However, 
in the ENCODE study, RBP-dependent splicing effects were confounded with batch. Although 
each batch contained a common experimental condition in the form of control shRNA-treated 
samples, RBP-knockdown samples for a given RBP were always confined to a single batch. This 
characteristic of the study design may limit the ability to estimate and remove batch effects 
whilst adequately preserving the signal associated with the condition of interest (RBP-
knockdown). To address this issue, both batch-adjusted and un-adjusted data were utilised for 
initial stages in the analysis, to assess potential downstream influence of the batch effect. 
 
Figure 3-8. PCA analysis of genome-wide splice junction PSI values before and after batch 
correction. Data shown for HepG2 cells only, similar patterns observed for K562 cells. Batch 




refers to the ENCODE experiment accession identifier. (A) Unadjusted data. (B) Data after 
batch correction via ComBat. 
 
To assess the effect of RBP-knockdown on splicing factor motif activity, the change in motif 
activity between control and knockdown samples was defined as the difference between the 
mean motif activity in all controls and that in RBP-knockdown sample duplicates. As some 
RBPs have multiple associated motifs, this was performed for each motif associated with such 
RBPs. The change in motif activity values were highly correlated whether using batch-adjusted 
or unadjusted PSI values (r = 0.766) (Figure 3-9). Since changes in motif activity are the primary 
outcome of interest, and to avoid potential issues of batch-adjustment with an unbalanced 
experimental design, the unadjusted data were selected for further use. 
 
 
Figure 3-9. Effect of batch correction on motif activity changes upon splicing factor 









3.3.3 Assessing the performance of MARA in identifying changes in splicing factor 
motif activity 
3.3.3.1 Splicing factor knockdown induced motif activity changes 
Of the 38 analysed splicing factor-knockdowns, 22 resulted in a change in activity for at least 
one of the splicing factor-associated motifs (FDR < 0.1). This corresponded to 17 splicing 
factors in HepG2 cells and 11 in K562 cells (Figure 3-10). Six splicing factors had a motif with 
significantly altered activity in both HepG2 and K562 cells, which is a non-significant overlap as 
assessed via hypergeometric test (probability of an intersection of this size or greater = 0.34) 
(Figure 3-11). In total, this equated to 25 motifs with a significant change in motif activity - 16 
in HepG2 cells and 13 in K562 cells, with 4 common to both cells. The two splicing factors for 
which shRNA treatment did not significantly reduce gene expression (SRSF3 in HepG2 cells and 
TRA2A in K562 cells) did not have a significant change in motif activity. However, overall the 
knockdown efficiency, as assessed via fold change reduction in expression, was not associated 
with significance of the change in motif activity (Figure 3-12A). Similarly, the number of splice 
junctions with differential usage upon splicing factor-knockdown was not related to 
significance of the motif activity change (Figure 3-12B). However, when considering the global 
change in activity across all 103 splicing factor motifs in controls relative to knockdown 
samples, an association with the number of differentially spliced junctions was present (Figure 
3-13) (Pearson correlation, r = 0.69, p = < 2.2 x 10-16). In particular, some splicing factor-
knockdowns with large effects on alternative splicing, but without significant changes in motif 
activity for their associated motif, such as U2AF2, did result in large changes overall across the 
103 tested motifs (Figure 3-13). Thus, whilst not all splicing factor knockdowns resulted in 
detected changes in associated motif activity, MARA is able to report motif activity changes in 
proportion to the magnitude of splicing changes between samples. 





Figure 3-10. Volcano plot of motif activity changes upon splicing factor knockdown. 
Horizontal line highlights FDR of 0.1. FDR is plotted on a -log10 scale.
 
Figure 3-11. Intersections between splicing factor knockdowns with associated motifs 
identified through either a MARA-based or a motif enrichment-based approach. 
“Enrichment” refers to motif enrichment analysis. Green circles indicate the analysis types for 
which the intersection number in the above bar chart refers to. p values are derived from 








Figure 3-12. Effects of splicing factor knockdown in cases with altered or non-altered motif 
activity. (A) Knockdown efficiency in splicing factor knockdowns resulting in significant or non-
significant change in motif activity. (B) Effect of the splicing factor knockdown on splicing in 
cases of significant vs non-significant changes in motif activity. 
 
Figure 3-13. Relationship between splicing factor knockdown effect on splicing and motif 
activities globally. Splicing factors producing greater than 500 differentially spliced junctions 
or a global change in motif activity greater than 1.5 are labelled.  





3.3.3.2 Prediction of splicing factor target splice junctions 
Potential target splice junctions of each splicing factor were predicted via a “leave-one-out” 
analysis (see Chapter 2 for details). The median number of predicted target junctions per motif 
was ~25,000. The top candidate junctions for each motif, defined as those with target scores > 
4 SDs from the mean, were selected for further analysis. This resulted in a reduced, “highest 
confidence”, target splice junction set per splicing factor, with a median of 158 predicted 
target junctions per splicing factor motif. As expected, predicted target junctions had higher 
counts of the regulatory motif in question relative to non-target, non-zero count junctions; 
with a median of three greater motif counts in the predicted target junctions relative to 
background junctions. The activity of these predicted target junctions upon knockdown of the 
associated splicing factors was investigated. This showed that predicted target junctions did 
not have greater absolute changes in PSI values compared to non-target junctions upon 
knockdown of the motif-associated splicing factor for any splicing factor-knockdowns (p > 0.05 
- Wilcoxon rank sum test). Additionally, there were no significant overlaps between the 
predicted target splice junctions and true target junctions, defined as those with significantly 
altered PSI upon splicing factor-knockdown (FDR > 0.05 - hypergeometric test). Thus, the 
leave-one-out analysis as currently implemented does not appear to accurately predict the 
splicing targets of specific splicing factors.   
3.3.3.3 Assessing effects of technical confounders on Motif Activity Response Analysis 
(MARA) 
Different motifs have different distributions across the transcriptome, and will vary in the 
mean and variance of their occurrence across genomic features. Further, the methodology 
used to count such motifs will also influence the distribution of motif counts. Such variance in 
distribution may influence how amenable different motifs are to study through MARA. Thus, 
the potential influence of motif count features on estimation of changes in motif activity was 
investigated. Motif information content did not differ significantly between motifs with or 
without a significant change activity upon splicing factor knockdown (mean information 
content is 7.77 bits and 7.5 bits respectively). To investigate the influence of motif count 
distribution features on the capacity of MARA to detect changes in motif activity, a PCA 
regression analysis was performed using matrices of splicing factor motif count occurrences as 




input. The first PC of variance was strongly associated with motif count features such as the 
maximum and standard deviation (SD), as could be expected. However, none of the first 20 
PCs were associated with whether a motif had significant knockdown-induced change in motif 
activity (Figure 3-14). This suggests that features of the motif count distribution did not have a 
major role in whether a given motif had a significant change in corresponding activity upon 
knockdown of the associated splicing factor. 
 
Figure 3-14. PCA regression analysis of motif count features and estimation of changes in 
motif activities. (A) HepG2 cells, (B) K562 cells. Only splice junctions with sufficient read 
coverage across samples were included in the analysis, and thus count data differs per cell line. 
Data from linear regression of principal components against count summary statistics 
(standard deviation [SD], sum, maximum, mean) or whether splicing factor knockdown 
resulted in a significant change in motif activity (“MARA hit”). * = FDR < 0.05.  
 
Since only two knockdown samples were available per RBP-knockdown, statistical power may 
be a limiting factor in identifying regulatory splicing factors. A good illustration of these 
limitations is HNRNPC. Knockdown of HNRNPC produced similar changes in motif activity in 
both cell lines (-0.38 in K562, -0.28 in HepG2), but the increased variance in activity amongst 
knockdown samples in K562 cells appears to have decreased the significance of this difference 
(Figure 3-15A).  





Figure 3-15. Motif-based analysis of HNRNPC knockdown. (A) HNRNPC motif activity in 
control and HNRNPC knockdown samples. Comparison between groups shows FDR from 
Student’s t-test. (B) HRNPC motif counts in regions flanking splice junctions with either altered 
usage upon HNRNPC knockdown or unaltered background junctions. Comparison between 
groups shows FDR of one-tailed Wilcoxon rank sum test. * indicates significant difference. (C) 
HNRNPC PSSM motif logo.  
3.3.3.4 Motif enrichment analysis of splicing factor knockdowns 
To contextualize the results from applying S-MARA, we employed a commonly used motif 
enrichment procedure. Motif enrichment was used to test for associations between splicing 
factor-knockdowns and their corresponding motifs. Specifically, the distribution of motif 
counts was compared between differentially spliced junctions and non-differentially spliced 
junctions which were used as a background set. Greater motif counts in the RNA regions 
flanking regulated splice junctions relative to unregulated background splice junctions was 
taken as evidence of a potential causative role in splicing regulation. For 20 knockdowns in 
K562 cells and 22 in HepG2 cells, a significant increase in motif counts amongst regulated 
splice junctions was identified (FDR < 0.05 one-tailed Wilcoxon rank sum test). The overall 
magnitude of splicing disruption induced by each knockdown influenced the results of this 




motif enrichment analysis. Knockdowns with a greater effect were more likely to result in 
significant cases of increased motif counts amongst differentially spliced junctions (Figure 3-
16). This contrasts with the observations made for S-MARA, where such an effect was not 
found.  
 
In total, 28 different splicing factors had significant enrichment of an associated motif upon 
knockdown, with 14 cases identified in both cell lines. This is a greater number of successes 
than that obtained from S-MARA, where 22 splicing factors had significant changes in 
associated motif activity, with 6 being common to both cell lines (Figure 3-11). This suggests 
motif enrichment analysis may have greater power to associate specific regulatory splicing 
factor motifs with differential splicing patterns.  
 
 
Figure 3-16. Relationship between the effect of each splicing factor knockdown on 
differential splicing and the results of motif enrichment analysis. Splicing factors are grouped 
on the x axis according to whether knockdown induced significant enrichment of an associated 
motif. Wilcoxon rank sum test p value is shown. 
 




We then asked whether motif enrichment and S-MARA identified significant “hits” for the 
same or different splicing factors. 7/11 MARA-based hits in K562 cells matched the K562 motif 
enrichment hits, which is a significant overlap as assessed via Fisher’s exact test (p = 1 x 10-4) 
(Figure 3-11). However, for HepG2 cells only 11 of the 17 motif enrichment hits were also 
identified through S-MARA, which is more consistent with an overlap size expected through 
chance alone (p = 0.333) (Figure 3-11). A number of splicing factor-knockdowns did not result 
in a significant motif-association using either methodology – with 10 such cases in HepG2 cells 
and 18 K562 cells. Of interest, HNRNPC motifs were enriched amongst differentially spliced 
junctions in both cell lines (Figure 3-15B), as opposed to the HepG2-specific effect seen with 
MARA (Figure 3-15A). However, the change in motif activity trended in the same direction in 
both cell lines for HNRNPC, and the disparity between the two cell lines may relate to the 
power to detect a significant effect, as discussed above. Interestingly, motif enrichment in 
differentially spliced junctions was not seen for HNRNPU in HepG2 cells (Figure 3-17B) despite 
MARA detecting a change in motif activity for a HNRNPU-associated motif (Figure 3-17A). 
Activity of the HNRNPU motif UGUAUUG showed significant but opposing effects upon 
knockdown in the two cell lines (Figure 3-17), possibly indicative of opposing splicing enhancer 
and repressor effects in each cell type. 





Figure 3-17. Motif-based analysis of HNRNPU knockdown. (A) HNRNPU motif activity in 
control and HNRNPU knockdown samples. Comparison between groups shows FDR from 
Student’s t-test. (B) HRNPU motif counts in regions flanking splice junctions with either altered 
usage upon HNRNPU knockdown or unaltered background junctions. Comparison between 
groups shows FDR of one-tailed Wilcoxon rank sum test. * indicates significant comparison. (C) 
HNRNPU PSSM motif logo.  
3.3.3.5 Sensitivity and specificity of regulatory motif identification  
The motif enrichment analysis approach was able to recover a greater number of regulatory 
motif “hits” upon splicing factor-knockdown than the MARA-based approach (Figure 3-11). 
This suggests the enrichment method may have a greater sensitivity to detect regulatory 
splicing factor motifs. However, the specificity of the two approaches is also of interest. The 
analysis performed so far was restricted to splicing factor motifs specifically associated with 
each knockdown-splicing factor. To assess specificity, the effect of each splicing factor-
knockdown was assessed across the full set of 103 splicing factor-motifs. Using this approach, 
those motifs which are specifically associated with each experimentally depleted splicing 
factor were considered as true positives. These motifs are expected to have a regulatory role 
in knockdown-induced differential splicing. In contrast, motifs associated with other splicing 




factors are not necessarily expected to have roles in regulating such differential splicing, and 
were thus considered as true negatives.  
 
When analysing all 103 motifs in the context of each knockdown experiment, the motif 
enrichment analysis identified more significant motifs than the S-MARA approach (Figure 3-
18). However, the motif enrichment approach also showed greater receiver operating 
characteristics (ROC) in identifying those motifs specifically associated with knockdown-
splicing factors (Figure 3-19). Indeed, the 95% confidence interval of the area under the ROC 
curve (AUC) for S-MARA overlapped the 0.5 line. Thus, the MARA approach did not perform 
better than chance at identifying motifs associated with knockdown-splicing factors (true 
positives) relative to other splicing factor motifs (true negatives). Using an FDR of 0.1, the true 
positive rate for detection of knockdown-splicing factor associated motifs was 0.182 and 0.403 
for S-MARA and motif enrichment respectively (Table 3-2). 
 
 
Figure 3-18. Numbers of splicing factor motifs associated with splicing factor knockdowns via 
S-MARA or motif enrichment analysis. Wilcoxon rank sum test p value shown. SF = splicing 









Figure 3-19. Receiver operating characteristics for the identification of regulatory splicing 
factor motifs. (A) MARA analysis, (B) motif enrichment analysis. AUC = area under the curve. 
95% confidence intervals are shown. Curves show ratios of sensitivity to specificity at varying 
FDR threshold values. True positives were defined as motifs associated with each knocked 
down splicing factor. 
 
Table 3-2. Confusion matrices for the identification of regulatory splicing factor motifs. 
Numbers of true positive (TP), true negative (TN), false positive (FP), and false negative (FN) 
splicing factor motifs identified through either MARA of motif enrichment are shown. True 
positive and true negative rates derived from these values are shown in the bottom rows. 
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Possible reasons for the improved performance of motif enrichment analysis could relate to 
assumptions underlying the MARA model. For instance, as S-MARA employs linear modelling, 
there is an assumption of linearity between the PSI of a splice event and the occurrence of 
splicing factor motifs flanking that splice event. Motif activity estimates are thus coefficients 
which describe the linear association between motif counts and PSI. This assumption may have 
several limitations. For instance, the probability of an RBP binding a specific pre-mRNA as a 
function of the number of motifs it contains will likely be characterised by saturation effects. 
That is, binding probability will not increase indefinitely with the number of binding motifs. In 
contrast, the motif enrichment procedure used here does not rely on any assumptions of 
linearity, being instead based on assessment of rank order through the Wilcoxon rank sum 
test.  
 
As a simple method of accounting for such saturation effects, the input splicing factor motif 
count matrix was modified such that the maximum motif count per splice junction region did 
not exceed a maximum value. Two values for this maximum motif count threshold were 
trialled: 15 and 30, such that counts were simply capped at the corresponding value. The full 
workflow was then performed again separately for both maximum values and ROCs re-
calculated (Figure 3-20A-B). This modification did not produce a performance increase in 
MARA. 
 
Another possible advantage of the motif enrichment strategy over MARA is the use of a 
reduced input set of “positive” splice junctions. This positive set consists of the splice events 
found to have a significantly altered PSI in knockdown relative to control samples, and is 
contrasted with a negative set of all other splice junctions. With MARA, in contrast, the motif 
activity is modelled as the relationship between motif occurrence and splice junction usage for 
all splice junctions genome-wide. In order to potentially improve the signal-to-noise ratio in 
the MARA input matrices, a pre-filtering step was performed to include only those splice 
junctions identified as having significantly altered usage in knockdown samples. This was 




performed on a per-splicing-factor knockdown basis per cell line, for a total of 71 analyses (2 
cell lines and a mean of 35.5 splicing factor knockdowns per cell line). To clarify, this approach 
results in the same input splice junctions being used as per the motif enrichment procedure. 
This per knockdown, “high signal-to-noise”, analysis did not produce an improvement in 




Figure 3-20. Receiver operating characteristics of S-MARA after adaptations to input data.  
The S-MARA workflow was applied with several modifications made to the input data in an 
attempt to improve performance. Performance characteristics after setting the maximum 
number of splicing factor motif matches per-splice site region, to (A) 15, or (B) 30. (C) 
Performance characteristics after running S-MARA separately for each splicing factor 




knockdown, using reduced input data consisting of only those splice junctions with significantly 
altered use in knockdown samples. 
3.3.4 Discussion 
In order to apply MARA for the inference of splicing factor motif activity, a pipeline was 
implemented which involved quantification of genome-wide splicing events, and counting 
splicing factor motif occurrences in RNA regions flanking these splice events. To facilitate this, 
a set of 103 splicing factor motifs was compiled. shRNA-induced RBP-knockdown data, 
generated through the ENCODE project, provided an opportunity to assess the effectiveness of 
MARA for splicing focused analyses. As expected, reduction in expression of genes encoding 
RBPs resulted in disrupted RNA splicing, an effect that was more pronounced in RBPs with 
established roles as splicing factors (Figure 3-5). The magnitude of the effect on splicing was 
not related to efficiency of the knockdown. However, the overall efficiency of knockdown was 
not particularly high, with the average reduction in gene expression being less than 50% 
relative to control samples. Modelling splicing factor motif activity through S-MARA provides a 
potential method for linking knockdown-induced splicing changes to the regulatory motifs 
associated with that splicing factor. For a subset of knockdowns, the S-MARA workflow 
provided such results. That is, motif activities relating to specific splicing factors that had been 
knocked down were significantly different between control and knockdown samples. A 
number of technical factors were investigated as potential confounders or sources of 
limitation. However, knockdown-efficiency, the magnitude of effect of knockdown on splicing, 
and motif count distribution features, did not affect whether a given splicing factor-
knockdown resulted in a significant change in motif activity between control and knockdown 
samples.  
3.3.5 Motif enrichment analysis outperforms splicing-MARA 
A motif enrichment approach, based on testing for over-representation of motif occurrences 
amongst regulated splice junctions, was used as a baseline against which to compare S-MARA.  
This motif enrichment approach identified a greater number of successful “hits” than the 
MARA-based approach (Figure 3-11). Further, an analysis of ROC characteristics revealed the 
motif enrichment procedure displayed greater sensitivity and specificity than S-MARA. Indeed, 
the MARA-based approach did not perform better than random chance in specifically 




identifying splicing factor-knockdown associated motifs (Figure 3-19). Thus, motif enrichment 
analysis clearly performs better than S-MARA as applied herein.  
 
3.3.6 Limitations in defining true and false positive effects of splicing factor 
knockdowns 
Despite the clarity of the ROC analysis in highlighting the differential performance 
characteristics of S-MARA and motif enrichment, several limitations to this approach should be 
considered. In particular, defining true positive and true negative splicing factor motifs has 
limitations for several reasons. Firstly, splicing factors are commonly under cross-regulation 
through the activity of other splicing factors in a given gene expression network (Jangi and 
Sharp, 2014). It is therefore difficult to define true negatives, since such downstream effects 
may show up as changes in the activity of splicing factor motifs outside of those which were 
knocked down. Whilst changes in gene expression of off-target splicing factors upon 
knockdown could be used as a proxy for altered activity, this is imperfect, as altered mRNA 
abundance does not necessarily indicate a change in splicing factor activity, and conversely, 
splicing factor activity can be regulated post-transcriptionally. Indeed, detection of these 
downstream off-target, “false positive”, effects in motif enrichment analysis of splicing factor-
knockdown data has been previously observed (Carazo et al., 2018).  
 
Similarly, defining true positives also has limitations. Knockdowns with lower efficiency or with 
limited effects on splicing would not necessarily be expected to result in a detectable signal 
through MARA or motif enrichment testing. Indeed, the number of differentially spliced 
junctions induced by splicing factor knockdown was greater in cases where significant motif 
enrichment was detected (Figure 3-16). Whilst a similar observation was not found for the 
relationship between numbers of differentially spliced junctions and change in MARA-
estimated motif activity (Figure 3-12B), this may be due to the reduced accuracy of MARA as 
determined through ROC analysis. With that said, some knockdowns producing low numbers 
of differentially spliced junctions did result in a significant change in motif activity or motif 
enrichment, thus highlighting the limitations in using the numbers of differentially spliced 
junctions as a filter for specifying true positives.  
 




A further challenge with defining true positives is the possibility that a splicing factor may not 
be acting through binding to the motif associated with that splicing factor in our motif set. For 
example, FUS, a splicing factor not identified as a hit by either motif analysis method, has the 
associated motifs CGCGC and GGGGG. However, in vivo in the context of neuronal 
development, FUS was found to bind RNA in a relatively non-specific manner, with only a 
limited sequence preference for G-rich regions (Rogelj et al., 2012). Therefore, the linear 
relationship between FUS binding and motif occurrence in vivo may be weak, precluding 
analysis with MARA or motif enrichment analysis. Similarly, many splicing factors have 
pleiotropic effects and may not be regulating splicing through directly binding to in cis 
elements in pre-mRNA to influence spliceosomal action, but through the regulation of splicing 
components via other RNA processing mechanisms. 
 
Despite these limitations, the ROC AUC for the motif enrichment analysis (0.662, Figure 3-19B) 
indicates that there is value in this validation approach. The poor ROC AUC of the S-MARA 
approach draws into question the reliability of the motif activity estimates. A number of the 
splicing factor-knockdown MARA hits were specific to the MARA approach and not identified 
through the motif enrichment method (Figure 3-11) (e.g. HNRNPU in HepG2 cells [Figure 3-
17]). Given the poor ROC AUC of MARA, it may be that such cases represent false positives.  
 
3.3.7 Possible limitations to the S-MARA methodology 
Several possible advantages of the motif enrichment method over S-MARA were investigated. 
Firstly, since MARA is based upon linear regression, there is an implicit assumption of linearity 
between splicing factor motif counts and splicing factor activity towards a splice event. This 
assumption will likely not hold true in many cases. For instance, binding saturation effects will 
occur, putting a limit to the increase in binding likelihood with increasing motif counts. This 
potential saturation effect limitation was investigated by placing restrictions on the values of 
the input motif count matrices. However, this failed to alter the performance characteristics of 
S-MARA (Figure 3-20A-B). Another possible advantage of motif enrichment analysis is the 
initial splitting of splice junctions into differentially regulated and non-differentially regulated 
groups. This initial process could improve the signal to noise ratio. In light of this, a modified S-
MARA method was trialled in which input junctions were limited to only those significantly 
differentially regulated per splicing factor knockdown. With this method, the same input splice 




junctions were used as for the motif enrichment procedure, making the two methods more 
comparable. However, this modification also failed to yield an improved ROC AUC (Figure 3-
20C). 
 
3.3.8 Small sample numbers limit statistical power 
The ENCODE shRNA experiments were performed in replicates of two. This meant that, whilst 
control shRNA samples were pooled for analysis herein resulting in greater replicate numbers, 
estimation of SF motif activity in knockdowns was limited to just two samples. This is of course 
far from ideal for the estimation of variance as required for statistical analyses such as the 
Students t-test applied here. As such, issues of statistical power appeared to be a limiting 
factor in detecting changes in motif activity for a subset of splicing factors. For instance, 
significant enrichment of HNRNPC associated motif counts amongst knockdown-induced 
differentially spliced junctions was identified in both cell lines (Figure 3-15). Conversely, 
sample variability appeared to impair the power to detect a significant change in motif activity 
of these motifs in K562 cells through S-MARA (Figure 3-15). The motif enrichment method uses 
a comparison of thousands of splice junctions to assess differences in motif counts. In contrast, 
the applied MARA-based analysis relies upon comparison of two knockdown samples with the 
group of control samples. It is possible that these methodological differences could make the 
motif enrichment methodology less sensitive to the low number of knockdown samples 
available. Future application of these methodologies to a dataset with greater sample sizes is 
therefore desirable in future. 
3.3.9 S-MARA target analysis 
Splicing factor-motif target splice junctions were predicted with a leave-one-out-analysis as 
implemented in the IMAGE pipeline (Madsen et al., 2018). The leave-one-out procedure has 
been previously validated for prediction of transcription factor targets (Balwierz et al., 2014; 
Madsen et al., 2018). However, whilst the predicted target junctions were enriched for the 
specified regulatory motifs in question, they were not enriched for splicing factor targets, 
defined as those with knockdown-induced differential splicing. The validity of these predicted 
splice junction targets is therefore questionable. Whilst the target prediction analysis was not 
the primary focus of this study, the performance of the leave-one-out approach is dependent 




upon changes in estimated motif activity. Therefore, any limitations to the motif estimation 
function of MARA will also affect the target prediction function. 
 
3.3.10 Splicing factor motif enrichment analysis is an effective means to infer 
regulatory motifs  
Whilst the focus of this study was on the development and benchmarking of the S-MARA 
workflow, the assessment of splicing factor motif enrichment analysis conducted here has its 
own merit. To our knowledge, the specificity and sensitivity characteristics of a splicing-
focused motif enrichment procedure have not previously been investigated. Indeed, this 
analysis relied upon the use of an extensive resource of splicing factor knockdowns, such as 
has been provided only recently through the ENCODE project (Nostrand et al., 2018). This work 
validates the concept of using RNA motifs to infer regulatory splicing factors through analysis 
of RNA-seq data (Figure 3-19). The motif enrichment approach used here could be further 
modified in future work to potentially improve upon the sensitivity and specificity 
characteristics identified here.  
3.3.11 Conclusions 
Motif activity analysis of splicing factor motifs represents a novel bioinformatic approach to 
investigating splicing using high-throughput data. The utility of this approach was investigated 
using a large scale RBP knockdown study. In select cases, S-MARA allowed identification of 
changes in splicing factor motif activity associated with changes in splicing factor gene 
expression. However, overall the approach showed poor sensitivity and specificity towards this 
end. In contrast, a simpler and commonly applied motif enrichment procedure showed 
reasonable performance in identifying regulatory motifs associated with splicing factor 
knockdowns. The results of this analysis provide a proof of principle for the utility of splicing 
factor motif enrichment approaches. A potential limitation of the current analysis relates to 
the limited sample sizes in the knockdown condition. Despite the identified shortcomings of S-
MARA, a further investigation of the approach applied to an experimental system with more 
biological replicates warrants further investigation 





Chapter 4. Motif Activity Response Analysis (MARA) of Splicing 
Regulators during CD4+ T cell Activation and Th2 Polarisation 
4.1 Introduction 
Activation of CD4+ T cells upon antigenic stimulation of the TCR is characterised by widespread 
regulation of alternative splicing (Ip et al., 2007; Martinez et al., 2012). The detailed function 
and control of splicing at several key loci has been well described, with CD45 being the prime 
example (Hermiston et al., 2003; Lemaire et al., 1999; Oberdoerffer et al., 2008; Rothrock et 
al., 2005; Wang et al., 2001). Likewise, polarisation of CD4+ T cells into functional subsets is 
associated with broad splicing regulation (Stubbington et al., 2015). Further elucidation of the 
regulatory splicing factors underlying control of such splicing regulation is necessary to fully 
understand the gene expression programmes which drive and maintain CD4+ T cell states. 
 
Henriksson et al. (Henriksson et al., 2019) recently performed a detailed timecourse 
investigation of the transcriptional regulatory programme driving both CD4+ T cell activation 
and polarisation to the Th2 lineage. A comprehensive sampling of the activation and 
polarisation timecourse was performed in primary human CD4+ T cells from three donors, with 
10 time points post-activation (0, 0.5, 1, 2, 4, 6, 12, 24, 48, and 72 hrs) being profiled through 
RNA-seq. Cells were activated through direct CD3 and CD28 stimulation, followed by IL-2 
treatment 48 hrs later. A subset of cells was additionally treated with IL-4 at time point 0 to 
initiate Th2 polarisation. These data provide a rich resource to study other aspects of the gene 
expression pathway, including splicing.  
 
Although initial benchmarking detailed in Chapter 3 drew into question the accuracy of the S-
MARA methodology, a potential limiting factor identified was the low number of biological 
replicates per experiment. The Henriksson et al. timecourse has greater replicate numbers 
(three) and more biological conditions (10 time points in two cell states). These features may 
make this a more powerful data set through which to test S-MARA. Further, the efficacy of 
splicing factor motif enrichment was demonstrated through analysis of splicing factor 
knockdowns, as presented in Chapter 3. Therefore, both of these motif-based methods will be 
applied to analysis of the Henriksson et al. timecourse. 




The program of gene expression following CD4+ T cell activation is dynamic, involving rapid 
transcriptional regulation to thousands of genes (Henriksson et al., 2019; LaMere et al., 2016, 
2016; Ni et al., 2016). Further, the activation process is thought to be modulated by distinct 
regulatory feedback processes acting through key protein nodes (Martínez-Méndez et al., 
2020). We therefore hypothesise that a network analysis approach aimed at identifying 
modules of co-regulated splicing events will reveal distinct groups of events regulated with 
different temporal dynamics and via distinct feedback mechanisms. To this end I will apply the 
network analysis tool Weighted Gene Co-expression Network Analysis (WGCNA) (Langfelder 
and Horvath, 2008; Zhang and Horvath, 2005) to both splice event quantifications and motif 
activities. WGCNA has been previously applied to identify groups of co-regulated genes across 
timecourse data (Smith et al., 2016). 
4.2 Aims 
Hundreds to thousands of genes are documented as being differentially spliced during the T 
cell activation process, and the mechanisms of control underlying many of these splicing 
events remains to be fully characterised. Here, I aim to profile the splicing regulatory network 
across a timecourse of CD4+ T cell activation. To this end I will combine a correlation-based 
splicing module discovery analysis with splicing factor motif-based analyses. I will utilise both 
S-MARA and motif enrichment analysis with the aim of identifying both known and novel 
candidate splicing factor regulators of the CD4+ T cell activation process. Specifically, I aim to: 
1. Identify and investigate modules of co-regulated splice events across the CD4+ T cell 
activation and polarisation timecourse. 
2. Identify candidate splicing factor regulators of such co-regulated modules through 
both S-MARA and motif enrichment analysis. 
3. Assess the ability of both S-MARA and motif enrichment analysis to identify known 
splicing factor regulators of activation-dependent splicing changes in CD4+ T cells.  
4. Apply S-MARA and motif enrichment analysis to identify novel candidate regulatory 
splicing factors.  





4.3.1 Genome-wide splicing profiles during CD4+ T cell activation and 
polarisation 
In order to capture and profile the potentially complex and diverse patterns of splicing 
regulation in CD4+ T cells undergoing an activation response, a correlation-based network 
approach was employed. To this end, we made use of WGCNA in order to identify modules of 
co-regulated splicing events. After initial filtering to remove junctions which were quantifiable 
in less than 50% of samples, a set of ~108,000 junctions from 9392 genes were used for 
downstream analysis. Using these junctions, PCA indicated that the main source of variance in 
splice junction PSI was time after activation (Figure 4-1).  
 
Figure 4-1. PCA of splice junction logit transformed PSI values from primary CD4+ T cells 
during a timecourse of activation and polarisation. Donor pool = set of 12 technical replicates 
from an individual donor pooled for analysis after RNA-seq and alignment. Cell type is 
indicated by opacity of data points. 
 
Application of WGCNA identified 30 splice junction modules ¾ groups of splice events with 
similar PSI profiles over time after CD4+ T cell activation. Since modules resulting from WGCNA 
vary in size, a common approach to summarise module behaviour is to use the first prinicipal 
component of variance of each module. In WGCNA nomenclature, this value is referred to as 




the module eigenGene; or here as the eigenJunction. The eigenGene expression is then used 
as a summary metric for the coordinated behavior of a given module. Initial observation of 
module eigenJunctions revealed that some of these modules were invariant across the 
timecourse, and instead showed patterns of differential splicing between biological donor. In 
order to identify splicing modules with variation over time, linear mixed effect spline modelling 
was utilised. The use of a spline-based method facilitates modelling of varied and complex 
temporal relationships, and this approach has been applied to analysis of the activity of varied 
biological molecules in timecourse experiments (Straube et al., 2015). This linear modelling 
approach identified 21 modules as having a significant relationship between the eigenJunction, 
and time after TCR stimulation (FDR < 0.05). As expected, other module eigenJunctions were 
predominantly correlated with donor of origin. These 21 modules were selected for further 
analysis. Individual splice junction PSI values were also tested for significant associations with 
time-after-activation with linear mixed effect spline modelling. Of the remaining 21 modules, 
15 had greater than 50% of their individual member splice junctions with a PSI significantly 
associated with time-after-activation. These 15 modules were selected for further analysis 
(Figure 4-2). Only a single module had an eigenJunction with a significant cell type vs time 
interaction effect, and this appeared to be driven by a single Th2 sample (Figure 4-2 – module 
14, FDR = 0.022). Thus, the splicing regulatory profile of activation appears to be similar in both 
naïve CD4+ T cells and those undergoing polarization to a Th2 subtype. 






Figure 4-2. Junction splicing profiles during CD4+ T cell activation and polarisation. Splice 
junctions are grouped into modules via WGCNA, with modules then being represented by the 
first principal component of variance of member junctions – the “eigenJunction” PSI, which is 
on a logit scale. Modules have been filtered to show only those with significant relationships 
with time-after-activation. J = number of splice junctions in each module, rounded to the 
nearest 1000 (K) for larger modules. G = number of genes represented in each module, 
rounded to the nearest 1000 (K) for larger modules. -> highlights the module with the highest 
similarity in terms of percentage of junctions which are part of the same local splicing variation 
(LSV). This occurs due to cases where individual splice junctions of an LSV are in different 




modules. Donor pool = set of 12 technical replicates from an individual donor pooled for 
analysis after RNA-seq. 
 
These 15 modules (Figure 4-2) collectively detail splicing of 8882 genes, ~50,000 local splicing 
variants (LSVs), and ~80,000 unique splice junctions (out of the 9392 genes, ~61,000 LSVs, and 
~108,000 splice junctions with sufficient read data to be quantifiable). Splice junction modules 
displayed a range of profiles, including steady changes in splicing behaviour (e.g. modules 1 
and 2), transient switches (e.g. modules 3, 4, 6, 7, 8, and 9), or more complex oscillating 
patterns (e.g. modules 10, 11, 12, and 15) (Figure 4-2). Several junction modules had inversely 
correlated eigenJunction profiles with one another, such as modules 1 and 2, 3 and 4, 6 and 7, 
or 8 and 9. This effect is at least partially driven by the structure of LSVs as defined by MAJIQ. 
The PSI of a junction is by definition dependent upon the PSIs of other junctions from the same 
LSV. For instance, as the usage of a potential alternative and upstream 5’ splice site increases; 
the relative usage of the corresponding potential downstream 5’ splice site necessarily 
decreases. This effect is most pronounced between modules 1 and 2, with 98% of module 2 
junctions being members of LSVs with junctions present in module 1 (Figure 4-2). 
 
Splice junctions were mapped to genes prior to performing a gene ontology analysis. This 
revealed enrichment for distinct biological processes within splice junction modules (Figure 4-
3). “Steady-switch” modules 1 and 2 were enriched for genes involved in many steps of the 
gene expression pathway, including transcription, splicing, translation, and other co-and-post-
translational processing. The “inverted-U” shape module 3 is enriched for genes involved in 
histone acetylation, “U-shaped” module 4 contains genes relating to co-translational protein 
transport, and module 5 is also enriched for genes involved in translation as well as splicing, 
consistent with auto or cross-regulation of splicing components. 





Figure 4-3. Gene ontology enrichment analysis of splice junction module genes. Modules 
with at least one enriched GO term are shown. Grey boxes indicate lack of significant 
enrichment for a GO term in a given module. GO terms are clustered via their “semantic 
similarity” within the GO graph structure. Similar GO terms are labelled with the most specific 
term that collectively describes that group of terms – the “common term ancestor” in the GO 
graph structure. Enrichment analysis was performed using the “Biological Processes” ontology.  
4.3.2 Splicing factor motif activity profiles during CD4+ T cell activation and 
polarisation 
Splice junction PSI values across the timecourse of activation were used to define splicing 
factor motif activities through S-MARA. To explore the properties of these motif activities 
across the timecourse, a similar module-based analysis was performed. Since there are many 
fewer splicing factor motifs relative to splice junctions, a reduced form of the WGCNA 
workflow was employed (see Methods). This resulted in 11 modules of motif activity, with a 
median of 7 motifs per module (range 3-38), and a range of profiles over the timecourse 
(Figure 4-4). Linear mixed effect spline modelling was performed to test for association of 
module eigenMotifs (first PC of variance of motif activities) with time after TCR stimulation. 




This identified 11 modules as having a significant relationship with time after activation (FDR < 
0.05), with module 7 being the sole non-significant case (Figure 4-4). Modules 2, 3, and 5 had a 
significant cell type versus time interaction (FDR < 0.05). This effect appeared relatively subtle 
however, and within these modules, time after activation rather than cell type appeared to be 
the main driver of motif activity (Figure 4-4). Patterns of splicing factor motif activity included 
steady and gradual changes (e.g. modules 1, 2, 3 and 10), transient changes (e.g. modules 4, 5, 
6), and more complex patterns of modulation (Figure 4-4). Of interest, motifs within modules 
often shared similar sequence content (Figure 4-5). For instance, module 5 contained motifs 
with prominent GC dinucleotide occurrences (Figure 4-5). Motif module 1 contained motifs of 
diverse sequence composition (Figure 4-5), whilst module 2 contained more homogenous 
clusters of motifs such as a group of U/AGGG based motifs associated with members of the 
HNRNP family (Figure 4-5). 
 





Figure 4-4. Splicing factor motif activity profiles during CD4+ T cell activation. Motifs are 
grouped into modules via hierarchical clustering, which are then represented by the first 
principal component of variance (“eigenMotif”). Motif activity values are scaled and centred 
prior to calculation of module eigen-motifs. N motif = number of splicing factor motifs in each 
module. FDR = false discovery rates relating to the null hypothesis that eigen-motif activity has 
no relationship with time after activation - assessed via linear mixed effect spline modelling. 
FDR < 0.05 except for module 7. Donor pool = set of 12 technical replicates from an individual 
donor pooled for analysis after RNA-seq. 





Figure 4-5. Motif logos of splicing factor motif activity modules. Modules as defined in Figure 
4-4. Nucleotide height is proportional to information content in bits. To allow visualisation, 
motifs were filtered to show only those which were most significantly associated with time 




after CD4+ T cell activation (defined as motifs with an FDR for association with time after 
activation < 5 x 10-4 as assessed via linear mixed effect spline modelling). Module 7 not shown 
since this module did not have a significant eigenMotif time profile. Motifs within a module 
are clustered according to Pearson correlation of the position weight matrices after Smith-
Waterman local alignment. Motifs are labelled with the associated splicing factors. To facilitate 
visualisation, the splicing factors used for labelling are also filtered. Splicing factors which are 
expressed and have gene expression correlated with motif activity are preferentially used for 
labelling, unless this resulted in removal of all splicing factors from a given motif. Splicing 
factors which are unexpressed or with low expression are indicated (LE). Splicing factors for 
which gene expression is correlated with motif activity are underlined. Pre-defined positive 
control splicing factors are marked with * (Table 4-1). 
4.3.3 Identifying potential regulatory interactions between splicing factor 
motifs and splice junction modules  
4.3.3.1 MARA-based inferences  
To gain insight into potential regulatory interactions between splicing factors and modules of 
splice junction activity during CD4+ T cell activation, a correlation-based approach was used. 
Correlation between a splicing factor motif activity and splice junction PSI suggests a potential 
role for the given splicing factor in regulating the splicing of that junction through binding the 
associated motif. Significant correlations between individual splicing factor motif activity and 
junction module eigenJunction PSIs were observed (Figure 4-6). Two clusters of junction 
modules having broadly inverse patterns of correlation with motif activity were present (Figure 
4-6). As expected, these two groups of junction modules contained module pairs with anti-
correlated PSI profiles such as junction modules 1 and 2. Splice junction modules 1 and 2 stand 
out as cases in which eigenJunction PSIs are highly correlated with a number of motif activity 
values, as do modules 3 and 4.  





Figure 4-6. Correlation between splice module eigenJunction PSIs and splicing factor motif 
activities. * indicates an absolute Pearson correlation > 0.6. Consensus motifs and associated 
splicing factors are shown. To simplify these row labels, and since multiple splicing factor can 
be associated with a given motif, splicing factors which are expressed are preferentially used 
for labelling, unless this resulted in removal of all splicing factors from a given motif. Splicing 
factors which are unexpressed or with low expression are indicated (LE). Only motifs with an 
absolute Pearson correlation > 0.6 with at least one splice junction module eigenJunction value 
are shown.  




4.3.3.2 Motif enrichment-based inferences  
A motif enrichment approach to infer potential regulatory interactions between splice junction 
modules and splicing factor motifs was also employed. To this end, the distributions of motif 
occurrences flanking splice junctions within each module were compared against a background 
distribution consisting of all other non-module junctions. This approach revealed that splice 
junction modules were enriched for a number of splicing factor motifs in flanking RNA 
sequences (Figure 4-7). Junction module 1 showed enrichment for a number of motifs, most 
strongly for motifs composed of U-stretches such as the UUUU motif associated with positive 
control splicing factor HNRNPC (Table 4-1). This is also observed with junction modules 5 and 
12, although the magnitude of enrichment is stronger in these modules. The strongest 
examples of enrichment are seen in the smaller junction module 15, which is strongly enriched 
for motifs associated with KHDRBS1 (AUAAA), DAZAP1 (AUAUA), and HNRNPD (UAUUA). 





Figure 4-7. Splicing factor motif count enrichment in splice junction modules. Modules having 
splice junctions with greater motif counts relative to non-module splice junctions are indicated 
with * (FDR < 0.05, one-tailed Wilcoxon rank sum test).  Mean motif count difference refers to 
count flanking module member splice junctions relative to non-module junctions. Splice 




junction modules were also underrepresented for counts of some motifs, as indicated by blue 
squares, although such underrepresentation was not directly tested for. Consensus motifs and 
associated splicing factors are shown. To simplify row labelling, and since multiple splicing 
factor can be associated with a given motif, splicing factors which are expressed are 
preferentially used for labelling, unless this resulted in removal of all splicing factors from a 
given motif. Splicing factors which are unexpressed or with low expression are indicated (LE). 
4.3.3.3 Comparison of MARA and motif enrichment approaches  
Both the MARA-based approach and the motif enrichment-based approach provide methods 
for associating motifs and splicing factors to groups of splice junction modules for inference of 
potential regulatory relationships. Results from the two approaches associated different 
numbers of splicing factor motifs with each splice junction module. The two methods 
identified largely independent sets of potential regulatory motifs (Figure 4-8). 
 
Figure 4-8. Numbers of splicing factor motifs associated with splice junction modules. MARA 
= numbers of splicing factor motifs with an activity correlated with each splice junction module 
eigenJunction PSI.  Enrichment = numbers of splicing factor motifs with enriched counts 
flanking module splice junction sequences relative to “background” junctions. Intersection = 
numbers of splicing factor motifs identified in common by both approaches. p = probability of 
an intersection of the observed size or greater through random sampling (hypergeometric 
test).  
4.3.4 Identifying candidate regulatory splicing factor motifs 
Application of WGCNA revealed widespread and complex patterns of differential splicing 
across the CD4+ T cell activation timecourse, and involving genes from distinct biological 
processes. The regulatory splicing factors responsible for coordinating these patterns of 
differential splicing are of interest. To this end, S-MARA and splicing factor motif enrichment 
will be applied to generate a set of candidate regulatory splicing factors. This aim is similar to 




that addressed in section 4.3.3, but is not specifically focused on associating splicing factor 
motifs to splicing modules. Rather, the aim is to identify motifs having the strongest 
associations with splicing variation across the timecourse using more focused approaches. 
4.3.4.1 MARA-based predictions 
To identify a higher confidence group of splicing factor motifs of interest, linear mixed effect 
spline modelling was performed at the individual motif level. Of the 103 motifs, 78 had 
significant relationships with time-after-activation (FDR < 0.05). To further refine this motif set, 
a more stringent filter of FDR < 5 x 10^-4 was used. The FDR was inversely correlated with the 
sample standard deviation of motif activity, and positively correlated with the range of motif 
activity values across the timecourse (a metric which acts as a motif activity effect size) (Figure 
4-9). Filtering with this more stringent value therefore allowed identification of 62 motifs with 
large variation in activity across the timecourse and high consistency between donors (Figure 
4-9). These 62 motifs were associated with 57 splicing factors collectively. 
 
 
Figure 4-9. Characteristics of splicing factor motif activities across a timecourse of CD4+ T cell 
activation and polarisation. FDR = FDR of the probability of the null hypothesis (motif activity 
has no relationship with time after activation), assessed via linear mixed effect spline 
modelling. Motif activity range is the difference between maximum and minimum motif 




activity across the timecourse. Mean activity standard deviation (SD) is the mean of SDs 
calculated across donors per time point and cell type. Motifs with an activity range > 1.5 are 
labelled with consensus motifs and associated splicing factors. * indicates a positive control 
splicing factor. 
 
A number of motifs are known to promote binding of several different splicing factors, any of 
which may be driving the associated motif activity signal of interest. In such cases, gene 
expression data was used to further refine potential regulatory relationships between splicing 
factors and motifs. Nine of these 57 splicing factors of interest were either unexpressed or 
expressed at very low levels, and thus likely not driving the motif activity signal of their 
associated motif. Of the 62 selected motifs, 17 had an activity that correlated highly with the 
expression of one of the associated splicing factors (defined as absolute Pearson correlation > 
0.55). In these instances, splicing factors without a correlative expression profile were no 
longer considered as potential regulators of these motifs. In cases where none of the 
associated splicing factors showed a correlative expression profile with a motif’s activity, such 
filtering was not performed.  
 
An illustrative example of the utility in this type of filtering is the GGGUA motif associated with 
both PCBP2 and HNRNPA2B1. The activity of this motif correlated highly with HNRNPA2B1 
gene expression but not PCBP2 expression (Figure 4-10), suggesting HNRNPA2B1 is more likely 
to be the splicing factor driving the associated motif signal. Interestingly, amongst the motifs 
with increasing activity over time, this motif has the second strongest time-after-activation 
profile (as assessed via FDR), suggesting HNRNPA2B1 may be a good candidate for a splicing 
regulator during the CD4+ T cell activation process. HNRNPA2B1 has not previously associated 
with CD4+ T cell biology.  
 





Figure 4-10. Motif activity and gene expression of PCBP2 and HNRNPA2B1 during CD4+ T cell 
activation and polarisation. (A) Activity of a PCBP2-HNRNPA2B1 motif during CD4+ T cell 
activation and polarisation. (B) PCBP2-HNRNPA2B1 motif logo. (C) PCBP2 expression during 
CD4+ T cell activation and polarisation. (D) HNRNPA2B1 expression during CD4+ T cell 
activation and polarisation. Donor pool = set of 12 technical replicates from an individual 
donor pooled for analysis after RNA-seq. 
 
These filtering steps resulted in a final set of 47 candidate splicing regulators (depicted in 
Figure 4-5). To estimate the utility of these inferences, a set of positive control splicing factors 
was defined as those with previous evidence for a role in regulating differential splicing during 
T cell activation (Table 4-1). Of these 13 positive control splicing factors, 12 were in the final 
set of 47 candidate regulators. This represents a significant intersection as assessed via 
Hypergeometric test (probability of recovering 12 or more positive controls = 0.015). Prior to 
filtering based on gene expression there are 57 candidate splicing factors. Including the 12 




positive controls, this is a less significant overlap (p = 0.18), and suggests value in incorporating 
gene expression information. Of note, the hnRNP LL CACACA motif did not have a significant 
relationship with time after activation (Figure 4-6A), despite hnRNP LL being a recognised 
splicing regulator during the CD4+ T cell activation process. Interestingly, the expression of 
HNRNPLL was relatively low (Figure 4-6A). The AUAAA motif associated with KHDRBS1 had the 
lowest FDR for an association with time after activation. KHDRBS1, which encodes the Sam68 
protein, shows an undulating pattern of expression with a net upregulation over time-after-
activation; whilst the activity of the AUAAA motif decreases over time (Figure 4-6B). This 
negative correlation between gene expression and splicing activity may suggest a splicing 
repressor action of KHDRBS1 through this motif. Of the motifs with a decreasing activity profile 
over time after activation, the SFPQ motif GUAGUGU had the lowest FDR. SFPQ expression 
initially increased before decreasing from the 2 hr time point (Figure 4-6C). This could be 
evidence of a negative feedback loop, where initial increases in expression increase the 
splicing activity of this factor, before expression levels are then decreased. 
 
Table 4-1. Splicing factors with recognised regulatory roles during T cell activation, and with 
binding motif data available to facilitate motif analysis. 
Splicing factor Role in T cell activation Alternative splicing 
demonstrated to act 
directly through binding 
in cis motifs? 
HNRNPA1 Splicing of CD6 upon activation 
(demonstrated in bulk T cells) (Glória et al., 
2014). 
Yes 
HNRNPC Regulation of Mkk7 splicing during 
activation (demonstrated in Jurkat Cells) 
(Martinez et al., 2015).  
Yes 
HNRNPL Splicing of CD45 in T cells in an activation 
responsive manner (demonstrated in JSL1 
cells) (Rothrock et al., 2005). Regulates 
broader control of splicing in genes 
important to T cell development (work done 
Yes 




in primary CD4+ T cells and JSL1 cells) (Cole 
et al., 2015; Shankarling et al., 2014). 
HNRNPLL Global splicing regulator (including of CD45) 
during CD4+ T cell activation (Oberdoerffer 
et al., 2008). 
Yes 
HNRNPU Splicing of MALT1 during CD4+ T cell 
activation (Meininger et al., 2016). 
Yes 
KHDRBS1/Sam68 Splicing of CD44 during T cell activation 
(demonstrated in murine cell line – EL4) 
(Matter et al., 2002). 
Yes 
PTBP1 Regulation of gene expression upon T cell 
activation through multiple mechanisms 
including RNA degradation of IL-2 and CD40 
transcripts (La Porta et al., 2016). Limited 
evidence for regulating CD45 splicing upon 
activation (Rothrock et al., 2005). 
Limited evidence of a 
role in regulating 
alternative splicing 
during CD4+ T cell 
activation. 
SFPQ/PSF Splicing of CD45 during activation 
(demonstrated in Jurkat based model, 
follow-up work in primary CD4+ T cells) 
(Heyd and Lynch, 2010; Melton et al., 2007). 
Yes 
SRSF1 Splicing of CD45 exon 5 in an activation-
responsive manner (Motta-Mena et al., 
2010; Tong et al., 2005). Splicing of CD3 
upon activation (Moulton and Tsokos, 
2010). Splicing of CD6 upon activation 
(demonstrated in bulk T cells) (Glória et al., 
2014; Lemaire et al., 1999). 
Yes 
SRSF2 Splicing of CD45 upon activation 
(demonstrated in murine T cells) (Wang et 
al., 2001). 
Direct binding to CD45 
RNA not demonstrated. 
SRSF3 Splicing of CD6 upon activation 
(demonstrated in bulk primary T cells) 
(Glória et al., 2014). 
Yes 




TIA1 Regulation of Fas splicing in a Jurkat cell 
model (Izquierdo and Valcárcel, 2007). 
Recapitulates the splicing of Fas exon 6 
inclusion seen upon activation of PBMCs (Liu 
et al., 1995). 
Yes 
U2AF2 Role as core spliceosome component, 
driving assembly of an RNA-protein 
interactome during CD4+ T cell activation 
(Whisenant et al., 2015). 
Role in assembly of 
interactome and through 
binding constitutive 
splicing elements (the 
polypyrimidine tract). 
 





Figure 4-11. Motif activity, gene expression, and motif logos of selected splicing factors 
during CD4+ T cell activation and polarisation. (A) HNRNPLL, (B) KHDRBS1 (Sam68), and (C) 
SFPQ/PSF. Donor pool = set of 12 technical replicates from an individual donor pooled for 
analysis after RNA-seq. 
4.3.4.2 Motif enrichment-based predictions  
In order to identify splicing factor motifs specifically associated with the splice junctions 
showing the strongest changes in splicing after CD4+ T cell activation, a motif enrichment 
procedure was tested. An initial differential splicing analysis comparing naïve cells with Th0 




cells at 12, 24, 48, or 72 hrs post-activation was performed. Differential splicing between naïve 
and activated cells was similar across all of these tested time points (Figure 4-12).  
 
 
Figure 4-12. Intersections between differentially utilised splice junctions at various times 
after activation in Th0 cells. Green circles indicate the time points for which the intersection 
number in the above bar chart refer to. All intersections are significant as determined through 
Fisher’s exact test.  
 
The intersection of differentially utilised splice junctions across these four pair-wise time point 
comparisons (7319 splice junctions) was used for a motif enrichment analysis. This allowed 
identification of 35 splicing factor motifs with greater counts in RNA sequences flanking 
differentially spliced junctions relative to “background”, non-differentially spliced junctions 
(one-tailed Wilcoxon rank sum test, FDR < 0.05). These 35 motifs are associated with 53 
splicing factors, of which 10 were pre-defined positive controls (Table 4-1). The probability of 
an intersection of this size or greater is relatively high (p = 0.462, hypergeometric test). Of 
these splicing factors, 10 had low levels of gene expression and an additional one had 
expression that did not vary with time after activation (as assessed via linear mixed effect 
spline modelling, FDR > 0.05). Filtering of these 11 splicing factors led to an increased but non-




significant enrichment of positive controls within the candidate regulatory set (10 positive 
controls out of 42 post-filtering candidate splicing factors, p = 0.094, hypergeometric test). Of 
these 42 splicing factors, 35 are in the final set of 47 splicing factors identified as candidate 
activation regulators derived through the S-MARA based analysis, which is a highly significant 
intersection (probability of an intersection of this size or greater = 5.82 x 10^-5 - 
hypergeometric test). Finally, the ten motifs with the greatest increase in motif counts relative 
to background junctions are depicted in Figure 4-13. These included the top MARA-based hit, 




Figure 4-13. Splicing factor motif counts which are over-represented in splice junctions that 
are differentially spliced after CD4+ T cell activation. Motif enrichment was calculated using 




the intersection of differentially spliced junctions at 12, 24, 48, and 72 hrs post-activation. The 
ten motifs with the highest increase in mean motif counts flanking differentially spliced (DS) 
junction sequences, relative to background (BG) junctions, are shown. Motifs are ordered from 
left to right in order of highest to lowest difference in mean motif counts. Motif consensus 
sequences and associated splicing factors are shown. To simplify labelling, and since multiple 
splicing factor can be associated with a given motif, factors with low expression levels are not 
shown, unless this resulted in removal of all splicing factors associated with a given motif 
(these cases are marked with LE – Low expression). 
 
4.3.5 Gene-level splicing factor motif analyses may be biased towards 
identifying positive control factors 
Thus far, the performance in identifying positive control splicing factors has been assessed via 
testing at the motif level, with S-MARA or motif enrichment analysis, before mapping to the 
gene level and employing hypergeometric enrichment testing. A limitation to this approach is 
that it does not account for the initial number of hypothesis tests performed relating to each 
splicing factor at the motif level. With this in mind, the numbers of motifs associated with each 
splicing factor in our compiled set 103 motifs was assessed. This revealed that positive control 
factors had significantly more motifs associated with them on average than non-positive 
control splicing factors. Specifically, positive control splicing factors had a median of three 
motifs, whilst non-positive control factors had a median of two motifs (Figure 4-14). This 
difference was significant as assessed via Wilcoxon rank sum test (p = 0.018). This feature of 
the data was not an intended characteristic of the compiled motif dataset. Indeed, since the 
results of the motif-based analysis conducted thus far are mapped to the splicing factor level in 
a post-hoc manner, the biased distribution in numbers of per-splicing factor motifs introduces 
a bias towards identifying positive control splicing factors.  





Figure 4-14. Distribution of number of associated motifs amongst positive control and non-
positive control splicing factors. Splicing factors grouped on x-axis according to whether they 
are considered as positive control regulators during the CD4+ T cell activation process (Table 4-
1). 
4.3.6 Receiver operating characteristics of S-MARA and motif enrichment 
analysis in identifying positive control splicing regulators of CD4+ T 
cell activation 
In light of the identified limitations in assessing performance of splicing factor motif analyses 
at the gene-level, an additional analysis was performed directly using motif-level data. To 
further assess the performance of the S-MARA and motif enrichment-based approaches in 
identifying positive control splicing factors, an assessment of the ROC AUC was performed. To 
this end, the per-motif FDR values derived from motif enrichment analysis (4.3.4.2) or S-MARA 
analysis (section 4.3.4.1) were used. Motifs were considered as true positives if associated 
with a positive control splicing factor, whilst all others were considered true negatives. This 
analysis identified the motif enrichment procedure as having greater performance 
characteristics. Indeed, although MARA showed an AUC > 0.5 (AUC = 0.561), the 95% 




confidence intervals contained 0.5, whilst those of motif enrichment analysis did not (Figure 4-
14). 
 
Figure 4-15. Receiver operating characteristics for the identification of positive control 
splicing factor motifs. (A) Performance of S-MARA. (B) performance of motif enrichment 
analysis. AUC = area under the curve. 95% confidence intervals are shown. Ratios of sensitivity 
to specificity in identifying positive control splicing factor motifs at varying FDR threshold 
values are depicted. True positives were defined as motifs associated with pre-defined positive 
control splicing factors (Table 4-1). 
4.4 Discussion 
Here, the regulation of splicing during the process of CD4+ T cell activation and polarisation to 
a Th2 subtype was studied through analysis of splicing factor motifs. To gain insight into the 
broad dynamics of splicing regulation, a correlation-network approach was used. Of the 103 
splicing factor motifs studied, 78 showed an activity profile that varied over time after initial 
TCR stimulation (Figure 4-9) – behaviour consistent with potential roles in regulating 
activation-dependent alternative splicing. Clustering of these activity profiles resolved the 
motifs into groups of modules which potentially reflected different patterns of splicing 
regulatory control (Figure 4-4). Correlation-network analysis at the splice junction-level 
revealed that the predominant pattern of splicing variation was a simple and steady switch in 
relative splice junction usage (Figure 4-2, modules 1 & 2). Genes characterised by this splicing 
profile were enriched for roles in a wide range of biological processes representing most steps 




of the gene expression pathway. These biological processes included splicing itself, in addition 
to other processes such as epigenetic modification and ribosomal biogenesis. This finding 
could reflect a role for alternative splicing in reprogramming gene expression to drive 
proliferation and production of key cytokines and associated receptors subsequent to CD4+ T 
cell activation. Indeed, CD4+ T cell activation is characterised by increased ribosomal 
biogenesis which is thought to facilitate increased cytokine production (Asmal et al., 2003). 
Further, the control of gene expression during the activation process is known to be influenced 
by several layers of epigenetics modifications (Schmidl et al., 2018). Across these modules of 
activity, the main source of variation in splicing was time after CD3/CD28 stimulation, rather 
than polarisation into a Th2 vs Th0 specification. However, a more directed analysis of 
differential splicing may highlight splicing modulations important to Th2 specification.  
 
In order to infer which splicing factors may be driving the patterns of differential splicing 
observed across the identified splice junction modules, both a MARA-focused approach and a 
motif enrichment approach were applied. In this regard, the two methods produced largely 
non-overlapping predictions with regards to inferring potential splicing factor regulators of 
each splicing module (Figure 4-8).  
 
To assess the relative performance of both S-MARA and motif enrichment analysis in 
identifying positive control regulatory splicing factors (Table 4-1), an additional analysis was 
performed. This additional approach focused on identifying patterns of strong splicing 
modulation across the timecourse, but unlike the previous analysis, did not rely upon 
identifying modules of distinct splice events. The S-MARA approach involved filtering motifs 
based on strength of association with time-after-activation, combined with a filtering of 
splicing factors based on gene expression profiles. This strategy resulted in a set of candidate 
regulatory splicing factors enriched for positive controls with known roles in regulation of 
alternative splicing during CD4+ T cell activation. Indeed, two of the top motif activity profiles 
of interest were for motifs associated with positive controls SFPQ and KHDRBS1/Sam68. Both 
of these splicing factors have been identified as regulators of splicing upon CD4+ T cell 
activation in the context of individual loci (Table 4-1). KHDRBS1/Sam68 showed a pattern of 
motif activity (motif = AUAAA) and gene expression consistent with a role as a splicing 
repressor (Figure 4-11). This contrasts with the documented role for Sam68 in promoting 
inclusion of CD44 exon v5 upon binding an AAAUU exonic sequence upon T cell activation 




(Matter et al., 2002). However, Sam68 has also been shown to act as a splicing repressor in the 
context of spinal muscular atrophy (Pedrotti et al., 2010), and to have both repressor and 
enhancer activity during neurogenesis (Chawla et al., 2009). The strong association between 
activities of these binding motifs and splicing during the activation process may suggest a 
broad role in regulating the splicing of a larger number of genes. 
 
Ranking splicing factor motifs by their relationship with time-after-activation in this manner 
can also highlight novel candidate regulators – genes without previously recognised roles in 
CD4+ T cell biology. For example, activity of the HNRNPA2B1 motif GGGUA is strongly 
associated with time after CD4+ T cell activation, and highly correlated with HNRNPA2B1 gene 
expression (Figure 4-10). A prediction from these results is that HNRNPA2B1, SFPQ, and 
KHDRBS1/Sam68 may have roles in regulating genome-wide programmes of alternative 
splicing during CD4+ T cell activation. This hypothesis could be tested via an experimental 
system in which splicing factor expression is reduced or overexpressed in CD4+ T cells exposed 
to an activation stimulus. These samples could then be re-analysed via RNA-seq to assess 
potential disruption to the activation-associated splicing regulatory programme.  
 
To contextualize the results of S-MARA, splicing factor motif enrichment analysis was again 
applied. This approach, aimed at identifying motifs associated with the strongest changes in 
splicing after activation, identified a set of candidate splicing factors that significantly 
overlapped with the highest confidence MARA-based candidates. Both the MARA and motif 
enrichment methods, when combined with a filtering of splicing factors based on gene 
expression data, led to identification of a candidate list containing a number of positive 
controls with known roles in regulating splicing during CD4+ T cell activation. However, a 
potential source of bias towards recovering positive control splicing factors was identified, in 
that positive controls had more associated motifs (Figure 4-14). Positive control factors were 
thus more likely to be identified ab initio. In light of this, a ROC analysis was performed. Being 
conducted at the motif, rather than gene-level, this ROC analysis was not sensitive to the same 
bias, and is thus a more objective method of assessing performance. This direct assessment of 
per-motif scores revealed that motif enrichment derived results had improved specificity and 
sensitivity compared with the results produced through combining S-MARA with linear mixed 
effect spline modelling (Figure 4-14).  
 




To give full consideration of these results, several limitations with the ROC analysis and the use 
of positive control splicing factors defined in Table 4-1 should be addressed. Firstly, one goal of 
applying splicing factor motif-based analyses in this study was to identify novel regulators of 
splicing during the CD4+ T cell activation and polarisation process. Indeed, several promising 
novel candidate regulators were highlighted through this analysis. This has obvious 
implications for the definition of true negatives when employing a ROC AUC analysis, whereby 
the splicing factors defined as true negatives will likely include a number of mislabelled cases 
of novel “positive case” splicing factor regulators. Similarly, defining true positives presents 
challenges. The strength of evidence for the pre-defined regulators of alternative splicing 
during CD4+ T cell activation is variable (Table 4-1). From extensively studied and high 
confidence cases such as hnRNP L, to factors such as hnRNP C which have only been studied in 
T cell lines rather than primary CD4+ T cells, or splicing factors for which only indirect evidence 
for a role in controlling alterative splicing during T cell activation has been demonstrated, such 
as PTBP1. Thus, there is a range of confidence with which each of the positive controls is 
indeed a key regulator of splicing during CD4+ T cell activation, and false positives may be 
present. 
 
S-MARA displayed poor performance when applied to analysis of shRNA-induced splicing 
factor-knockdown data (Chapter 3). Initial application to the timecourse of CD4+ T cell 
activation herein proved more promising, since S-MARA identified a variety of splicing factor 
motif activity profiles that were consistent across replicates and may represent modular 
patterns of splicing regulatory activity (Figure 4-4). Further, identification of a subset of splicing 
factor motifs with high consistency across replicates and large variation across the timecourse 
(Figure 4-9) highlighted a group of splicing factors enriched for positive controls and including 
promising novel candidates. Issues of statistical power linked to low replicate numbers were 
identified as a possible cause of the poor performance in identifying regulatory factors in 
analysis of the ENCODE project data in Chapter 3. Thus, the greater numbers of biological 
replicates and the number of timepoints available for estimation of motif activity here may 
have aided the performance of S-MARA. However, as with the previous analysis, the ROC AUC 
of S-MARA was still inferior to the motif enrichment procedure (Figure 4-14). This finding thus 
warrants caution over interpretation of the results of S-MARA and highlights the need for 
experimental validation of novel predictions. In light of this, the predictions resulting from 




application of motif enrichment analysis (Figure 4-13) are more promising and should be the 
focus of any potential follow-up investigations. 
4.5 Conclusions 
Herein, MARA was applied to infer splicing factor motif activity profiles across a timecourse of 
CD4+ T cell activation. Activity profiles which showed similar behaviour across replicates and 
were consistent with potential splicing regulatory profiles were identified. These profiles were 
filtered to produce a set of candidate splicing regulators. Although the results from application 
of S-MARA showed promise, analysis of differential splicing coupled with motif enrichment 
analysis again showed improved sensitivity and specificity characteristics. Thus S-MARA needs 
further refinement upon its current implementation before firm conclusions regarding the 
results of its application can be drawn. 
 




Chapter 5. Assessment of the Genome-Wide Targets of the RNA 
Binding Protein Sam68 upon CD4+ T cell Activation 
5.1 Introduction 
KH domain containing, RNA binding, signal transduction associated 1 (KHDRBS1) encodes the 
multifunctional Src-associated in mitosis 68 kDa (Sam68) protein. Sam68 is a member of the 
Signal Transduction and Activation of RNA (STAR) family of proteins, which have roles in linking 
signal transduction pathways to post-transcriptional control of gene expression (Vernet and 
Artzt, 1997). The hnRNP K Homology (KH) domain of Sam68 confers RNA binding affinity 
towards several AU based motifs (Taylor and Shalloway, 1994). Sam68 has roles in multiple 
aspects of gene expression including transcription (Fu et al., 2013), alternative splicing (Matter 
et al., 2002; Paronetto et al., 2007), 3’ end processing (La Rosa et al., 2016), and translation 
(Paronetto et al., 2009). The activity of Sam68 is modulated in response to extracellular 
signalling such as through stimulation of the TNF-alpha receptor (Kunkel and Wang, 2011) or T-
cell receptor (Fusaki et al., 1997). In response, Sam68 acts as a scaffolding protein, interacting 
with the SH3 domain of various SRC kinases, including those downstream of TCR-signalling 
such as Fyn or Lck (Fusaki et al., 1997; Paronetto et al., 2003). Sam68 was identified as a 
regulator of CD44 exon v5 splicing, mediated through binding an in cis AAAAUU sequence, in 
response to T cell stimulation in the mouse T lymphoma EL4 cell line (Matter et al., 2002). In 
this context, Sam68 was proposed to be activated via phosphorylation subsequent to Ras-ERK 
signalling after T-cell stimulation (Matter et al., 2002).  
 
A more widespread role for Sam68-regulated splicing during cellular differentiation processes 
has also been observed, specifically during neurogenesis (Chawla et al., 2009), adipogenesis 
(Huot et al., 2012), and spermatogenesis (Paronetto et al., 2011). In addition to its RNA-
binding capacity, Sam68 mediates the activities of other proteins through direct protein-
protein interaction. For example, the upregulation of CD25 upon TCR engagement was shown 
to depend upon Sam68 binding to the NF-κB complex, which in turn  facilitates interaction 
with the CD25 promoter (Fu et al., 2013). 
 
A genome-wide assessment of the role of Sam68 in transcriptional or post-transcriptional 
regulation of gene expression in CD4+ T cells has not been performed. During neurogenesis, 




Sam68 was shown to regulate splicing of a specific set of pre-mRNAs enriched for Sam68-
associated binding motifs (Chawla et al., 2009), and we hypothesise that this may also be true 
during the CD4+ T cell activation process. To investigate this hypothesis, KHDRBS1 (Sam68) 
expression was knocked down in primary CD4+ T cells via RNA interference (RNAi), and RNA-
seq was used to profile the transcriptome of both knockdown and wild type cells before and 
after activation. An activate, transduce, rest, reactivate protocol was employed to facilitate 
Sam68 knockdown in these primary CD4+ T cells (see Materials & Methods for details). 
5.2 Aims 
Differential splicing is widespread during the CD4+ T cell activation process. However, the 
underlying regulatory splicing factors controlling these events are unknown for many genes. 
Sam68 is a multifunctional RBP the activity of which is regulated through TCR signalling. We 
propose that Sam68 may contribute to the widespread regulation of differential splicing during 
CD4+ T cell activation. Using a genetic knockdown approach, we aim to:  
1. Confirm knockdown of Sam68 in primary CD4+ T cells. 
2. Identify genes with altered splicing or expression profiles induced via Sam68 knock 
down. 
3. Intersect genes from aim 2 with genes also regulated specifically upon CD4+ T cell 
activation. 
4. Assess enrichment of Sam68 binding motifs in genes with disrupted splicing in 
knockdown cells. 
5.3 Results 
5.3.1 Sam68 knockdown in primary CD4+ T cells  
To functionally investigate Sam68, several experimental conditions were used - two control 
conditions (untransduced and scramble shRNA treated) and two knockdown conditions 
(Sam68 shRNA 1 & 2). Analysis of RNA-seq from these four conditions confirmed that Sam68 
was depleted at the mRNA level (Figure 5-1) with an ~80% and ~56% reduction in expression in 
activated and resting cells respectively. PCA using either gene expression or splicing 
quantifications identified the first principal component of variance as being driven by 
activation state and the second by cell donor source (biological replicate) (Figure 5-2). Sam68 
knockdown was associated with the fourth PC of variance (Figure 5-2). 





Figure 5-1. Sam68 mRNA expression in wild type and Sam68 knockdown CD4+ T cells. For 
hypothesis testing, control samples (untransduced and control shRNA), and knockdown 
samples (Sam68 shRNA 1 and 2) were pooled. FDR values for comparison of wild-type with 
Sam68 knockdown are depicted. 
 
 
Figure 5-2. Principal component analysis of wild type and Sam68 knockdown CD4+ T cells. (A) 
& (B) Principal components of variance of : (A) Gene expression (regularized log transformed 
TPM), and (B) splicing (logit transformed PSI). (C) & (D) Linear regression of experimental 




conditions against principal components of: (C) gene expression, and (D) splicing. * indicates a 
significant association. 
 
In order to profile the regulation of gene expression upon CD4+ T cell activation and the 
effects of Sam68 knockdown, the three biological replicates from different biological 
conditions were compared in a pairwise manner (Table 5-1). Different control conditions 
(untransduced and scramble shRNA transduced) and knockdown conditions (Sam68-targeting 
shRNA 1 & 2) were pooled for this analysis. Differential mRNA abundance was assessed using 
Sleuth, and differential splicing via MAJIQ (See Methods for further details). As expected, 
differential gene expression and splicing analysis identified large numbers of regulated events 
upon CD4+ T cell activation (Figure 5-3A & D). Indeed, 72.9% of genes expressed in at least one 
sample (17633/24204) were identified as differentially expressed upon CD4+ T cell activation 
(FDR < 0.05). Sam68 knockdown also resulted in widespread differential gene expression in 
both activated (Figure 5-3B & E) or resting state cells (Figure 5-3C & F).  
 
Table 5-1. Experimental conditions and pairwise comparisons used for 
differential gene expression and splicing analysis. 
Reference condition Comparison condition Total sample number 
Untransduced & control 
shRNA-treated – resting cells 
Untransduced & control 
shRNA-treated - activated cells 
12 (3 biological 
replicates per condition) 
Control shRNA-treated & 
untransduced – resting cells 
Sam68 targeting shRNA 1 & 2 – 
resting cells 
12 (3 biological 
replicates per condition) 
Control shRNA-treated & 
untransduced –activated cells 
Sam68 targeting shRNA 1 & 2 – 
activated cells 
12 (3 biological 
replicates per condition) 
 
 





Figure 5-3. Volcano plots of differential splicing and gene expression in CD4+ T cells. (A-C) 
Differential gene expression. (D-F) Differential splicing. (A & D) activated control 
(untransduced & scramble shRNA transduced) samples relative to resting control samples, (B 
& E) Sam68 knockdown samples in resting state relative to control samples in resting state, (C 
& F) Sam68 knockdown samples in activated state relative to control samples in activated 
state. Comparisons as detailed in Table 5-1. 
5.3.2 Sam68 dependent splicing during CD4+ T cell activation 
In resting CD4+ T cells, 32 local splicing variants (LSVs) from 30 different genes were 
differentially spliced upon Sam68 knockdown (>= 95% probability of change in PSI >= 20% [see 
Appendix 8.4 for lists of these genes]). Upon activation, splicing of 30 LSVs from 28 genes was 
disrupted in Sam68 depleted cells relative to wild-type activated cell. The LSVs affected in the 
resting and activated states were largely independent, with only two LSVs disrupted in both 
cell states (Figure 5-4, Appendix 8.4). Activation of wild type CD4+ T cells stimulated altered 
splicing of 563 LSVs from 463 genes (Appendix 8.4), which overlapped modestly yet 
significantly with the set of Sam68 knockdown-sensitive LSVs in both resting or activated cell 
states (Figure 5-4). These gene sets were not enriched for any “Biological Process” gene 
ontology terms. Counter to previous findings in the mouse EL4 cell line (Matter et al., 2002), 








Figure 5-4. Intersections between local splicing variations with altered splicing upon Sam68 
knockdown in CD4+ T cells. Green circles indicate the analyses for which the above 
intersection numbers relate to. * indicates cases with significant intersections relative to 









Figure 5-5. Splicing of CD44 exon v5 in two local splicing variations. Splicing of exon v5 is 
captured by two local splicing variations. (A) and (C): Splice junction usage in resting relative to 
activated CD4+ T cells. (B) and (D): Splice junction usage in wild type relative to Sam68 
knockdown cells. Constitutive splicing of exon v5 with exon v4 not shown. 
 





Figure 5-6. Two patterns of differential splicing upon CD4+ T cell activation and knockdown 
of Sam68. (A-D) Example of a locus at which Sam68 appears to promote a resting cell-like 
splicing profile. (A) Schematic shows gene structure and isoforms of AL162258.1, an antisense 
lncRNA. (B-D) change in PSI of two splice junctions: (B) upon activation, (C) upon knockdown 
of Sam68 in resting cells, or (D) knockdown of Sam68 in activated cells. Colours relate to splice 
junctions depicted in (A), the red splice junction is used in two annotated transcripts. (E-H) 




Example of a locus at which Sam68 appears to promote an activation-associated splicing 
profile. (E) Schematic of AGO3 isoforms. (F-H) change in PSI of two splice junctions: (F) upon 
activation, (G) upon knockdown of Sam68 in resting cells, or (H) knockdown of Sam68 in 
activated cells. Colours relate to use of splice junctions depicted in (E). (I-L) Example of a locus 
at which Sam68 appears to promote an activation-associated splicing profile. (I) Schematic of 
CASP8 isoforms. (J-L) change in PSI of two splice junctions: (J) upon activation, (K) upon 
knockdown of Sam68 in resting cells, or (L) knockdown of Sam68 in activated cells. Colours 
relate to use of splice junctions depicted in (I). Isoform schematics adapted from Ensembl 
genome browser release 97 (Hunt et al., 2018).  
 
Addressing whether Sam68 has a functional contribution to differential splicing during CD4+ T 
cell activation is a priority. Six LSVs were differentially spliced both upon activation and after 
Sam68 knockdown, providing evidence for a potentially minor role of Sam68 in controlling 
activation-associated differential splicing (Table 5-1). Several genes displayed patterns of 
differential splicing upon activation that were also promoted upon Sam68 knockdown, namely 
AL162258.1 (Figure 5-6A-D), GOLGA8B, and TMEM116. This suggests Sam68 acts to maintain 
the resting state-associated splicing profiles at these loci. Splicing at AGO3 (Figure 5-6E-H), 
CAPS8 (Figure 5-6I-L), and RRP7BP showed a different response in which Sam68 knockdown 
inhibited the activation-associated alternative splicing pattern. At these loci, Sam68 may thus 
act to enhance splicing modulation during the T-cell activation process. Examining the gene 
models of several of these differentially spliced loci suggests that Sam68 knockdown may 
promote a change in isoform usage (Table 5-1). Some instances of differential splicing involved 
the use of novel, unannotated exons or splice sites (RRP7BP and GOLGA8B – Table 5-1).  
 
Table 5-2. Effects of CD4+ T cell activation and Sam68 knock down on splicing of selected 
exons and corresponding transcript isoforms. Ensembl transcript identifiers and associated 
biotypes are shown (Ensembl version 97). Co-ordinates of alternative and differentially spliced 
exons relate to GRCh38/hg38 assembly. lncRNA = long non-coding RNA. 
Gene Isoform/s 
upregulated in wild 
type cells upon 
activation 
Isoform/s upregulated in 
Sam68 knockdown 
relative to wild type cells  










































Motif enrichment analysis was performed to assess the distribution of Sam68-associated motif 
occurrences in regions flanking differentially spliced events. Splice junctions with altered 
splicing upon activation had greater counts for Sam68 motifs AUAAA and UUUUA in their 
flanking RNA sequences relative to background junctions (one tailed Wilcoxon rank sum test, 
FDR = 0.009). Junctions affected by Sam68 knockdown in resting cells, but not those affected 
in activated cells, also showed greater counts for the Sam68 AUAAA motif (one tailed Wilcoxon 
rank sum test, FDR = 0.043) (Figure 5-7). 
 





Figure 5-7. Motif enrichment analysis for Sam68-associated motifs using differentially 
regulated splice junctions. (A-C) Count distributions for motif UUUUA amongst differentially 
spliced junctions after: (A) CD4+ T cell activation, (B) depletion of Sam68 mRNA in activated 
cells, (C) depletion of Sam68 in resting cells. (D-F) Count distributions for motif UUUUA 
amongst differentially spliced junctions after: (D) CD4+ T cell activation, (E) depletion of Sam68 
mRNA in activated cells, (F) depletion of Sam68 in resting cells. Background = count 
distribution amongst non-differentially regulated background junctions. * indicates the 
differentially regulated junctions were over-represented for motif counts relative to 
background splice junctions.  
5.3.3 Sam68-dependent gene expression during CD4+ T cell activation 
Sam68 can regulate multiple steps in the gene expression pathway. Therefore, a differential 
gene expression analysis was performed to assess the effects of Sam68-depletion on gene-
level mRNA abundances. This analysis identified 3758 genes with altered expression upon 
Sam68 knockdown in resting CD4+ T cells (Figure 5-3B). Upon activation of Sam68 depleted 
cells, 675 genes had altered expression relative to wild-type activated cells (Figure 5-3C). A 
significant overlap between the genes affected in both the resting and activated state was 
present (Figure 5-8). A number of genes differentially expressed in Sam68 knockdown cells 
also displayed altered splicing (Figure 5-8). Counter to previous findings (Fu et al., 2013), IL2RA 




(CD25) expression was not reduced by Sam68 knockdown (Figure 5-9A). Gene ontology 
analysis revealed that Sam68 regulated genes in resting cells were enriched for a role in “DNA 
strand elongation involving in DNA replication”, whilst those genes affected in the activated 
cells state were enriched for roles in “catecholamine metabolic process”, “T cell costimulation” 
(including CD28 – Figure 5-9B), and “interferon-gamma-mediated signalling pathway”. 
 
Figure 5-8. Intersections between genes with altered expression or splicing upon activation 
or Sam68 knockdown in CD4+ T cells. exp. = altered gene expression, splic. = altered gene 
splicing. KD = knockdown. Green circles indicate the analyses for which the above intersection 
numbers relate to. * indicates cases with significant intersections relative to random sampling 
from the background set of all expressed genes, as assessed vis Fisher’s exact test.  





Figure 5-9. Gene expression of selected cell surface marker genes in wild type and Sam68 
knockdown CD4+ T cells. (A) IL2RA (CD25) and (B) CD28. FDR shown, * highlights FDR < 0.05. 
For hypothesis testing, control samples (untransduced and control shRNA treated), and 
knockdown samples (Sam68 shRNA 1 and 2 treated) were pooled. 
5.3.4 Comparison of activation and re-activation induced splicing in CD4+ T 
cells 
In this study, CD4+ T cells were stimulated using a re-activation procedure wherein CD3/CD28 
stimulation was initially applied to facilitate transduction with lentiviral vectors containing 
Sam68-targeting shRNA. The activation stimulus was then removed to allow cells to return to a 
resting state for three days, before being reactivated. This method contrasts with some 
previous investigations of CD4+ T cell activation. For instance, Henriksson et al. (Henriksson et 
al., 2019) activated naïve CD4+ T cells via CD3/CD28 stimulation followed by IL-2 exposure, 
whilst Ni et al. (Ni et al., 2016) studied CD4+ T cells at 18 hrs post-activation via CD3/CD28 
stimulation. These studies therefore investigated differential splicing in true naïve CD4+ cells 
exposed to a “primary” activation stimulus, rather than after a secondary activation exposure 
(re-activation). Different activation protocols may produce differing effects on alternative 
splicing. We therefore compared the splicing modulation induced through these various 
activation protocols.  
 
Large and highly significant intersections were observed between the sets of genes with 
altered splicing at 12, 24, 48, or 72 hrs post-activation in the study from Henriksson et al. and 




those with altered splicing at 18 hrs post-activation in the Ni et al. study (Ni et al., 2016) 
(Figure 5-10). Indeed, the majority of differentially spliced genes identified in the Henriksson et 
al. data are also observed in the Ni et al. data. The Ni et al. genes are thus essentially a 
superset of the Henriksson et al. genes. In contrast, pairwise intersections between the genes 
with altered splicing upon re-activation (this study) and those regulated at 12 or 24 hrs post-
activation (Henriksson study) were smaller but statistically significant (Figure 5-10). The genes 
alternatively spliced at 18 hrs post-activation (Ni study) also significantly overlapped with the 
re-activation sensitive gene set, with a somewhat larger overlap of 195 genes (Figure 5-10). 
Therefore, although there is similarity between differential splicing in CD4+ T cells in response 
to primary activation vs secondary re-activation, two independent experiments investigating 
splicing directly after a primary activation stimulus showed much greater similarity. 
 
 
Figure 5-10. Intersections between genes with altered splicing upon CD4+ T cell activation or 
re-activation after various time points and from multiple studies. Genes with altered splicing 
at: 18 hrs post-activation (Ni et al. – 18 hrs), 12, 24, 48, or 72 hrs post-activation (Henriksson et 
al.), or 3 days after re-activation (this study, Re-activation). Green circles indicate the analyses 
for which the above intersection numbers relate to. * indicates cases with significant 




intersections relative to random sampling from the background set of expressed genes, as 
assessed via Fisher’s exact test. 
 
In line with the data generated from this study (Figure 5-5), CD44 exon v5 was not 
differentially spliced upon activation in the Ni et al. or Henriksson et al. studies (Figure 5-11). 
This suggests that, although Sam68 has been previously reported to regulate splicing of CD44 
in response to T-cell stimulation (Matter et al., 2002), this may be a consequence of the 
experimental system used. Specifically, Matter et al. (Matter et al., 2002) utilised the mouse T 
lymphoma EL4 cell line to study Sam68-mediated alternative splicing. 
 
Figure 5-11. Alternative splicing of CD44 exon v5 in two local splicing variations. (A) & (B): 
splice junction usage in CD4+ T cells 24 hrs post-activation relative to resting cells – data from 
Henriksson et al.. (C) Splice junction usage in CD4+ T cells 18 hrs post-activation relative to 
resting cells – data from Ni et al.. Splice junctions from the LSV in (A) were not utilised in RNA-
seq data from the Ni et al. experiment, instead the splice junction shown in brown was 




constitutively utilised. Exon v5 is spliced with exon v4 but this is a constitutive event not 
captured in an LSV. 
5.4 Discussion 
Sam68 is recognised as a regulator of multiple steps in the gene expression pathway during T-
cell activation. Here, RNAi-mediated silencing was used to investigate the genome-wide 
splicing targets of Sam68. Gene expression was successfully reduced at the mRNA level in both 
the resting and activated CD4+ T cell state (Figure 5-1). Several thousand genes had altered 
RNA abundance after knockdown of Sam68, and a smaller number showed altered patterns of 
alternative splicing (Figures 5-3 & 5-8). The splice junctions with altered patterns of use in 
Sam68 knockdown cells in the resting state were over-represented for the Sam68 motif 
AUAAA in their flanking RNA sequences (Figure 5-7). This suggests a potentially direct 
mechanism of splicing regulation involving Sam68 binding to in-cis elements. 
 
Several splicing events that were altered in Sam68 knockdown cells appeared to control 
switches in expression of distinct annotated isoforms (Table 5-1). This included CASP8, which 
was differentially spliced upon CD4+ T cell activation to favour expression of a protein coding 
transcript over an alternative lncRNA (Figure 5-6I-L). Knockdown of Sam68 in both the resting 
and activated state altered the splicing profile to favour expression of the resting state-
associated lncRNA coding variant. This suggests a role of Sam68 in either repressing usage of 
the protein coding isoform or promoting usage of the non-coding transcript in an activation-
associated manner. Potential functions of the non-coding transcript are unknown, but the 
protein coding product caspase-8 has been shown to be necessary for T-cell development and 
activation in the mouse (Salmena et al., 2003). Sam68 has been previously shown to promote 
the apoptotic activity of caspase-8 via recruitment of RIP to the FADD-caspase-8-complex 
which is necessary for caspase-8 activation (Ramakrishnan and Baltimore, 2011). However, this 
process is mediated through protein-protein interactions and is independent of the RNA-
binding and splicing function of Sam68. Other Sam68-sensitive splicing events were related to 
the use of unannotated splice junctions, as with GOLGA8B (Table 5-1). This set of activation-
sensitive, Sam68-regulated splicing events could be selected for future study. For instance, in 
silico analysis could be employed to predict whether the induced patterns of alternative 
splicing may alter protein coding sequences, such as via introduction of premature termination 
codons or functional protein domains. Future experimental work could include functional 




investigation through over-expression or knockdown assays of specific Sam68-regulated 
isoforms. Further, although only six genes were differentially spliced both in response to 
activation and Sam68 knockdown, splicing of additional genes was altered specifically in 
response to Sam68 knockdown (Figure 5-4), and these events may also be of interest for 
future study. 
 
Knockdown of Sam68 resulted in differential splicing of ~30 genes. Counter to expectations, 
CD44 was not amongst these genes. The role of Sam68 as a signaling-dependent splicing 
modulator was initially established through work showing that exon v5 of CD44 is differentially 
spliced in response to T cell stimulation (Matter et al., 2002). However, this exon was not 
differentially spliced upon Sam68 knockdown in our experiments (Figure 5-6). However, CD44 
exon v5 was also not found to be differentially spliced upon CD4+ T cell activation in data from 
several other studies examined herein (Henriksson et al., 2019; Ni et al., 2016) (Figure 5-5 & 
Figure 5-11). This discrepancy may be due to differences in the cell models utilised. The study 
linking Sam68 with CD44 splicing was conducted in a mouse T-lymphoma line (EL4 cells). In 
one study, expression of CD44 variable exons (including v5) was specifically observed in 
lymphocytes from patients with lymphoma, but not from healthy donors (Khaldoyanidi et al., 
1996). These observations suggest that Sam68-dependent splicing of CD44 may then be 
specific to the cancer-induced cell environment. 
 
In our previous analysis, the activity of the Sam68 binding motif AUAAA was strongly 
associated with splicing modulation across a timecourse of CD4+ T cell activation, and was 
over-represented in events that were differentially spliced upon activation (Chapter 4, data 
from Henriksson et al. (Henriksson et al., 2019)). One interpretation of these finding is that 
Sam68 may play a widespread role in splicing regulation upon CD4+ T cell activation. However, 
knockdown of Sam68 resulted in a relatively small set of genes with perturbed splicing in CD4+ 
T cells after re-activation, and these genes were not enriched for roles in distinct biological 
processes. This suggests that in fact Sam68 has only a minor role in regulating activation-
induced differential splicing. Several important caveats to this conclusion should be considered 
however. Firstly, in this study Sam68 expression was successfully reduced (Figure 5-1), but a 
complete knockout was not performed, and may have resulted in greater alterations to 
cellular alternative splicing regulation. Redundancy effects may also be a contributing factor, 




whereby other splicing factors with partially overlapping functionality and binding preferences 
to Sam68 could compensate for the reduced Sam68 splicing activity in knockdown cells.  
 
In addition, the experimental activation protocol employed should be considered. In this study, 
a rest, activate, rest, re-activate protocol was used to facilitate RNAi-mediated Sam68 
depletion. Thus, the functions of Sam68 were investigated in previously activated cells 
exposed to a second activation stimulus. Two independent studies of naïve CD4+ T cell primary 
activation showed a high similarity in activation-induced differential splicing (Figure 5-10). In 
contrast, the re-activation-induced splicing pattern identified herein showed less similarity 
(Figure 5-10), suggesting that the secondary activation response may only partially reflect the 
transition from naïve to activated CD4+ T cells. Indeed, previous work has found that 
expression of some cell surface markers, including CD45 variants, was less responsive to 
stimulation of CD4+ T cells that had been previously exposed to antigen (i.e. re-activation) 
(Brenchley et al., 2002). 
 
Sam68 knockdown resulted in a greater number of changes to gene expression (i.e. mRNA 
abundances) than to splicing. This included regulation of genes enriched for roles in T cell co-
stimulation, such as a down-regulation of CD28 (Figure 5-9). Modulation of CD28 expression 
has been documented in response to TCR stimulation and CD28 co-stimulation as part of a 
negative feedback response (Vallejo et al., 1999). Sam68  is known to contribute to 
transcriptional regulation through interacting with NF-kB (Fu et al., 2013), but has not been 
previously associated with CD28 expression. Whilst the focus of this study was differential 
splicing, the widespread changes to RNA abundance in Sam68 knockdown cells are interesting 
and could be further investigated. For instance, we may hypothesise that the changes in gene 
expression upon Sam68 knockdown are mediated through modulation to NF-kB activity. One 
option for investigating this hypothesis further could be to use MARA to estimate NF-kB motif 
activity in wild-type compared with Sam68 knockdown cells. Down-regulation of NF-kB motif 
activity would then provide initial support to this hypothesis which could be investigated 
further. This application of MARA would be as per the published and validated use for the 
inference of transcription factor activity (Balwierz et al., 2014; Madsen et al., 2018).  





Sam68 was investigated for its genome-wide contributions to gene expression and splicing 
during the CD4+ T cell activation process. A number of genes that were differentially regulated 
upon activation were also affected by Sam68 depletion, and these could be investigated 
further to determine the potential functional consequences of the specific Sam68-associated 
splicing modulations. The results of this study suggest that Sam68 regulates gene expression in 
CD4+ T cells through control of both RNA abundance and alternative splicing, but that the role 
in control of alternative splicing may be less widespread.




Chapter 6. Alternative Splicing of HIV-1 Transcripts 
is Disrupted by Introduction of CpG Dinucleotides to 
the Viral Genome 
6.1 Introduction 
6.1.1 CpG suppression in the HIV-1 genome facilitates evasion of host 
restriction 
HIV-1 possesses a ~9kb genome which encodes 15 distinct proteins (Watts et al., 2009).  After 
viral integration, the proviral DNA is processed through the host gene expression pathway to 
facilitate transcription, 5’ capping, splicing, polyadenylation, nuclear export, and translation 
(Karn and Stoltzfus, 2012). In addition to encoding for viral proteins, the HIV-1 genomic RNA 
contains conserved cis-acting elements which facilitate these various steps in the viral lifecycle 
(Mayrose et al., 2013; Ngandu et al., 2008). Well characterised elements include the RRE 
located in env (Pollard and Malim, 1998), splicing signals within pol, vif, vpr, tat, rev, and env 
(Stoltzfus, 2009), the polypurine tracts within nef and pol which facilitate reverse transcription 
(Le Grice, 2012), and the ribosomal frameshift element within gag necessary for Pol 
translation (Brierley and Dos Ramos, 2006).  
A comprehensive characterisation of all cis-acting HIV-1 RNA elements is necessary to fully 
understand the viral gene expression pathway. In order to identify novel putative cis-acting 
HIV-1 RNA elements necessary for viral replication, both Takata et al. (Takata et al., 2017) and 
Antzin-Anduetza et al. (Antzin-Anduetza et al., 2017) employed a codon modification approach 
based around introduction of synonymous mutations into the genomic RNA. Takata et al. 
codon modified the HIV-1 genome in a series of blocks which in total covered a majority of the 
HIV genome. They identified numerous regions spanning across the genome which were 
sensitive to codon-modification and able to induce restriction of viral replication. Antzin-
Anduetza et al. focused on modification of the gag region, and observed viral restriction that 
increased as the length of the codon modified region in gag was increased.  
Both Takata et al. and Antzin-Anduetza et al. observed that these codon modifications had 
inadvertently increased the CpG dinucleotide frequency of the viral genome. The CpG content 
of many RNA vertebrate viruses is suppressed (Karlin et al., 1994; Rima and McFerran, 1997; 




Simmonds et al., 2013), including in HIV-1 (Kypr et al., 1989). This suggests that CpG 
dinucleotides may be deleterious to RNA viruses and under negative selection. Supporting this, 
it has been previously shown that increasing the CpG content of picornaviruses and influenza A 
virus reduces their ability to replicate (Atkinson et al., 2014; Fros et al., 2017; Gaunt et al., 
2016; Tulloch et al., 2014).  
With these observations, a natural question is thus whether the effects of codon modification 
on HIV-1 replication are mediated solely through increases in CpG dinucleotide frequency. In 
light of this, Antzin-Anduetza et al. investigated the specific effects of a “CpG-only” codon 
modification and contrasted this with a codon modification approach that avoided introducing 
any novel CpGs. This analysis revealed that CpGs were necessary for the observed restriction 
phenotype, but that modifications to the surrounding nucleotide context present in the fully 
codon-modified viruses also contributed. In their work, Takata et al. used a similar strategy to 
demonstrate the causal role of CpGs in mediating the codon-modification-induced HIV-1 
restriction. Further, Takata et al. were able to identify the host protein Zinc anti-viral protein 
(ZAP) as being necessary for the CpG-mediated restriction. They observed that ZAP directly 
binds CpGs within the HIV-1 viral RNA, and thus binds to codon modified HIV-1 transcripts with 
increased frequency relative to wild-type virus. ZAP itself does not possess enzymatic activity. 
However, Ficarelli et al. (Ficarelli et al., 2019) identified KHNYN, a protein with endonuclease 
activity, as an interacting partner of ZAP that is additionally necessary for the CpG-mediated 
phenotype. Thus, both ZAP and KHNYN are necessary for CpG-mediated restriction, with 
KHNYN likely responsible for mediating degradation of ZAP-bound HIV-1 RNA. 
6.1.2 ZAP-independent mechanisms of CpG-mediated HIV-1 restriction 
We have observed that introduction of CpGs into certain regions of the HIV-1 genome 
produces a ZAP-independent restriction phenotype. Specifically, codon modification or 
introduction of CpGs into gag resulted in a ZAP-independent reduction in infective virus 
production, whilst in contrast, codon modification of env had ZAP-dependent effects (Figure 6-
1). This raises the question of whether an additional antiviral factor may be involved in sensing 
the CpGs within the gag region of these modified viruses. Other mechanisms may be involved. 
For instance, the modified region of gag may contain uncharacterised cis-acting elements. 
Disrupting this region could alter interactions between host proteins and viral RNAs and thus 
disrupt steps of the gene expression pathway. To investigate these possibilities, we utilized the 




codon modified viral constructs from Antzin-Anduetza et al. (Antzin-Anduetza et al., 2017) 
(Figure 6-2, Table 1) to transfect HeLa cells, before extracting RNA for RNA-seq. This allowed 
investigation of both the host transcriptome and of the expressed HIV-1 transcripts. Since 
constructs with varying numbers of introduced CpGs were used for transfections, the relative 
effects of differing CpG loads could be determined.  
 
Figure 6-1. Introducing CpG dinucleotides into gag has both ZAP-dependent and ZAP-
independent effects on HIV-1 replication. Each column shows data from a different 
experimental condition. Several viral constructs with varying degrees of codon modification 
were transiently transfected into HeLa cells (Table 1), as depicted via ‘HIV-1 condition’. 
Additionally, three HeLa cell conditions were used, either wild-type control cells, or CRISPR-
mediated ZAP knock-out HeLa cells, targeted with one of two guide sequences (Zap-ex4, Zap-
ex6), as depicted under ‘HeLa condition’. Each row of data then shows the results of a 
different assay. To measure infectious-virus production, supernatants were collected from 
these transfected HeLa cells and used to infect TZM-bl reporter cells. Infectivity was 
determined by induction of β-Galactosidase and subsequent light emission, and normalized to 




levels produced upon transfection of control HeLa CRISPR cells with wild-type HIV-1. Top bar 
charts show the mean of four independent experiments. Error bars show standard deviations. 
Results of pairwise quantitative comparisons are depicted: * = P < 0.05, ns =not significant, as 
determined by a two-tailed unpaired t-test. Red asterisks and ns relate to comparison of Zap 
CRISPR HeLa cells (red bars) with control CRISPR HeLa cells (black bars). Black asterisks 
compare control CRISPR HeLa cells transfected with HIV-1, HIV-1gag22–378CM, HIV-1gag22–378CpG, 
or HIV-1env88-561CpG (black bars). The gel shows results of western blotting for various viral 
proteins across the different experimental conditions. Expression of the Gag polyprotein p55 
and of the Gag product p24 in the cell lysate, and of p24 in the media specifically (Virions), was 
detected via immunoblotting with Hsp90 as a control. Experimental work performed by Irati 
Antzin-Anduetza and Mattia Ficarelli (Ficarelli et al., 2020). 
 
Figure 6-2. Codon modified HIV-1 viral constructs. (A) Schema of the HIV-1 gag region with 
the length of codon modified region depicted in orange for HIV-1gag22–165CM, HIV-1gag22–261CM, 
and HIV-1gag22–378CM. Numbers of introduced CpG dinucleotides are shown (B) Multiple 
sequence alignment of gag regions in HIV-1, HIV-1gag22–165CM, HIV-1gag22–261CM, and HIV-1gag22–
378CM. Introduced CpGs are highlighted in red. CpGs found in the wild-type HIV-1 gag are 
highlighted in yellow. Green shows a cryptic splice donor (CD1) that was found to be activated 
by the synonymous mutations introduced in gag, as detailed below (Figure 6-6). CM = codon 
modification. 
 




Table 6-1. Number of CpGs and mutations introduced by codon modification into HIV-1 
constructs. CM = codon modification. Subscript text indicates the region to which mutations 
were introduced. 
Virus CpGs in wild-type 
virus 
CpGs introduced  Mutations 
introduced 
HIV-1gag22-165CM 4 11 49 
HIV-1gag22-261CM 4 18 80 
HIV-1gag22-378CM 4 26 109 
HIV-1gag22-378CpG 4 26 30 
HIV-1env86-561CpG 1 36 43 
6.1.3 Aims: 
The HIV-1 lifecycle depends upon the interactions between host RBPs and viral transcripts to 
facilitate processes such as splicing and nuclear export. CpG dinucleotides inhibit HIV-1 
replication through the actions of the RBP ZAP, but a ZAP-independent mechanism also 
appears to exist. We aim to identify the mechanism of this ZAP-independent CpG effect, 
including through investigating the hypothesis that additional host RBPs with CpG binding 
preferences may be involved. Specifically, we aim to: 
1. Analyse the splicing and abundance of expressed viral transcripts in HeLa cells 
transfected with codon modified or wild type HIV-1 constructs. 
2. Compare host changes in gene expression in response to transfection with codon 
modified viruses relative to wild type virus. 
6.2 Results 
6.2.1 Codon modification reduces the abundance of HIV-1 RNA produced in 
transfected cells 
HIV-1 constructs were codon modified to introduce increasing numbers of CpGs into gag as 
detailed in Table 6-1 (and in further detail in Chapter 2 - Methods). HeLa cells were transfected 
with these constructs using two replicate experiments. For use as control conditions, cells 
were either left untrasfected or transfected with a viral construct containing the wild-type 




unmodified HIV-1 genome. Subsequently, RNA was extracted from lysed cells and used for 
poly(A) selected RNA-sequencing. 
Principal component analysis revealed that after transfection of HeLa cells with either wild 
type or codon modified HIV-1, the largest source of variation was whether cells were 
transfected or untransfected (Figure 6-2). Consistent with previous work (Antzin-Anduetza et 
al., 2017), codon modification reduced the expression of total HIV-1 RNA (Figure 6-3). The 
magnitude of reduction to HIV-1 RNA abundance increased with successively greater regions 
of codon modification in gag, and results were concordant between RNA-seq (Figure 6-3A) and 
qPCR (Figure 6-3B).  
 
Figure 6-2. Principal component analysis of gene expression after infection with wild-type or 
codon modified HV-1. Gene expression in HeLa cells after transfection with: wild-type HIV-1, 
HIV-1gag22–165CM, HIV-1gag22–261CM, and HIV-1gag22–378CM constructs as per Table 6.1. NT = non-
transfected control, PC = principal component. Different shapes denote independent replicate 
experiments. Regularized log transformed TPM values were used as input for PCA. 





Figure 6-3. Codon modification reduces HIV-1 RNA abundance in transfected HeLa cells.  
Approximately 48 hours after transfection, HeLa cells were lysed and RNA was extracted for 
analysis with RNA-seq or qRT-PCR. (A) The percentage of total reads in RNA-seq libraries which 
mapped to the HIV-1 genomic RNA. (B). Total and genomic-RNA abundances as quantified by 
qRT-PCR and normalized to wild-type HIV-1. Genomic RNA is quantified using primers which 
specifically amplify the full-length unspliced RNA, whilst total RNA is quantified using primers 
which amplify all HIV-1 transcripts whether spliced or unspliced. Bar charts show the mean of 
two independent experiments. N.B experimental work in (B). performed by Irati Antzin-
Anduetza and Mattia Ficarelli. 
6.2.2 Codon modification of HIV-1 disrupts splicing of viral transcripts 
A possible mechanism by which codon modification could disrupt viral replication is through 
modulating the splicing of viral transcripts. To investigate HIV-1 alternative splicing, RNA-seq 
data was used to identify usage of both known and novel splice junctions within HIV-1 
transcripts. The relative usage of the identified splice junctions in expressed viral transcripts 
was then quantified (Figure 6-4). Codon modification resulted in altered patterns of splice site 
usage, including though an increase in the usage of non-canonical junctions.  





Figure 6-4. Codon modification of HIV-1 induces use of non-canonical splice sites. Each 
column shows the usage of a unique splice junction. Splice junctions are labelled with the 
canonical donor (D) and acceptor (A) numbers or the respective genomic RNA co-ordinates for 
non-canonical splice sites. Rows show pairs of independent replicates of HeLa cells transfected 
with viral constructs:  HIV-1gag22–165CM, HIV-1gag22–261CM, and HIV-1gag22–378CM. Splice junction 
usage is quantified as the per-sample percentage of junction-spanning HIV-1-mapping RNA-seq 
reads. Grey boxes indicate that a splice junction was not used in a given sample. Only junctions 
with relative usage greater than 1% of total HIV-1-mapping junction-spanning reads in at least 
a single sample are shown. CD = cryptic donor. 
 
The most striking alteration to wild-type HIV-1 splicing was an apparent shift in the usage of 
canonical donor 1 (D1) for a downstream non-canonical donor (Figure 6-4). Closer examination 
of this splice event showed an almost perfectly linear shift from the use of D1 to this non-
canonical donor with increasing lengths of gag codon-optimised sequence (Figure 6-5). 
Importantly, this donor site is outside of the region of codon modification (Figure 6-2B), and 
thus is a pre-existing cryptic donor we term cryptic donor 1 (CD1). Activation of the cryptic 
splice donor acted to increase the length of the first exon incorporated into the spliced viral 
transcripts to include a region of the gag sequence containing the Gag initiation codon (Figure 
6-6). Inclusion of this additional start codon could interfere with translation initiation at 
downstream start codons, including those utilised for translation of proteins encoded by singly 
or fully spliced mRNAs such as Rev and Tat, which are essential for HIV-1 gene expression. This 
would decrease viral replication and could account for the observed decrease in viral RNA 
(Figure 6-3), whilst abundance of gag proteins would remain potentially unaltered (Figure 6-1). 






Figure 6-5. Codon modification of gag reduces use of canonical splice donor 1 in favour of a 
cryptic donor. Data shows the per-sample percentage of junction spanning reads using either 
canonical splice donor 1 or cryptic splice donor 1 with any splice acceptor. Pearson correlation 
(R) and associated p value (PR) are shown for the relationship between usage of donor 1 and 
cryptic donor 1. 
 
 





Figure 6-6. Relative usage of splice donor 1 and cryptic donor 1 upon codon modification of 
HIV-1. The 9173 nt HIV-1 genomic RNA and features are depicted in the “HIV-1 genome” track. 
The HIV-1 open reading frames are shown as yellow-filled boxes. Canonical donors (D1-4) and 
acceptors (A1-7), codon modification-induced-cryptic donor (CD1), and gag start codon (AUG), 
are shown in the “Splice Sites and Gag AUG” track. The numbers of reads supporting use of D1 
(nt 290) or CD1 (nt 717) paired with any canonical or non-canonical acceptor and summed 
across duplicate samples is shown; depicted by line width (y-axis). Line height is arbitrary. 
Gapped vertical lines trace the position of D1, CD1, and gag AUG.  
In light of these findings, we hypothesize that codon modification of gag in the region 
downstream of the cryptic donor may have introduced an exonic splicing enhancer (ESE). 
Usage of the cryptic donor increased with the number of introduced CpGs and the proximity of 




CpGs to the donor site (Figure 6-2B & Figure 6-6). Therefore, a splicing factor which 
preferentially binds to CpGs may be responsible for the usage of this cryptic donor. Of the 
RBPs that have well characterised binding preferences, a number have motifs which contain 
consensus CpG dinucleotides (Figure 6-7) (Ray et al., 2013), and these proteins are thus 
candidates for splicing enhancers of the cryptic donor. Of course, there are many RBPs with as 
yet undetermined binding preferences (Gerstberger et al., 2014), and these may also bind to 
motifs containing CpGs. 
 
Figure 6-7. RNA-binding proteins with binding motifs containing CpG. Position weight 
matrices depicted are from (Ray et al., 2013). 
 
6.2.3 Codon modified and wild type HIV-1 induce similar changes in host 
gene mRNA abundance 
The disruption to splicing induced by codon optimization of gag may account for the ZAP-
independent reductions in infectious viral production (Figure 6-1) and production of viral RNA 
(Figure 6-3). It is possible that additional mechanisms exist however. For instance, there may 
be host restriction factors in addition to ZAP which can recognize the codon modified HIV-1 
RNA sequences. To identify changes in host gene expression which may reflect activation of an 
anti-viral response, differential gene expression analysis was performed. Transfection with 
wild-type HIV-1 induced altered mRNA abundance for 356 genes, relative to untransfected 
control cells (Figure 6-8A). Transfection with the most highly modified virus (gag22-378CM) 




produced similar changes in host gene mRNA abundance. Differential expression analysis 
comparing cells transfected with either wild-type or gag22-378CM HIV-1 identified only nine 
genes with significantly altered mRNA abundance (Figure 6-8B). Eight genes had greater mRNA 
abundance after transfection with unmodified HIV-1, and a single gene had significantly 
greater abundance in response to transfection with the codon modified virus. Genes with 
increased expression after transfection with wild-type HIV-1 may reflect the effects of more 
productive viral gene expression. For instance, CXCL8 is upregulated upon transfection with 
wild-type virus (Figure 6-8A) but to a lesser extent after transfection with gag22-378CM 
(Figure 6-8B). Increased CXLC8 expression has been previously shown to promote productive 
HIV-1 infection (Mamik and Ghorpade, 2014). Increased gene expression in cells transfected 
with gag22-378CM relative to wild-type virus could potentially represent activation of a host 
anti-viral response. There is a single gene robustly upregulated specifically in gag22-378CM 
transfected cells - AP001267.1 (Figure 6-8B). AP001267.1 is an uncharacterised anti-sense 
transcript and is an interesting candidate for a ZAP-independent anti-viral gene that recognizes 
CpGs in the HIV-1 genomic RNA.    
 
Figure 6-8. Volcano plot of host gene expression upon transfection with wild type and codon 
modified HIV-1. Gene expression in: (A) untransfected control HeLa cells relative to HeLa cells 
transfected with wild-type HIV-1, (B) HeLa cells transfected with gag22-378CM HIV-1 relative 
to wild-type HIV-1. FDR = false discovery rate. Genes considered as differentially expressed 




(FDR < 0.05 and log fold change > 1) are labelled. Vertical lines mark log fold change of -1 and 
1, whilst the horizontal line marks an FDR of 5%.  
6.3 Discussion 
Codon modification of the HIV-1 genome has been previously shown to reduce viral replication 
(Antzin-Anduetza et al., 2017; Takata et al., 2017, 2018). However, the mechanisms by which 
this occurs have been unclear. Codon modification in the 5’ region of gag reduces total and 
genomic HIV-1 RNA relative to wild-type HIV-1 (Figure 6-3). This phenotype is largely mediated 
by increased HIV-1 CpG content (Antzin-Anduetza et al., 2017), which sensitizes the virus to 
both ZAP-dependent and independent effects (Figure 6-2) (Takata et al., 2017). We have 
shown here that the ZAP-independent CpG-mediated phenotype after gag modification 
appears to be mediated via disrupted splicing due to the activation of a pre-existing cryptic 
splice donor (Figure 6-5 & 6-6). The usage of this alternative donor is predicted to interfere 
with subsequent translation of the HIV-1 spliced mRNAs via introduction of the gag AUG 
codon into the first exon of all HIV-1 transcripts (Figure 6-6). This would be predicted to induce 
inefficient translation of spliced and incompletely spliced HIV-1 mRNAs. Activation of this 
cryptic donor in response to codon modification of the HIV-1 genome was recently reported 
independently (Takata et al., 2018), although the role of CpG content in the associated 
restriction phenotype was not specifically addressed. We hypothesise that a splicing enhancer 
which binds CpGs may be regulating the use of this cryptic donor. Future work to identify this 
factor/s could focus on knockdown of splicing factors with known CpG preferences (e.g. those 
in Figure 6-7) to assess whether the use of the cryptic splice donor in gag codon modified HIV-
1 transcripts is attenuated. 
 
The observed disruption to viral splicing could account for the totality of the ZAP-independent, 
codon-modification induced HIV-1 restriction phenotype. However, other mechanisms may 
also be involved. For instance, a host immune response may be mounted against the codon-
modified virus, such as that mediated via ZAP. Through analysis of host gene expression, we 
identified a long non-coding RNA, AP001267.1, that is more abundant at the mRNA level after 
transfection with gag22-378CM relative to transfection with wild-type HIV-1 (Figure 6-8). This 
gene could be investigated further, again such as via genetic knockdown, to assess the 
dependency of the codon-modification associated viral restriction phenotype upon expression 
of this gene. Further, the introduction of  CpGs into the HIV-1 genome could have a number of 




additional, currently un-investigated effects, such as through altering local or long-range RNA 
structures (Lavender et al., 2015), or post-transcriptional modifications such as cytosine 
methylation (Courtney et al., 2019). 
 
Codon optimisation of viruses has been investigated as a strategy for the creation of vaccines 
(Gaunt et al., 2016; Tulloch et al., 2014). For instance, infection with a modified influenza A 
virus with increased CpG frequency protected animals from subsequent lethal challenge to the 
wild-type virus (Gaunt et al., 2016). Knowledge of the mechanisms underlying such 
attenuation can facilitate the further design of attenuated viruses. The multiple mechanisms 
underlying CpG-mediated HIV-1 restriction identified here highlight the complexity in design of 
an attenuated virus, and this may also be the case for other RNA viruses. 
6.4 Conclusion 
CpGs are suppressed in the genome of HIV-1 and other RNA viruses, and introduction of CpGs 
to the HIV-1 genomic RNA has been previously shown to cause ZAP-mediated viral restriction. 
Here we have identified that introduction of CpGs into gag results in aberrant splicing via 
activation of a cryptic donor, and that this independent of ZAP. Future work could determine 
whether a known or novel splicing factor with CpG binding preferences regulates the use of 
this pre-existing cryptic donor. 




Chapter 7. Discussion 
In this thesis, the over-arching aim was to investigate how alternative pre-mRNA splicing is 
regulated through the actions of splicing factors mediated through cis-acting RNA elements. To 
this end, I have employed a number of approaches for the analysis of RNA-seq datasets. I have 
benchmarked the performance characteristics of two different motif-based analysis methods 
for the identification of regulatory splicing factors. Subsequently, the two approaches were 
compared further through application to a dataset richer in experimental variables and which 
represented a potential typical use case for which these methods could be applied. The work 
detailed in the latter chapters addressed specific biological hypotheses. Firstly, the genome-
wide effects of the RBP Sam68 on alternative splicing and mRNA abundance were investigated 
in primary CD4+ T cells. Additionally, alternative splicing was investigated in the context of 
HIV-1, a virus with tropism towards CD4 expressing cells. Specifically, the relationship between 
CpG dinucleotides in the genome of HIV-1 and control of alternative splicing was examined. 
7.1 Splicing-based motif enrichment analysis is an effective 
means to infer regulatory factors 
Motif enrichment analysis is a method which involves differential splicing analysis followed by 
testing for enrichment of splicing factor motifs in RNA sequences flanking the identified 
differentially spliced events. Whilst our main motivation in using this method was to provide a 
baseline against which S-MARA could be compared, the formal assessment of splicing factor 
motif enrichment analysis also has its own merit. To our knowledge, the specificity and 
sensitivity characteristics of a splicing-focused motif enrichment procedure have not 
previously been investigated. Indeed, this analysis relied upon the use of an extensive resource 
of splicing factor knockdowns, such as has been provided only recently through the ENCODE 
project (Nostrand et al., 2018).  
 
Applied to identifying regulatory motifs associated with RNAi-depleted splicing factors, motif 
enrichment analysis displayed reasonable sensitivity and specificity as assessed via analysis of 
the ROC AUC (Figure 4-14). The AUC from the ROC analysis was 0.661, indicating that positive 
control knockdown splicing factors had more significant enrichment scores than non-
knockdown negative control factors ~66% of the time. There are limitations on defining true 
positives and true negatives in an experimental knockdown system. For instance, unknown 




downstream effects may occur such as alterations to activity of other, non-target, splicing 
factors. Further, the depletion of some splicing factors had low efficiency and, even in the case 
of efficient knockdown, there may be redundancy between splicing factors acting through 
similar motifs. However, these results show that splicing factor motif enrichment analyses 
have merit. The motif enrichment approach used here could be further modified in future 
work to potentially improve upon the sensitivity and specificity characteristics identified here. 
Further, this work validates the concept of using RNA motifs to infer regulatory splicing factors 
through analysis of RNA-seq data.  
7.2 S-MARA requires further development 
7.2.1 Motif enrichment analysis outperforms S-MARA 
In this study, MARA was applied to predict which splicing factors regulate gene expression 
under specific biological conditions. This is a novel application of this methodology, with MARA 
most commonly applied to study transcription factors. To adapt MARA, a workflow was 
implemented to generate a matrix of splice event usage quantifications, and a matched matrix 
of splicing factor motif counts flanking the RNA sequences of these events (Chapter 3). These 
two matrices then acted as input to S-MARA. The performance of S-MARA was assessed using 
data from a large-scale shRNA RBP-knockdown experiment published through the ENCODE 
resource (Burge et al., 2018; Nostrand et al., 2018). This data provided a powerful resource, 
containing cells specifically depleted for a range of splicing factors. RNA-sequencing of these 
cells allowed the investigation of knockdown-induced differential splicing.  
 
Applying MARA to these data allowed quantitative estimates of motif splicing activities. Initial 
benchmarking analysis showed that MARA could infer splicing factor motif activities that 
varied in response to knockdown-induced changes in splicing between samples. For a subset of 
splicing factors that were depleted by RNAi, significant modulation to activity of the associated 
splicing factor motifs could be identified. However, analysis of the receiver operating 
characteristics revealed poor sensitivity and specificity properties with regards to identifying 
motifs associated with splicing factors targeted for depletion (Figure 3-19). This finding 
contrasts with the respective performance of motif enrichment, which displayed reasonable 
receiver operating characteristics, as discussed. The relative success of the motif enrichment 
approach demonstrates that there exists useful information in the distribution of splicing 




factor motifs across splice junction regions which can be leveraged to infer splicing factor 
activities. Thus, the analysis of ENCODE RNAi experiments suggests that S-MARA requires 
further development to improve its function in towards this aim.  
 
After this initial benchmarking process, S-MARA was applied to a timecourse of CD4+ T cell 
activation and polarization (Chapter 4). This analysis proved more promising, as S-MARA was 
able to reveal modules of splicing factor motif activity with distinct profiles suggestive of 
different splicing regulatory programmes. To identify candidate regulatory motifs, stringent 
filtering for activity profiles associated with time after TCR stimulation was performed (Figure 
4-9). This was combined with additional filtering by gene expression, which led to 
identification of a set of candidate regulators of splicing during the CD4+ T cell activation 
process. Application of the hypergeometric test revealed that this gene list was enriched for 
genes with previously demonstrated roles in the control of alternative splicing during CD4+ T 
cell activation, in addition to containing novel candidate regulatory splicing factors. Motif 
enrichment analysis of events differentially spliced after activation, again coupled with filtering 
of splicing factors with low expression, identified a group of candidate regulatory splicing 
factors that significantly overlapped with those derived from the S-MARA analysis, albeit not 
significantly enriched for positive control factors. The more promising results of S-MARA as 
applied to this timecourse analysis may relate to the increased numbers of replicates in each 
condition (three), in addition to the biological complexity of the experiment – whereby the 
timecourse of CD4+ T cell activation and polarisation was sampled with high resolution. 
Indeed, MARA has primarily been optimised using experiments in which a number of biological 
conditions were investigated, such as timecourses of development or differentiation (Balwierz 
et al., 2014; The FANTOM Consortium et al., 2009). 
 
However, as with analysis of the ENCODE knockdown experiments, analysis of the ROC AUC 
showed an improved performance of the motif enrichment analysis method as compared to S-
MARA (Figure 4-15). Indeed, although the AUC for S-MARA was improved relative to that 
obtained from analysis of the ENCODE data; the 95% confidence intervals still contained the 
0.5 value, indicating that the method may not perform greater than chance at specifically 
identifying motifs associated with positive control splicing factors. Importantly, a potential 
source of bias in the previously discussed hypergeometric testing was identified. Positive 
controls had more associated motifs on average as compared to other splicing factors in the 




analysis (Figure 4-11). As such, positive control factors were more likely to be identified ab 
initio, and this was not accounted for through hypergeometric testing. However, the ROC 
analysis was performed directly at the motif level, and was thus able to account for this bias. 
There are limitations with defining true positive and negative regulatory splicing factors in this 
analysis. For instance, there are potentially novel unidentified splicing factors which act to 
control alternative splicing during the CD4+ T cell activation process, and such factors would 
thus in effect be mis-labelled as negative control cases. However, the results from this ROC 
AUC analysis are consistent with the analysis of ENCODE shRNA-knockdown data outlined in 
Chapter 3. Therefore, motif enrichment methods currently appear to outperform S-MARA, 
which places a caveat over the predictions made through application of S-MARA to the CD4+ T 
cell activation timecourse. 
 
Our main hypothesis was that S-MARA would perform better than the simpler motif 
enrichment approach, since it has theoretical advantages. For instance, S-MARA leverages the 
full genome-wide quantitative splicing information, whilst motif enrichment testing does not 
make direct use of quantitative splicing information. With this in mind, the greater 
performance of motif enrichment testing over S-MARA was unexpected. A potential advantage 
of the motif enrichment procedure is that a reduced set of differentially spliced junctions is 
used as input, as opposed to the genome-wide splice junction data input to S-MARA. This 
could provide a stronger signal to noise ratio with regards to motif count features. The central 
analysis of MARA is a linear regression of quantitative measures of gene activity against motif 
count features. Several other studies have employed a regression analysis of splicing as a 
function of sequence features with the aim of identifying regulatory motifs. These studies have 
all incorporated an initial differential splicing analysis to select only highly differentially spliced 
events as input to the latter regression stages (Wen et al., 2013; Xin Wang et al., 2008; Zhang 
et al., 2012). An initial attempt to incorporate a similar strategy was applied here, whereby 
input to S-MARA was reduced to include only those splice junctions with significantly altered 
usage after RNAi-mediated splicing factor depletion. However, this approach did not improve 
the performance of S-MARA in identifying regulatory splicing factors (Figure 3-20).  
 
Another possibility relates to the use of the Wilcoxon rank sum test as the method for inferring 
motif enrichment. This non-parametric test should be relatively unaffected by characteristics 
of the underlying motif count distributions for different splicing factor motifs. In contrast, S-




MARA as applied here employs linear modelling of logit transformed PSI values against motif 
count values. As such, this method assumes a linear relationship between motif count 
occurrence and logit-PSI values, and could therefore be affected by count distribution features 
such as the presence of outlier counts.  
 
In this analysis, the presence of potential binding sites was assessed for each RNA sequence of 
interest using splicing factor PSSMs and a sliding window approach with the RBPmap 
methodology (Paz et al., 2014). The sum of predicted binding sites per sequence was then 
used for linear modelling with MARA. In many cases, outlier sequences having hundreds of 
predicted binding sites/motif counts were observed (e.g. Figure 4-13). In a cell, saturation 
effects will exist whereby further increases in potential binding sites will not increase the 
likelihood of splicing factor binding. For instance, an assessment of the binding characteristics 
of three RBPs (PUM2, QKI, and ELAVL1), revealed that the likelihood of binding increased with 
the number of high motif match sites in a given sequence up until ten sites were reached, 
before plateauing or even decreasing with further increases in motif counts (Yu et al., 2019). 
An initial investigation of potential saturation effects was performed herein, whereby motif 
counts for a given splice junction region were capped at either 15 or 30. This approach, 
however, did not alter the performance characteristics of S-MARA (Figure 3-20).  
 
In the application of MARA to transcription factor analysis, various strategies have been 
applied for estimating transcription factor binding site/motif occurrences. These include using 
the sum of binding site probabilities across a sequence (Balwierz et al., 2014), a single per-
sequence PSSM-match P-value (Madsen et al., 2018), or a sum of the counts of predicted 
binding sites across a sequence (The FANTOM Consortium et al., 2009). Only the last approach 
was applied in this study, and there are therefore several alternatives which could potentially 
improve S-MARA. 
7.2.2 Discrepancies between S-MARA and MARA as applied to transcription 
factor biology 
It should be noted that a formal analysis of the ROC AUC of MARA as applied to the analysis of 
transcription factors has not been performed. However, the predictive power of MARA in 
identifying positive control regulatory transcription factors has been assessed through other 
methods (Madsen et al., 2018; The FANTOM Consortium et al., 2009). For instance, the IMAGE 




implementation of MARA was able to predict regulators of adipogenesis which showed a 
greater enrichment for known positive control regulators as compared with simpler analyses 
of transcription factor gene expression, transcription factor motif enrichment, or a 
combination of the two (Madsen et al., 2018). Thus, it would appear that S-MARA does not 
achieve the same performance as “transcription factor-MARA”.  
 
A possible source of this discrepancy relates to the underlying properties of RBP motifs, which 
as a group represent a relatively small subset of the total potential sequence space, and are 
typically of low entropy (Burge et al., 2018). Indeed, a comparison to transcription factor 
motifs herein (Figure 3-3) showed that splicing factor motifs were on average lower in 
information content. Further, previous work in which a deep learning methodology was 
applied to model both RBP and transcription factor binding preferences found that training 
RBP models was more challenging, as these models tended to perform worse at predicting 
both in vivo and in vitro true binding affinities (Alipanahi et al., 2015). Analysis of the 
timecourse of CD4+ T cell activation identified many motifs with highly similar activity profiles, 
as evidenced by the presence of several large motif modules which were grouped according to 
their correlative activity profile (Figure 4-4). Unsurprisingly, motifs within a module often 
shared similar sequence content such as di-nucleotide preferences (Figure 4-5). This highlights 
the difficulty in resolving activity of motifs with similar PSSMs, which in turn have similar motif 
count distributions across the genome. Therefore, there may be an inherent challenge to 
motif-based analyses focused on RBPs. 
7.2.3 Limitations and future improvements to S-MARA analysis 
7.2.3.1 Importance of RNA secondary structure and higher order sequence 
features in RBP binding 
RNA molecules encode more information than is represented within a PSSM, and this 
information contributes to RBP binding specificities. Spacing between bound nucleotides, local 
motif-flanking sequences, and RNA secondary structure, amongst other features, all influence 
RBP binding specificity (Burge et al., 2018; Taliaferro et al., 2016). A relevant example is the 
TIA1 and hnRNP C binding motif UUUUU. This motif is represented by a single PSSM in this 
study, and thus a single motif activity is estimated for both of these splicing factors. However, 
hnRNP C and TIA1 bind distinct targets in vivo, and this is contributed to by structural contexts, 
with hnRNP C preferentially binding to unstructured RNA relative to TIA1 (Burge et al., 2018). 




Importantly, this preference was observed at exons for which hnRNP C binding directly 
regulates alternative splicing. 
 
Modelling of higher order RNA features has been shown to improve splicing factor binding site 
predictions for a number splicing factors (Burge et al., 2018; Taliaferro et al., 2016). Alipanahi 
et al. (Alipanahi et al., 2015) developed DeepBind, a deep learning approach for the 
development of DNA and RNA binding models, and for predicting sequence-specific binding 
affinities. DeepBind takes as input a set of sequences with associated binding scores derived 
from any of a number of high-throughput approaches (e.g. HT-SELEX (Jolma et al., 2010) or 
RNAcompete (Ray et al., 2009)). These sequences are used for de novo identification of motifs 
which are weighted and combined to generate binding models through use of deep 
convolutional neural networks. DeepBind predictions trained on in vitro derived RNAcompete 
data predicted in vivo binding sites (measured through CLIP-seq), with greater accuracy than a 
simple PSSM-based method. Additionally, DeepBind binding prediction scores showed 
patterns of enrichment and depletion surrounding splice sites in a manner consistent with 
roles in splicing regulation. Of note, DeepBind was not compared against the binding site 
prediction method applied in this study, RBPmap (Paz et al., 2014), which uses PSSMs but 
additionally takes into account factors such as the propensity of motifs to cluster around true 
binding sites. Thus, the potential improvement associated with integrating DeepBind into the 
S-MARA pipeline is unknown and could be further investigated. DeepBind models can be 
visualised as weighted sets of PSSM-like sequence logos. This visualisation revealed that a 
variety of sequence features are implicitly captured by the deep learning approach employed, 
including the presence of sequence position interdependence, variable spacing of bipartite 
motifs, or the presence of splicing factors with multiple motifs of variable binding affinities. 
The implicit modelling of these higher levels of sequence complexity likely accounts for the 
improvement over the more simplistic PSSM-based methods. DeepBind is available as a tool 
for RBP binding site prediction, with pre-calculated models for the 85 human RBPs studied via 
RNAcompete by Ray et al. (Ray et al., 2013). 
 
The degree to which the DeepBind method implicitly models RNA secondary structures is not 
reported. Indeed, as recognised by the authors, RNAcompete was not designed to elucidate 
RBP structural binding preferences (Ray et al., 2009). In 2014, Maticzka et al. released 
GraphProt (Maticzka et al., 2014), a tool specifically developed for the modelling and 




predictions of RBP sequence and secondary structural binding preferences. Secondary 
structures of CLIP-derived RBP-bound RNA sites are predicted in silico and utilised in addition 
to RNA primary sequence information as input to a machine learning based approach for 
generation of binding models. The resulting models capture nucleotide-specific and position-
interdependent structural features, such as the presence of double stranded RNA or hairpin 
loops, and outperformed previous approaches for binding site prediction (prior to publication 
of DeepBind which was therefore not included in the comparison). A limitation to these 
structure-based methods is the non-trivial added computation time and memory needed to 
estimate complex RNA secondary structures, both during initial model training and subsequent 
binding prediction steps. Further, GraphProt requires CLIP-seq data for any RBP of interest.  
 
Recently, a new RBP binding site prediction method, beRBP, was published (Yu et al., 2019). 
The authors employed a hybrid approach, which as per RBPmap, incorporates PSSM-based 
scoring, analysis of clustering propensity of motif matches, and sequence conservation 
analysis, but additionally considers RNA sequence accessibility through secondary structure 
prediction, and consolidates these data into a per-RBP binding model using a Random Forest 
method. When applied to the prediction of genome-wide in vivo bound sequences, as 
determined through enhanced CLIP (eCLIP), beRBP displayed improved specificity and 
sensitivity across 26 RBPs as compared to both RBPmap and DeepBind. One limitation to 
beRBP is that in order to develop RBP-specific binding models, both a PSSM and large numbers 
of positive and negative sequences, as determined through high-throughput analyses such as 
RNAcompete, are required as input. This contrasts to RBPmap for which only a PSSM is 
necessary. 
 
7.2.3.2 Direct Inference of RBP mRNA binding sites 
This thesis has focused on the prediction of RBP targets through use of RBP binding models in 
the form of PSSMs. However, the transcriptome-wide binding targets of individual RBPs can 
alternatively be directly inferred through the use of immunoprecipitation-sequencing 
approaches such as CLIP-seq. Indeed, previous analyses have shown improved prediction of 
splicing regulatory activity using CLIP-based rather than motif based predictions of splicing 
factor binding (Carazo et al., 2018). In addition to the shRNA-RNA-seq data employed herein, 
the ENCODE project has generated eCLIP for a range of RBPs in both HepG2 and K562 cell lines 




(Van Nostrand et al., 2016). These data would be valuable in future analysis of S-MARA and 
motif enrichment. For instance, they could be directly incorporated into the work detailed in 
Chapter 3 to estimate splicing factor binding locations, particularly as the shRNA knockdowns 
were performed in these same cell lines. The use of CLIP-seq data is thus an additional way in 
which performance of S-MARA may be improved. 
7.2.3.3 Expanding the repertoire of known RBP binding preferences 
The above developments to the modelling of RBP binding preferences represent promising 
strategies through which the accuracy of splicing factor binding site prediction can be 
improved. Such improvements could help to reduce false negatives of motif-based analyses, in 
addition to allowing differentiation of binding for splicing factors which share motifs with 
similar linear motifs (PSSMs). A further avenue for improvement of splicing factor motif-based 
analyses is to increase the number of splicing factors for which binding models exist. The 
Attract database (Giudice et al., 2016), which contains the largest single collection of data on 
RBP-RNA interactions from heterogeneous experimental sources, contains data for 
approximately only 10% of the ~1500 documented human RBPs (Gerstberger et al., 2014).  
To date, two large-scale in vitro high-throughput analyses of RBP binding preferences have 
been published, both of which were utilised in this study. Ray et al. (Ray et al., 2013) probed 
85 human RBPs with RNAcompete, whilst Dominguez et al. (Burge et al., 2018) used RNA Bind-
n-Seq to study 78 human RBPs. These included 32 and 46 splicing factors respectively, and 
resulted in motif data for a total of 64 of the custom defined list of 122 splicing factors used in 
this study. Additionally, Jolma et al. (Jolma et al., 2019) recently developed high-throughput 
RNA-SELEX to capture sequence and structural preferences for 86 human RBPs, although these 
data are not currently available for public use. High-throughput in vivo data has also been 
utilised to derive RBP motifs. For instance, Feng et al. (Feng et al., 2019) utilised eCLIP data for 
119 human RBPs produced through the ENCODE project to generate high quality motifs. 
Future work to expand the number of RBPs with profiled binding preferences will advance 
both the application of splicing factor activity modelling and the understanding of splicing 
regulation. 
7.2.3.4 Splicing-specific adaptations to the MARA model 
The characteristics of our splicing quantification tool of choice, MAJIQ (Vaquero-Garcia et al., 
2016), should also be considered. One of the desirable features of MAJIQ is its flexibility with 




regards to the types of splicing events that can be profiled. The local splicing variant (LSV) 
model employed by MAJIQ allows events of arbitrary complexity to be considered, thus 
capturing the full complexity of alternative splicing across the genome. One limitation to the 
application of MAJIQ in this study, however, is that different categories of splicing events are 
not considered separately. That is, a given PSI value is considered in the same manner by S-
MARA whether it relates to the relative usage of an exon skipping event, alternative 3’ or 5’ 
splice site, intron retention event, or any other splice event type. This method assumes that 
the regulation of such classes of event does not differ on a global level with regards to the role 
of splicing factor motifs and corresponding splicing factor activities. Whether this assumption 
is true is unclear. Deep learning studies aimed at deciphering the splicing code underlying the 
relative usage of alternative splicing events, and which employed separate models for exon 
skipping, alternative 3’, and alternative 5’ splice site usage, have been employed (Busch and 
Hertel, 2015; Louadi et al., 2019). The relative value of sequence features in predicting usage 
of these three types of splicing events was assessed, and revealed that the main features 
discriminating use of each event type related to exon length and the splice donor and acceptor 
sequences, rather than occurrence of specific cis-acting splicing factor motifs. However, S-
MARA could be adapted to model the usage of different classes of splicing events separately, 
so as to investigate the potential effects on improving estimation of splicing factor motif 
activity. This could be achieved by deconstruction and annotation of LSVs into discrete splice 
event classes, or through the use of an alternative splicing quantification tool which analyses 
these events separately ab initio, such as VAST-TOOLS (Tapial et al., 2017). 
 
Further improvements to how splicing factor motif activity are modelled could be investigated. 
As discussed, a limitation of MARA is the assumption of linearity between motif frequencies 
and regulator activity. This assumption does not account for potential variable repressor-
enhancer functions of a given regulator towards different targets. This limitation is pertinent 
to both splicing factor activity and transcription factor activity, and has been recognised as an 
area for future development by the MARA developers (Balwierz et al., 2014). Previous 
approaches to model such dual regulatory roles have been employed. For instance, Bauer et 
al. (Bauer et al., 2010) utilised thermodynamic models to estimate transcription factor activity 
as a function of motif occurrences and transcription factor binding preferences in Drosophila 
melanogaster. They demonstrated that allowing transcription factor action to vary between 
repressor and activator on a per transcription unit (cis-regulatory module) basis improved 




estimates of gene expression. However, this approach was employed to model a limited 
number of 44 sites, and may need adaptation to be tractable for genome-wide application.  
 
A key difference between the dual activity of splicing factors and transcription factors is the 
dependence upon splicing factor binding location and the corresponding splicing factor action. 
For instance, splicing factors can exhibit opposing enhancer or repressor activity when binding 
a motif located in an exon vs an intron, or when binding upstream or downstream of a 
regulated exon (Fu and Ares, 2014). As the S-MARA workflow implemented in this study is 
naïve to such effects, this may negatively affect the performance of S-MARA as compared to 
the application of MARA to transcription factor biology. One solution includes the use of two 
input motif count matrices, where the up-and-downstream regions of each splice event or 
exon are scanned for the presence of motifs independently. Each motif activity would then be 
modelled twice per sample, with these estimates contrasting for splicing factors with variable 
activity determined by binding site location. Such an adaptation would be relatively simple to 
implement as part of future study and may improve splicing factor motif activity estimates.  
Previous approaches to linear modelling of splice event usage as a function of in-cis sequence 
elements have addressed this aspect of splicing biology by explicitly modelling the regional 
context of motifs. For instance, Wen et al. (Wen et al., 2013) modelled the frequency of 
putative regulatory sequences in upstream and downstream exonic and intronic regions 
flanking splicing events as separate coefficients in a lasso regression model. This allowed 
estimation of splicing factor motif count coefficients (i.e. motif activity) that varied based upon 
their regional context. A procedure was used to identify potential splicing regulatory elements 
(SREs) from the set of all possible hexamers, and cassette exon PSI values were then modelled 
as a function of the frequencies of these hexamers and of potential combinatorial effects 
between them. This model was able to capture a large percentage of the variance in 
alternative splicing events across nine human tissues (49.1%–66.5%), performing comparably 
in this regard to models of gene transcription (Gertz et al., 2009). 




7.3 Implications for the understanding of alternative pre-mRNA 
splicing by RNA-binding proteins 
7.3.1 Regulation of alternative splicing during CD4+ T cell activation 
A comprehensive understanding of CD4+ T cell function, including the activation of naïve cells 
in the generation of effector Th cells, requires elucidation of the full gene expression regulatory 
networks governing these processes. Re-analysis of the CD4+ T cell activation and polarisation 
timecourse investigation performed by (Henriksson et al., 2019) using module-based 
investigation revealed that splicing variation was more strongly associated with the activation 
process than with CD4+ T cell polarisation. Specifically, CD4+ T cells polarised to a Th2 subtype 
via IL-4 treatment showed broadly similar splicing responses with cells activated through 
CD3/CD28 stimulation but not exposed to IL-4, a pattern also observed at the transcriptional 
level by Henriksson et al.. The activation stimulus caused splicing modulation to large modules 
of genes associated with a broad range of biological functions, particularly regarding functions 
relating to various steps of the gene expression pathway, and suggestive of a contribution to 
protein production during the activation process (Figure 4-3). The splicing of these genes 
followed a wide range of temporal patterns of control, from simple switches in splicing 
behaviour to more complex and intricate modules of splicing regulation (Figure 4-2). 
 
Application of S-MARA combined with linear mixed effect spline modelling identified a set of 
splicing factor motifs with temporal activity profiles strongly associated time-after activation 
and consistent across replicates (Figure 4-9). Prioritisation of these motifs and the associated 
splicing factors provided a method for identifying candidate regulators of the CD4+ T cell gene 
splicing programme for further study. However, the sensitivity and specificity characteristics of 
S-MARA needs to be improved and at this time these predictions should not be over-
interpreted. Splicing factor motif enrichment was also applied for the inference of putative 
regulatory motifs and associated factors. Using this approach, a reduced set of motifs showing 
the strongest association with differential splicing across the activation timecourse was 
identified (Figure 4-13). This method demonstrated value in identifying regulatory splicing 
factors (Chapter 3, Figure 3-19). As such, the putative novel regulators of CD4+ T cell 
activation-mediated differential splicing identified by this method could be prioritized for 
validation and future investigation.  




7.3.2 The role of the RNA-binding protein Sam68 in regulating CD4+ T cell 
gene expression  
The role of the RBP Sam68 in regulating CD4+ T cell gene expression was investigated through 
an RNAi-based depletion dataset. This analysis allowed identification of Sam68-regulated 
genes, a subset of which were also regulated in response to activation via CD4+ T cell 
stimulation (Figure 5-4), and thus potentially represent the contribution of Sam68 to the 
activation process. The function of these splicing variants, in addition to the specific 
mechanisms of alternative splicing control could be investigated further, such as by using CLIP-
seq based assays to map the Sam68 binding profile across the CD4+ T cell transcriptome. One 
of the striking observations of this analysis was that Sam68 depletion had a much greater 
effect on transcript abundance than alternative splicing (Figure 5-8). This finding was 
somewhat unexpected given the previously documented roles of Sam68 in the regulation of 
widespread alternative splicing during various cellular developmental processes (Chawla et al., 
2009; Huot et al., 2012; Matter et al., 2002). A more detailed investigation into the expression 
of these genes during the CD4+ T cell activation process could be performed with the data 
presented in this chapter (Chapter 5). For instance, an investigation into how Sam68 mediates 
changes in mRNA abundance of these transcripts could be investigated. For example, the 
upregulation of CD25 upon TCR engagement was shown to depend upon Sam68 binding to the 
NF-κB complex, which in turn facilitates interaction with the CD25 promoter (Fu et al., 2013). 
Therefore, a role for NF-κB activity being modulated downstream to Sam68 depletion could be 
investigated using these data. Further, Sam68 regulates multiple steps of gene expression 
including transcription, polyadenylation, translation, and splicing (La Rosa et al., 2016; Matter 
et al., 2002; Pandit et al., 2013; Paronetto et al., 2007, 2009). Therefore, a comprehensive 
analysis of how Sam68 regulates gene expression should include an investigation into the 
totality of these RNA processing steps.   
7.3.3 The influence of CpG dinucleotides on alternative HIV-1 splicing 
HIV-1 undergoes extensive splicing via the host splicing machinery. Here we identified a role 
for CpG dinucleotides in influencing alternative pre-mRNA splicing of expressed proviral 
transcripts. Specifically, introducing CpGs into gag promoted the use of a cryptic splice donor 
site that interfered with the use of the canonical donor D1 (Figure 6-6). Interestingly, the 
number of CpGs introduced correlated with the use of the cryptic donor site (Figure 6-5). 




Based on this observation, we hypothesised that a CpG-based splicing enhancer element was 
introduced into gag which promoted the actions of a host splicing factor towards this site. 
Future work could centre around identification of this hypothesised splicing factor. CpG 
dinucleotides are suppressed in the HIV-1 genome (Kypr et al., 1989). This appears in at least 
part to be the result of negative selection, allowing HIV-1 to avoid the effects of the anti-viral 
protein ZAP, which binds CpG dinucelotides to mediate viral restriction (Ficarelli et al., 2019; 
Takata et al., 2018). Our findings suggest that CpG suppression also maintains correct HIV-1 
alternative splicing. Increasing the CpG frequency of viruses through codon optimisation has 
been investigated as a potential strategy for viral attenuation in the creation of vaccines 
(Gaunt et al., 2016). It is important to know the mechanisms of how such codon modification 
strategies can inhibit viral replication, and we have here shown that splicing is one potential 
mechanism. Whether CpG suppression in other RNA viruses also influences alternative splicing 
remains to be investigated.  
7.4 Conclusion 
In this thesis I have analysed RNA-sequencing datasets to investigate how alternative splicing is 
regulated through the actions of splicing factors and RNA regulatory elements. To this end, I 
have employed a novel workflow, S-MARA, for the inference of regulatory splicing factors in a 
given biological condition. I benchmarked this approach using resources from the ENCODE 
project. Contrary to expectations, a simple analysis of differential splicing coupled with motif 
enrichment testing outperformed S-MARA with regards to identification of regulatory splicing 
factor motifs. When applied to a timecourse of CD4+ T cell activation, candidate splicing 
regulators including both known regulators and interesting novel candidates were identified 
through application of both S-MARA and motif enrichment analysis. However, motif 
enrichment analysis again showed improved sensitivity and specificity characteristics as 
compared to S-MARA. Therefore, S-MARA currently does not perform favourably. However, 
improving both the preparation of input data and the MARA model itself will likely enhance 
performance for the specific aim of identifying regulatory splicing factors. Further, I 
investigated the genome-wide targets of the RNA binding protein Sam68. This revealed that 
Sma68 has a more widespread role in regulating mRNA abundance than alternative splicing in 
a model of CD4+ T cell activation. Finally, a role for CpG suppression in contributing to correct 






Chapter 8. Appendix 
8.1 ENCODE project shRNA RBP knockdown experiment 
sample accession codes 
ENCSR000KYM, ENCSR000YYN, ENCSR003EKR, ENCSR003LSA, ENCSR004OSI, ENCSR004RGI, 
ENCSR007XKL, ENCSR009PPI, ENCSR010ZMZ, ENCSR011BBS, ENCSR012DAF, ENCSR016IDR, 
ENCSR016XPB, ENCSR017PRS, ENCSR023HWI, ENCSR024FOF, ENCSR028ITN, ENCSR028YAQ, 
ENCSR029LGJ, ENCSR030ARO, ENCSR030GZQ, ENCSR031RRO, ENCSR032YMP, ENCSR034VBA, 
ENCSR040FSN, ENCSR040WAK, ENCSR042QTH, ENCSR047AJA, ENCSR047EEG, ENCSR047IUS, 
ENCSR047QHX, ENCSR047VPW, ENCSR048BWH, ENCSR052IYH, ENCSR056QEW, 
ENCSR057GCF, ENCSR060IWW, ENCSR060KRD, ENCSR064DXG, ENCSR066VOO, 
ENCSR067GHD, ENCSR067LLB, ENCSR070LJO, ENCSR074UZM, ENCSR076PMZ, ENCSR077BPR, 
ENCSR079IPT, ENCSR079LMZ, ENCSR081IAO, ENCSR081QQH, ENCSR081XRA, ENCSR082UWF, 
ENCSR082YGI, ENCSR084SCN, ENCSR090UMI, ENCSR092WKG, ENCSR094KBY, ENCSR098NHI, 
ENCSR101OPF, ENCSR104ABF, ENCSR104OLN, ENCSR105OXX, ENCSR110HAA, ENCSR110ZYD, 
ENCSR112YTD, ENCSR113PYX, ENCSR116QBU, ENCSR116YMU, ENCSR117WLY, ENCSR118EFE, 
ENCSR118KUN, ENCSR118VQR, ENCSR118XYK, ENCSR119QWQ, ENCSR124KCF, ENCSR126ARZ, 
ENCSR129ROE, ENCSR129RWD, ENCSR134JRE, ENCSR135LXL, ENCSR137HKS, ENCSR143COQ, 
ENCSR143UET, ENCSR147ZBD, ENCSR148MQK, ENCSR149DMY, ENCSR152IWT, 
ENCSR152MON, ENCSR153GKS, ENCSR154OBA, ENCSR155BMF, ENCSR155EZL, ENCSR164MUK, 
ENCSR164TLB, ENCSR165BCF, ENCSR165VBD, ENCSR167JPY, ENCSR169QQW, ENCSR174OYC, 
ENCSR180XTP, ENCSR181RLB, ENCSR182DAW, ENCSR182GKG, ENCSR185JGT, ENCSR188IPO, 
ENCSR191VWK, ENCSR192BPV, ENCSR192GBD, ENCSR193FFA, ENCSR201WFU, ENCSR205VSQ, 
ENCSR208GPE, ENCSR210DML, ENCSR210KJB, ENCSR210RWL, ENCSR215FRI, ENCSR219DXZ, 
ENCSR220TBR, ENCSR222ABK, ENCSR222COT, ENCSR222Csplicing factor, ENCSR222LRL, 
ENCSR222SMI, ENCSR227AVS, ENCSR230ORC, ENCSR231DXJ, ENCSR232CPD, ENCSR232XRZ, 
ENCSR234YMW, ENCSR237IWZ, ENCSR237YZT, ENCSR243IGA, ENCSR244SIO, ENCSR245BNJ, 
ENCSR246RRQ, ENCSR246SOU, ENCSR251ABP, ENCSR253DCB, ENCSR256PLH, ENCSR258VGD, 
ENCSR264TUE, ENCSR267RHP, ENCSR268JDD, ENCSR269HQA, ENCSR269SJB, ENCSR269ZAO, 
ENCSR274KWA, ENCSR278CHI, ENCSR279HMU, ENCSR281IUF, ENCSR281KCL, ENCSR286OKW, 
ENCSR295XKC, ENCSR296ERI, ENCSR300IEW, ENCSR300QFQ, ENCSR302JQA, ENCSR305XWT, 





ENCSR312SFA, ENCSR312SRB, ENCSR313CHR, ENCSR318HAT, ENCSR318OXM, ENCSR322XVS, 
ENCSR324WIS, ENCSR325OOM, ENCSR330KHN, ENCSR330YOU, ENCSR334BTA, ENCSR336DFS, 
ENCSR338CON, ENCSR341PZW, ENCSR342EDG, ENCSR343DHN, ENCSR344XID, ENCSR345VVZ, 
ENCSR346DZQ, ENCSR347ZHQ, ENCSR354XQY, ENCSR355OQC, ENCSR361LBE, ENCSR362XMY, 
ENCSR364GRM, ENCSR366FFV, ENCSR372UWV, ENCSR373KOF, ENCSR374NMJ, ENCSR376FGR, 
ENCSR376RJN, ENCSR379VXW, ENCSR382Qknockdown, ENCSR384BDV, ENCSR385KOY, 
ENCSR385TMY, ENCSR385UPQ, ENCSR386YEV, ENCSR388CNS, ENCSR389HFU, ENCSR392HSJ, 
ENCSR395FYF, ENCSR398GHW, ENCSR398HXV, ENCSR398LZW, ENCSR408SDL, ENCSR409CSO, 
ENCSR410UHJ, ENCSR410ZPU, ENCSR416ZJH, ENCSR419JMU, ENCSR422JMS, ENCSR424JSU, 
ENCSR424QCW, ENCSR424YSV, ENCSR426UUG, ENCSR438MDN, ENCSR448JAM, 
ENCSR450VQO, ENCSR453HKS, ENCSR454KYR, ENCSR455VZH, ENCSR457WBK, ENCSR459EMR, 
ENCSR464ADT, ENCSR471GIS, ENCSR477TRX, ENCSR478FJK, ENCSR481AYC, ENCSR485ZTC, 
ENCSR486AIO, ENCSR490DYI, ENCSR491FOC, ENCSR492BKM, ENCSR492UFS, ENCSR494UDF, 
ENCSR494VSD, ENCSR496ETJ, ENCSR500WHE, ENCSR509LIV, ENCSR511BNY, ENCSR511SYK, 
ENCSR517JDK, ENCSR517JHY, ENCSR518JXY, ENCSR519KXM, ENCSR524YXQ, ENCSR527IVX, 
ENCSR527QNC, ENCSR528ASX, ENCSR529JNJ, ENCSR529MBZ, ENCSR529QEZ, ENCSR530BOP, 
ENCSR532ZPP, ENCSR533HXS, ENCSR535YPK, ENCSR538QOG, ENCSR542ESY, ENCSR545AIK, 
ENCSR546MBH, ENCSR547NWD, ENCSR552NBS, ENCSR555LCE, ENCSR556FNN, ENCSR558XNA, 
ENCSR560AYQ, ENCSR560RSZ, ENCSR561CBC, ENCSR562CCA, ENCSR563YIS, ENCSR570CWH, 
ENCSR572AMC, ENCSR572FFX, ENCSR573UBF, ENCSR576GOW, ENCSR577OVP, 
ENCSR577XBW, ENCSR584JRB, ENCSR584LDM, ENCSR584UYK, ENCSR585KOJ, ENCSR594DNW, 
ENCSR597IYB, ENCSR597XHH, ENCSR598GKQ, ENCSR598YQX, ENCSR599PXD, ENCSR599UDS, 
ENCSR602AWR, ENCSR603TCV, ENCSR605MFS, ENCSR606QIX, ENCSR608IAI, ENCSR610AEI, 
ENCSR610VTA, ENCSR611LQB, ENCSR611ZAL, ENCSR618IQH, ENCSR620HAA, ENCSR620OKS, 
ENCSR620PUP, ENCSR624FBY, ENCSR624OUI, ENCSR624XHG, ENCSR629EWX, ENCSR629RUG, 
ENCSR631RFX, ENCSR634KBO, ENCSR634KHL, ENCSR635BOO, ENCSR635FRH, ENCSR637JLM, 
ENCSR639LKS, ENCSR643UFV, ENCSR644AIM, ENCSR647NYX, ENCSR648BSC, ENCSR648QFY, 
ENCSR656DQV, ENCSR660ETT, ENCSR660MZN, ENCSR661HEL, ENCSR667PLJ, ENCSR667RIA, 
ENCSR674knockdownQ, ENCSR674KEK, ENCSR676EKU, ENCSR678MVE, ENCSR678WOA, 
ENCSR681SMT, ENCSR684HTV, ENCSR685JXU, ENCSR688GVV, ENCSR689MIY, ENCSR689PHN, 
ENCSR689ZJC, ENCSR691IVR, ENCSR693MZJ, ENCSR694LKY, ENCSR695XOD, ENCSR696JWA, 
ENCSR696LLZ, ENCSR701GSV, ENCSR706SXN, ENCSR708GKW, ENCSR710NWE, ENCSR711ZJQ, 





ENCSR720BPO, ENCSR721MXZ, ENCSR728BOL, ENCSR732IYM, ENCSR741YCA, ENCSR744PAQ, 
ENCSR744YVR, ENCSR745WVZ, ENCSR746EKS, ENCSR746NIM, ENCSR754RJA, ENCSR755KOM, 
ENCSR760EGM, ENCSR762FEO, ENCSR767LLP, ENCSR769GES, ENCSR770LYW, ENCSR770OWW, 
ENCSR771QMJ, ENCSR774BXV, ENCSR775TMW, ENCSR776SXA, ENCSR777EDL, ENCSR778AJO, 
ENCSR778RWJ, ENCSR778SIU, ENCSR778WPL, ENCSR780YFF, ENCSR781YNI, ENCSR782MXN, 
ENCSR783LUA, ENCSR783YSQ, ENCSR784FTX, ENCSR788HVK, ENCSR788YGG, ENCSR792CBM, 
ENCSR792XFP, ENCSR794NUE, ENCSR795VAK, ENCSR807ODB, ENCSR808FBR, ENCSR809ISU, 
ENCSR810FHY, ENCSR810JYX, ENCSR812EIA, ENCSR812TLY, ENCSR813NZP, ENCSR815CVQ, 
ENCSR815JDY, ENCSR818TZM, ENCSR820ROH, ENCSR823WTA, ENCSR825QXH, ENCSR831YGP, 
ENCSR835RMN, ENCSR837QDN, ENCSR838SMC, ENCSR840QOH, ENCSR843LYF, 
ENCSR844QNT, ENCSR849STR, ENCSR850CKU, ENCSR850FEH, ENCSR850PWM, ENCSR851KEX, 
ENCSR853PBF, ENCSR853ZJS, ENCSR856CJK, ENCSR856ZRV, ENCSR861ENA, ENCSR866XLI, 
ENCSR871BXO, ENCSR874DVZ, ENCSR874ZLI, ENCSR880DEH, ENCSR883BXR, ENCSR885YOI, 
ENCSR891AXF, ENCSR891DYO, ENCSR896CFV, ENCSR896MMU, ENCSR898OPN, 
ENCSR902WSK, ENCSR904BCZ, ENCSR904CJQ, ENCSR905HID, ENCSR906RHU, ENCSR906WTM, 
ENCSR907UTB, ENCSR910ECL, ENCSR910YNJ, ENCSR911DGK, ENCSR913CAE, ENCSR913ZWR, 
ENCSR914WQV, ENCSR916WOI, ENCSR921knockdownS, ENCSR925RNE, ENCSR925SYZ, 
ENCSR927JXU, ENCSR927SLP, ENCSR927TSP, ENCSR927XBT, ENCSR929PXS, ENCSR939ZRA, 
ENCSR942MBU, ENCSR943LIB, ENCSR945GUR, ENCSR945UYL, ENCSR945XKW, ENCSR946OFN, 
ENCSR947OIM, ENCSR952OOP, ENCSR952QDQ, ENCSR952RRH, ENCSR954HAY, ENCSR957EEG, 
ENCSR958KSY, ENCSR958NDU, ENCSR960MSV, ENCSR961WVL, ENCSR961YAG, ENCSR963RLK, 
ENCSR964YTW, ENCSR967QNT, ENCSR968BBQ, ENCSR968YWY, ENCSR973QSV, ENCSR978CSQ, 
ENCSR984CLJ, ENCSR992JGE, ENCSR995JMS, ENCSR995RPB, ENCSR995ZGJ, ENCSR997FOT, 
ENCSR997HCQ, ENCSR998MZP, ENCSR998RZI 
8.2 Henriksson et al. 2019 CD4+ T cell activation and 
polarisation timecourse RNA-seq sample accessions 
ERX2271389, ERX2271390, ERX2271391, ERX2271392, ERX2271393, ERX2271394, 
ERX2271395, ERX2271396, ERX2271397, ERX2271398, ERX2271399, ERX2271400, 
ERX2271401, ERX2271402, ERX2271403, ERX2271404, ERX2271405, ERX2271406, 
ERX2271407, ERX2271408, ERX2271409, ERX2271410, ERX2271411, ERX2271412, 
ERX2271413, ERX2271414, ERX2271415, ERX2271416, ERX2271417, ERX2271418, 





ERX2271425, ERX2271426, ERX2271427, ERX2271428, ERX2271429, ERX2271430, 
ERX2271431, ERX2271432, ERX2271433, ERX2271434, ERX2271435, ERX2271436, 
ERX2271437, ERX2271438, ERX2271439, ERX2271440, ERX2271441, ERX2271442, 
ERX2271443, ERX2271444, ERX2271445 
8.3 Splicing factors analysed in this study 
Splicing Factor 
 
Does the splicing factor have a PSSM 












































































































































8.4 Lists of genes with regulated alternative splicing in the 
Sam68 knock down experiments – Chapter 5 
Genes with altered splicing upon Sam68 knockdown in resting CD4+ T cells 
AGAP4, AGO3, ANKRD36, CASP8, CIC, CLDND1, COPS8, CSRNP1, DCAF8, LRRN3, MBD5, MBNL1, 
MELK, METTL21A, NOL12, OSBPL1A, PCGF1, PMM2, PPP1R12B, RP11-1035H13.3, RP11-
156P1.3, RP11-206L10.2, RP11-223C24.1, RP1-178F15.5, SATB1-AS1, TBC1D3D, TCFL5, TYW5, 
UBXN8, ZNF829 
 
Genes with altered splicing upon sam68 knockdown in activated CD4+ T cells 
AGO3, BICDL1, BTBD1, C5orf63, CASP8, CCR6, CTC-326K19.6, DDX5, GALM, GOLGA8B, 
GPAT2P1, IL4I1, ITIH4, JPX, LDLRAD4, LRIF1, LST1, PCMTD1, PER2, PREPL, RBM41, RP11-
223C24.1, RP11-681B3.4, RP1-178F15.5, RRP7BP, SNX5, SYCP2, TMEM116 
 
Genes with altered splicing upon activation in CD4+ T cells 
ABC7-42389800N19.1, ABCA5, ABCC4, ABL1, AC006129.2, AC093616.4, AC147651.4, ACIN1, 
ADAP1, ADAT2, AGO3, AHRR, AKAP13, AKAP2, ALG13, ALKBH6, ANK3, ANKRD13D, ANKRD28, 
ANKRD49, APOO, APP, ARGLU1, ARHGAP17, ARRDC2, ASB2, ASXL1, ATAD3B, ATE1, ATP8A1, 
ATXN7, BACH2, BCL2, BCL2L1, BDH1, BOD1, BORA, BPTF, BSCL2, BTAF1, BTN2A2, C19orf12, 
C1orf228, C1orf52, C22orf29, C2orf48, C9orf72, CABIN1, CALM1, CARS2, CASK, CASP8, CBX3, 
CCDC82, CCM2, CCNB1IP1, CCND3, CCNL2, CCNT1, CDK6, CELF2, CEP128, CEP63, CFLAR, CH17-
264B6.3, CH17-472G23.4, CHORDC1, CIITA, CLASP1, CLASRP, CMAHP, CNOT1, CNTRL, COA1, 
COG1, COPS7B, COQ7, CPNE7, CREB3L2, CREBZF, CRELD1, CREM, CSGALNACT1, CTC-459F4.3, 
CUTA, DBP, DGKD, DGKE, DHX30, DHX34, DIDO1, DNAJC25, DPH7, DTWD1, DYNC1LI2, E2F8, 
ECE1, EFCAB14, EGLN3, EIF2AK1, EIF4G2, ELF4, EML2, ENGASE, ENO3, ENTPD1-AS1, EP400, 
EPB41, EPC1, ESPL1, EXOC7, EXOG, FAM107B, FAM122B, FAM136A, FAM221A, FAM49B, 
FAM60A, FAM65B, FBLN5, FBRSL1, FGFR1, FLVCR1, FOXN3, FOXP1, FPGS, FRG1BP, G2E3, 
GALNS, GK, GK5, GLUD1P3, GLUL, GOLGA4, GOLGA8B, GON4L, GORAB, GOSR2, GPBP1L1, 





HMCES, HMGB1, HNRNPH1, HS3ST3B1, HYAL3, IER3, IFT27, IL18BP, IMMP2L, INCENP, INF2, 
INTS6L, IQCG, IRF4, KDM2A, KDM2B, KDM6B, KIAA0391, KIAA1671, KIF1B, KIF21A, KLC1, 
KLHDC4, KLHL24, KLHL7, L3HYPDH, LIMS1, LINC-PINT, LRRC23, LRRC27, LRRFIP2, LTA, LTBP3, 
LUC7L, LUC7L2, LUC7L3, LYAR, MACF1, MAD1L1, MAGED2, MAP2K7, MAP3K1, MAPK8, 
MAPK9, MBNL1, MBOAT1, MCM7, METTL3, MFSD13A, MGA, MIB2, MICA, MINDY3, MLLT10, 
MMP24-AS1, MPRIP, MPV17, MRI1, MRPL32, MSTO2P, MTERF2, MTMR4, MTRF1, MYEF2, 
N6AMT1, NAA38, NABP1, NADK, NAP1L4, NAPB, NBPF9, NCOA2, NCOA5, NCOA7, NDUFAF5, 
NDUFAF6, NDUFAF7, NEDD9, NET1, NFATC1, NFE2L2, NFIC, NKTR, NOC2L, NPEPL1, NPIPB14P, 
NPIPB5, NR2C1, NR3C1, NSD3, NT5C3A, NUMA1, NUMB, NUP43, NXT2, OGFOD2, ORAOV1, 
P2RX4, PACRGL, PAM16, PARGP1, PARP12, PARP8, PASK, PAXBP1, PCGF3, PCMTD2, PCNX2, 
PDCD6, PER1, PFAS, PHF19, PIDD1, PIGB, PIGL, PISD, PITPNM2, PKD1P5, Pknockdown1P6, 
PLCXD1, PMM2, PMS2P7, PNRC1, POC1B-AS1, POMT1, POU2F2, PPFIA1, PPIEL, PPM1K, 
PPP2R5C, PPP3CB, PPP4R3A, PRAG1, PRR3, PSMA1, PTK2B, PTPN4, PVT1, PXN, QRICH1, 
RABL2A, RALGAPA1, RALGAPB, RALGDS, RBM19, RBM25, RBM28, RBM39, RBM41, RC3H1, 
RCAN1, RCC1, RCOR3, REPIN1, RERE, REV3L, RGS19, RGS3, RNASEH1-AS1, RNASEL, RNFT1, 
RNPC3, RP11-1035H13.3, RP11-206L10.2, RP11-43F13.1, RP11-465B22.3, RP11-479O9.4, RP11-
514P8.7, RP1-178F15.5, RP13-942N8.1, RPL6, RPP25L, RPS18, RPS9, RPTOR, RREB1, RRP7BP, 
RSRP1, RTN4, RWDD2A, S100A13, SATB1, SBDSP1, SBNO2, SCAI, SCLT1, SDHAP3, SEC61A2, 
SELENOI, SEMA4D, SEPT9, SFMBT1, SFMBT2, SFT2D1, SGK1, SH3YL1, SIN3B, SIPA1, SKP2, 
SLC25A13, SLC25A14, SLC25A30, SLC2A8, SLC38A1, SLC39A10, SLMAP, SMARCD1, SMC5, 
SMG1P2, SMN2, SNHG4, SNHG7, SNRNP27, SNRNP70, SNRPA1, SOCS2, SPATA33, SPG20, 
SRBD1, SREBF1, SREK1, SRPK2, SRRM1, SRRT, SRSF10, SRSF11, SRSF2, SS18L1, ST20, 
ST6GALNAC6, STIM2, STX2, SUPT3H, SVIL-AS1, TAOK3, TARBP1, TARBP2, TBC1D1, TBC1D4, 
TBCCD1, TBCD, TBRG1, TCAF2, TEPSIN, THAP4, THAP6, THOC3, THUMPD3-AS1, TIA1, TIAL1, 
TJP2, TM2D2, TMEM116, TMEM126B, TMEM156, TMEM187, TMEM62, TMEM63B, TMEM91, 
TMTC4, TNFAIP8, TNFRSF25, TNKS1BP1, TNPO2, TOGARAM1, TP53BP1, TP53I13, TRA2A, 
TRABD, TRAF2, TRAF3IP3, TRERF1, TRIB1, TRIM14, TRIM5, TRMU, TRNT1, TTC12, TTC13, TTC32, 
TUG1, UBA1, UBE2V1, UBXN8, UNKL, USP9Y, UTY, UXS1, VEZT, WASH2P, WDR4, WRB, 
XPNPEP3, YIPF1, ZBTB41, ZBTB7B, ZFP57, ZMAT5, ZMIZ1, ZMIZ2, ZMYM6, ZNF213-AS1, ZNF28, 
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